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1. INTRODUCTION 
1.1. Neurodegenerative disorders 
Neurodegenerative disorders affect over 30 million of individuals in the world leading 
them to disability and death. They are characterized by important pathological changes 
in specific areas of the central nervous system (CNS) and degeneration of distinct neuron 
subsets. Despite the different symptomatology and neuronal vulnerability, the 
pathological processes seem to be similar, suggesting common neurodegenerative 
mechanisms. Neurodegenerative disorders include common diseases, such as the well-
known Parkinson’s disease (PD), Alzheimer’s disease (AD), but also uncommon 
conditions, such as Huntington’s disease (HD)1. 
Some diseases, such as AD, are characterized by cognitive decline, while others, such as 
PD, are mainly characterized by motor impairments. HD shows simultaneously motor, 
psychiatric, and cognitive symptoms as predominant features early on. 
 
▪ Alzheimer’s disease (AD) 
Alzheimer’s disease is the most common neurodegenerative disorder and it is 
characterized by memory decline. In the early stage, patients present episodic memory 
dysfunctions, with more recent events being more difficult to remember while more 
distant memories are generally preserved. Patients also have early impairment in 
semantic memory regarding the knowledge of facts about the world while procedural 
memory is not affected. Other cognitive disfunctions of AD include language, visuospatial 
function, and executive function1. AD patients also present language difficulties that 
manifest early in the disease as reduced verbal fluency and naming. Patients often have 
neuropsychiatric disturbances, including depression, delusions, hallucinations, behavioral 
disturbances, such as agitation, and personality changes.  
 
▪ Parkinson’s disease (PD) 
PD has been defined as a motor disorder. The motor symptoms include resting tremor, 
bradykinesia, rigidity, and gait imbalance. However, also nonmotor features have been 
observed such as cognitive impairment, psychiatric symptoms, autonomic dysfunction, 
and sleep disturbances1. Autonomic dysfunction includes constipation, gastrointestinal 
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motility issues, urinary symptoms, orthostatic hypotension. Common psychiatric features 
include depression and anxiety. In later stage of the pathology patients develop cognitive 
decline and in some cases dementia. Differently from AD, memory decline is rare while 
cognitive impairments such as deficits in attention, hallucinations, or psychosis often 
occur in PD. Sleep disturbances include sleep apnea, daytime sleepiness, and rapid eye 
movement sleep behavior disorder (RBD). 
 
▪ Huntington’s disease (HD) 
This disorder is characterized psychiatric illness, cognitive impairment, and motor 
dysfunction. When HD manifests during adulthood, patients can show simultaneously 
either motor symptoms or behavioral symptoms. Psychiatric symptoms include 
depression, anxiety, and less likely mania and psychosis. Suicide is also a very common 
event in patients with HD. Patients may also be aggressive toward others. Cognitive 
impairments are also not rare with decline in attention, motivation, problem solving, and 
executive function. The motor dysfunction is typically marked by choreiform movements, 
which are excessive, together with involuntary movement. Differently from AD and PD, 
HD occurs during childhood and the clinical manifestations are quite different and include 
akinesia, rigidity along with cerebellar ataxia and seizures. 
 
Mechanisms implicated in neurodegeneration  
Despite causes of each neurodegenerative disorder are different, some mechanisms 
involved in neurodegeneration seem to be similar. In fact, the mechanisms leading to 
neurodegeneration and cell death include: 
• Mitochondrial Dysfunction.  
• Oxidative Stress.  
• Excitotoxicity. 
•  Protein Aggregation.  
• Prion-Like Spread.  
• Neuroinflammation.  
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Among these mechanisms, no one appears to be the main cause of neurodegeneration, 
and these pathogenic mechanisms act synergistically through complex interactions to 
promote neurodegeneration. 
 
Current treatment options  
At present, the therapeutic treatments available to patients with neurodegenerative 
disorders are few and those that are available address only symptoms and not affecting 
the mechanisms underlying the disease. Despite these therapies can make a big 
difference in the quality of life of patients, it is urgent to develop effective and safe 
therapies able to stop or slow the progression of diseases. To achieve this we need a 
better understanding of the mechanisms and causes regulating the neurodegeneration 
that could provide new promising targets for drug the discovery programs1. 
 
1.2 Adenosine in brain disorders 
In central nervous system (CNS), adenosine plays the double role of neuro- and 
homeostatic modulator. The neuromodulatory effect results from a balanced activation 
of inhibitory A1 receptors and facilitatory A2A receptors, mostly controlling excitatory 
glutamatergic synapses2. A1 adenosine receptor (AR) induces a tonic brake on excitatory 
transmission, whereas the A2AAR is involved in promoting synaptic plasticity phenomena. 
The neuromodulatory role of adenosine is very similar to the role of adenosine in the 
control of brain disorders; in fact, A1ARs mostly act as a hurdle that needs to be overcame 
to begin neurodegeneration and, accordingly, A1AR only effectively control 
neurodegeneration if activated in the temporal vicinity of brain insults; in contrast, the 
blockade of A2AAR leads to beneficial effects in different neurodegenerative conditions 
such as ischemia, epilepsy, Parkinson's or Alzheimer's disease and also seem to afford 
benefits in some psychiatric conditions2. Despite this qualitative agreement between 
neuromodulation and neuroprotection by A1AR and A2AAR, it is still not clear if the role of 
A1AR and A2AAR in the control of neuroprotection is mostly due to the control of 
glutamatergic transmission, or if it is instead due to the different homeostatic roles of 
these receptors related with the control of metabolism, of neuron–glia communication, 
of neuroinflammation, of neurogenesis or of the control of action of growth factors. 
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Althoughthis current mechanistic uncertainty, it seems evident that targeting the A1 and 
A2AARs might constitute a novel strategy to control the progression of different 
neurological and psychiatric disorders. Based on these premises, I focused my PhD 
research activity on the identification of new compounds designed as antagonists of the 
human (h) A2AAR or of both hA1 and hA2AARs. 
 
1.3 Adenosine 
Adenosine is an endogenous purine nucleoside that plays an important role in the human 
body. Its existence was demonstrated for the first time in 1927 when a adenine 
compound able to slow the heart rhythm and rate was discovered in extracts from cardiac 
tissues3. Since then, adenosine physiopathological roles have been investigated in various 
disciplines (biology, physiology, medicine,) thus generating a new field of research. Fifty 
years later, this findings led to the introduction of adenosine in the diagnosis and 
treatment of supraventricular tachycardia4,5. At present, adenosine is known to be an 
ubiquitous endogenous molecule involved in several biological functions, both 
physiological and pathological6,7. These include cardiac rhythm and circulation8,9 
lipolysis10 , renal blood flow11,12, immune function13 , sleep regulation14,15 and 
angiogenesis16 , as well as inflammatory diseases17,18, ischaemia–reperfusion19 and 
neurodegenerative disorders20. 
 
1.3.1 Origin and metabolism of adenosine 
In physiological conditions, extracellular adenosine levels are between 20 and 300 nM, 
rising to a low micromolar values in particular situations (physical exercise or low 
atmospheric oxygen levels) and high micromolar levels (30 µM) in pathological conditions. 
The concentration of adenosine in the extracellular compartment is the consequence of 
biological processes such as extracellular adenosine production, adenosine transport, 
adenosine formation from intracellular pathways or adenosine breakdown to inosine or 
AMP (Figure 1). Extracellular adenosine derives from two sources. First, it may be derived 
from the external transport of intracellularly generated adenosine otherwise may also be 
formed as a consequence of extracellular hydrolysis of adenine nucleotides. In many 
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instances, extracellular adenosine arises from the degradation of extracellular 
nucleotides ATP and ADP. 
 
 
 
Figure 1. Adenosine metabolism and transport in the extra-intracellular milieu.21 
 
In particular, adenosine originates from ATP through a two-step enzymatic reaction in 
which ATP or ADP are turned into AMP by ectonucleoside triphosphate 
diphosphohydrolase 1 (ENTPD1; also known as CD39) and followed by AMP hydrolysis to 
adenosine by ecto-5′-nucleotidase (NT5E; also known as CD73). ATP can be released from 
different cell types by various mechanisms including the releasing from storage vesicles 
together with other hormones but it can be also released via a ‘kiss and run’ mechanism22 
(a type of synaptic vesicle release where the vesicle opens and closes transiently) or from 
the lysosome by exocytosis23. The ATP is also released by mechanisms including 
uncontrolled leakage from necrotic cells9 or from cells undergoing other forms of cell 
death24,25 as well as release from inflammatory cells or vascular endothelia through 
connexin hemichannels and channels such as P2X purinergic receptor 726-28. In 
physiological conditions, adenosine is mainly originated intracellularly, from hydrolysis of 
AMP and S-adenosylhomocysteine (SAH) through the endo-5-nucleotidase, and SAH 
hydrolase, respectively29. Also the extracellular adenosine, once generated, is captured at 
the intracellular level trough the SLC28 family of cation-linked concentrative nucleoside 
transporters (CNTs) and the SLC29 family of energy-independent, equilibrative nucleoside 
transporters (ENTs), which regulate the free passage of adenosine across the cell 
                                    1.INTRODUCTION 
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membrane. The adenosine passage across the membrane is regulated by a concentration-
dependent mechanism which suggests how the uptake or release from cells is determined 
by the adenosine gradient. The role of ENTs in this transfer is more important than that 
of CNTs, indeed, the four isoforms of ENT (1–4) allows the passage into or out of cell 
membranes on the basis of adenosine concentrations, while the three isoforms of CNT 
(1–3) facilitate adenosine influx against a concentration gradient, using the sodium ion 
gradient as a source of energy. Normally the adenosine flux is from the extracellular to 
intracellular compartment, while during hypoxia, it is reversed. After intracellular uptake, 
adenosine is rapidly metabolized to inosine by adenosine deaminase (ADA) or 
phosphorylated to AMP through adenosine kinase (AK). The Michaelis constant (Km) 
values for these enzymes are 2 µM (AK) and 17–45 µM (ADA) respectively thus suggesting 
that AK is the principal means of adenosine clearance in physiological conditions, while 
deamination occurs preferentially in case of pathological processes featuring higher 
adenosine levels. In such situations, deamination through ecto-ADA or influx through 
ENTs may occur to reduce the extracellular adenosine concentration30-32. 
 
1.3.2 Adenosine receptors (ARs) 
Adenosine mediates its effects through specific interactions with G protein-coupled 
receptors (GPCRs) divided into four subtypes termed A1, A2A, A2B, and A3 (ARs, Figure 2). 
 
 
 
Figure 2. Adenosine receptors (ARs) and their corresponding intracellular signal pathways.33 
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ARs are widely expressed in the human body, and are present in the nervous, 
cardiovascular, respiratory, gastrointestinal, urogenital, and immune systems as well as 
in bone, joints, eyes, and skin34—a pattern of distribution that explains the role of 
adenosine in the control of a broad spectrum of physiological and pathophysiological 
conditions.  
Each AR is characterized by specific cell and tissue distribution (Figure 3), secondary 
signaling transductors (Table 1), and physiological effects.  
 
 
Figure 3. ARs anatomical distribution and corresponding physiological effects. 
 
In particular, A1AR and A3AR signals are mediated through Gi and Go which are able to 
reduce adenylyl cyclase (AC) activity and cAMP levels, while A2AARs and A2BARs are 
coupled to Gs proteins, through which they stimulate AC and increase cAMP levels, thus 
leading to the activation of a plethora of effectors, depending on the signaling triggered 
by cAMP in specific cells35 (Table 1). 
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1.3.3 Adenosine receptor molecular structures 
All four ARs have been well identified, cloned and pharmacologically studied, and present 
a common structure consisting in a core domain which crosses the plasma membrane 
seven times, in which each helix is 20–27 amino acids long and linked by three intracellular 
and three extracellular loops36. The extracellular amino-terminal contains one or more 
glycosylation sites, while the intracellular carboxylic-terminus provides sites for 
phosphorylation and palmitoylation thus regulating desensitization and internalization 
processes. The AR subtypes present different numbers of amino acids. For instance, a 
longer COOH terminus, with 122 amino acids, is found on A2AAR, whereas A1AR, A2BAR, 
and A3AR bear COOH-terminal tails consisting of ~30–40 amino acids35. The sequence 
identity between the hA1 and hA3 ARs is 49%, and the hA2A and hA2B ARs are 59% Some of 
these charateristic conserved residues are involved in specific functions. In particular, 
there are two peculiar His residues in TMs 6 and 7 of hA1, hA2A, and hA2B ARs while in the 
hA3 AR, one of this His residue is lacking but another His residue can be found in TM3. All 
this His residues have been indicated by mutagenesis studies to be important in 
recognition and/or activation of the receptor35,37. In the beginning, adenosine receptors 
were divided in subtypes A1 and A2 following their ability to increase or decrease the 
activity of adenylate cyclase (AC), respectively38,39. Then, A2 receptors were further 
classified, by Daly and collaborators40, on the basis on their affinity for the endogenous 
ligand adenosine, indeed, A2A affinity (0.1-1 μM) is higher than and A2B one (>10 μM). A3 
Table 1. Classification and mechanism of action of adenosine receptors 
Name A1 A2A A2B A3 
G protein coupling 
effector system 
Gi/0 Gs Gs/q11 Gs/q11 
 Adenylyl  
cyclase 
Adenylyl  
Cyclase     
Adenylyl  
cyclase 
Adenylyl  
cyclase 
 Phospholipase C MAP kinase Phospholipase C Phospholipase C 
 K+/Ca+  MAP kinase PI 3-Kinase 
 PI 3-Kinase   MAP kinase 
 MAP kinase    
Adenosine affinity 1-10 nM 0.1-1 μM >10 μM 100 nM 
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AR was identified fort the first time in 1991 through a polymerase chain reaction (PCR) 
performed on rat cDNA encoding a GPCR that showed high affinity (58%) with A1 and A2A 
AR41. This “new” receptor revealed an unconventional low homology between its 
homologous in other species (e.g. 72% versus rat A3 AR) considering the other ARs (85-95 
% of homology versus rat). Moreover, the presence of several GPCRs (including ARs) in 
homomer, oligomer or heteromer forms has been observed42-47. GPCR heteromers are 
considered to be new signaling entities characterized by different functional properties 
when compared with homomers. In this field, the adenosine A1AR-A2AAR unit represents 
the first reliable structure of a macromolecular complex, including two different receptors 
but also two different G proteins coupled to them42,45. Indeed A1AR is coupled to Gi and 
A2AAR to Gs, thus making this heteromer able to activate opposite signals affecting the 
cAMP-dependent intracellular pathway. In particular, this entity plays the role of sensor 
a cell surface of adenosine concentration, able to discriminate between low and high 
levels of nucleoside45. In the case of low adenosine levels, it binds preferentially the A1AR 
protomer of the heteromer and activates Gi/o protein, thus inhibiting adenylate cyclase 
(AC), protein kinase A (PKA), and GABA uptake. Instead, when adenosine levels are higher, 
its binding is favored to A2AR component of the complex, which reduces A1AR activation 
and, through Gs protein, associates with the AC/cAMP/PKA cascade, resulting in the 
increase of GABA uptake48. Interestingly, the heteromerization phenomenon appears as 
a general mechanism affecting also A3ARs, forming homodimers and A1AR-A3AR 
heterodimers49,50. This opens up new perspectives in the drug development44, in 
particular, A2AAR-D2 dopamine receptor heterodimers have been detected in the striatum 
and may be a viable therapeutic target in PD51-53. 
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1.3.4 A1 adenosine receptor 
 
 
Figure 4. Overview of A1AR intracellular signaling pathways. A1AR stimulation decreases adenylate cyclase 
(AC) activity and cAMP production, thus inhibiting protein kinase A (PKA), while activated phospholipase C 
(PLC)-β and Ca2+. K+ and Ca2+ channels are opened and closed, respectively, by A1AR enrollement. Mitogen 
activated protein kinases p38, ERK1/2, and JNK1/2 phosphorylation are induced by A1AR activation.21 
 
The A1AR is expressed in the central nervous system (CNS) especially in the brain cortex, 
cerebellum, hippocampus, autonomic nerve terminals, spinal cord, and glial cells29. This 
broad distribution reflects the wide range of physiological functions regulated by A1AR in 
the brain incuding neurotransmitter release, dampening of neuronal excitability, control 
of sleep/wakefulness, pain reduction, as well as sedative, anticonvulsant, anxiolytic, and 
locomotor depressant effects54-56. This subtype is also present at high levels in peripheral 
organs such as the heart, kidney, adipose tissue, and pancreas, where it induces negative 
chronotropic, inotropic, and dromotropic effects, reduces renal blood flow and renin 
release, and inhibits lipolysis and insulin secretion, respectively57-63. It is also located on 
airway epithelial and smooth muscle cells, where it stimulates a bronchoconstrictory 
response, and in several immune cells such as neutrophils, eosinophils, macrophages, and 
monocytes in which it modulates essentially proinflammatory effects64-66. A1AR also 
stimulates phospholipase C (PLC)-β activation, thereby increasing inositol 1,4,5-
trisphosphate (IP3) and intracellular Ca2+ levels, which induces calcium-dependent 
protein kinases (PKC) and/or other calcium-binding proteins. At the neuronal and 
myocardial level, A1AR stimulates potassium (K) pertussis toxin-sensitive and K-ATP 
channels, while reducing Q-, P-, and N-type Ca2+ channels. Furthermore, involvement of 
A1AR in the intracellular phosphorylative cascade of the mitogen-activated protein kinase 
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(MAPK) family—including extracellular signal-regulated kinase (ERK), p38, and Jun NH2-
terminal kinase (JNK)— has been reported67,68(Figure 4). 
 
1.3.4.1 A1AR in neurological diseases 
The A1AR subtype is widely and homogeneously expressed in the CNS, mainly in excitatory 
synapses, and plays an important role in regulating the physiological synaptic 
transmission. In detail, A1AR stimulation inhibits the excitatory transmission through the 
inhibition of N-type calcium-channel and neuronal hyperpolarization by regulation of 
potassium current69,70. This leads to a reduction in glutamate release and inhibition of 
NMDA effects, which maintains an A1ARs-dependent inhibitory tonus in the brain71-73, an 
effect that is beneficial in several central disfunctions such as epilepsy, pain, and cerebral 
ischemia74. 
 
➢ A1AR in epilepsy, pain and cerebral ischemia 
During investigations, adenosine proved to be an endogenous anticonvulsant molecule, 
able to reduce the frequency of action potentials induced by electrical stimulation 
through involvement of overexpressed A1ARs75. Several studies have reported protection 
against seizures resulting from an increase in adenosine levels produced by a ketogenic 
diet, which apparently inhibits adenosine kinase76 (ADK). It seems that this effect may also 
be related to adenosine interfering with the S-adenosyl methionine (SAM)-induced DNA 
methylation pathway— involved in epileptogenesis—as a result of ADK reduction, 
adenosine increase, SAH accumulation, and SAM inhibition77. These data constitute the 
rationale supporting ADK inhibitors as therapeutic agents. However, despite these may 
increase adenosine and reverse such epigenetic changes, their toxic side effects have not 
yet been overcome78. As an alternative, adenosine-based treatments have been 
proposed. For example, adenosine administration might be useful as a preventative 
treatment or following surgical resection of an epileptogenic focus79.  
The neuroprotective properties of A1ARs have been investigated in several models of 
inflammation and neuropathic pain, in which A1AR agonists showed antinociceptive 
and/or antihyperalgesic properties. A1AR activation reduces pain by acting on spinal, 
supraspinal, and peripheral neurons as well as in glial cells. The molecular mechanisms 
involved in pain mitigation include the classical signal pathways described for A1AR-AC 
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and PKA reduction; PLC induction; Ca2+ and K+ channel regulation; and ERK, CREB, 
calmodulin kinase (CaMKIIα) inhibition, as well as reduction of excitatory amino acid 
release55. In addition, the pathway involving the nitric oxide/cGMP/protein kinase 
G/KATP channel emerged as a molecular effector in the A1AR-mediated pain suppression 
through induction of nociceptive neuron hyperpolarization and inhibition of microglia 
hyperactivation80. However, since the systemic administration of A1AR agonists may lead 
to central and cardiovascular side effects, several candidates have failed in clinical trials. 
In this sense, partial agonists or allosteric modulators could represent a solution to this 
problem. Furthermore, the A1AR’s inhibitory effect on the glutamate release appears to 
be fundamental in the prevention/protection against ischemic damage. However, A1AR 
only seems to be effective in the early hours after damage while the chronic stimulation 
is responsible for the opposite effects. Indeed, a role for A1AR has been retrieved during 
preconditioning—a state of tissue protection by exposure to sublethal insults— probably 
occurring through modulation of NMDA preconditioning- mediated increase of glutamate 
uptake81.  
 
➢ A1AR in Alzheimer’s disease 
A1 receptors reduces the synaptic transmission and release of various 
neurotransmitters82. In the hippopcampus, adenosine inhibits the release of acetylcholine 
and the excitatory amino acid glutamate82-84. This latter and its receptors have been 
recognized to play a central role in the pathogenesis of AD and the dysfunction of this 
excitatory amino acid system may be responsible for some of the AD clinical 
manifestations85,86. Alexandre de Mendoca first described that endogenous adenosine, 
through A1 receptor activation, modulates long-term synaptic plasticity phenomena, such 
as long-term potentiation87 (LTP), and then showed that tonic activation of A1 receptors 
decreases88 LTP. In accordance with the notion that synaptic plasticity is the basis for 
learning and memory in different brain areas89, adenosine correspondingly modulates 
rodent performances in various learning and memory paradigms90. Administration of 
adenosine receptor agonists (mainly A1) disrupts learning and memory in rodents91,92 
while the nonselective adenosine receptor blockade by caffeine/theophylline or selective 
blockade of A1 and A2A receptors improve the performances of rodent different 
behavioral tasks92,93. A1 receptors are highly expressed in the CA1 region of 
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hippocampus94 in a normal healthy brain. A change in the pattern of A1 receptor 
expression has been found in AD patients when compared with age-matched control 
brains95. Most of the studies regarding the AD models for adenosine receptors were 
performed in hippocampus and striatum and showed reduced levels of A1 receptors in 
these areas96. In AD patients, a reduced density of A1 receptors, along with reduced 
binding sites for adenosine agonists and antagonists, has been found in the molecular 
layer of the dentate gyrus. In addition, altered binding of adenosine agonists and 
antagonists to A1 receptors in CA1 and CA3 regions of hippocampus has been observed97. 
Kalaria and colleagues have demonstrated that A1 receptors are significantly reduced by 
40-60% in AD after assessing the hippocampal samples collected from postmortem AD 
subjects as well as they observed an highest reduction of A1 receptors in the molecular 
layer of the dentate gyrus including perforant pathways98, which is the principal source of 
cortical input to the hippocampal formation99. On the contrary, Albasanz and co-workers 
highlighted that an upregulation of both the A1 and A2A receptors take place in frontal 
cortex both in early and advanced stages of AD100, associated with sensitization of the 
corresponding transduction pathways. In agreement with theses results, a study carried-
out in a transgenic mouse model (APP Swedish mutation) also found the higher levels of 
cortical A1 and hippocampal A2A receptors as compared with the non-transgenic mouse101. 
On the other hand, it is not clear if A1 receptors influence the processes involved in the 
formation of abnormal APP and hyperphosphorylated tau proteins in AD patients. 
However, the role of A1 receptors in APP processing, tau phosphorylation and cellular 
signaling has been investigated in a model of human neural cells (neuroblastoma SH-SY5Y 
cells) that naturally express A1 receptors95. This study shows that activation of A1 
receptors led to the production of soluble APP, mediate tau phosphorylation and its 
translocation towards the cytoskeleton of neuroblastoma cells. A marked increase in A1 
receptor immunoreactivity was also observed in degenerating neurons with 
neurofibrillary tangles and in dystrophic neurites of Aβ plaques in the hippocampus and 
frontal cortex of AD. The positive involvement of A1 receptors in in vitro APP processing, 
tau phosphorylation and the presence of A1 receptors in the neurodegenerative 
structures of AD suggest that A1 receptors may play a role in the pathogenesis of AD.  
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➢ A1AR in Parkinson’s disease 
Regarding the involvement of A1 adenosine receptor in Parkinson’s diesease, quantitative 
autoradiographic studies in rodent, postmortem human brain samples102, as well as [11C-
MPDX] PET imaging in human subjects103 highlighted that adenosine A1 receptors are 
highly expressed in neocortex, hippocampus, and striatum. Based on anatomical and in 
vivo microdialysis studies, A1ARs seem to be localized presynaptically of dopamine (DA) 
axon terminals where they reduce the DA release104. Futheremore it was been observed 
that A1ARs blockade improves DA release in the striatum and similarly to the A2A 
receptors, potentiate DA-mediated responses. Furthermore, the A1 receptor is also 
concentrated in neocortical and limbic brain areas that are important for cognitive 
function and have been implicated in antidepressant action. Inhibition of A1 receptors 
enhances neurotransmitter release in the hippocampus105 and is effective in improving 
performance in animal models of learning and memory106. ASP-5854 is a dual A2A/A1 
antagonist able to bind the A2A and A1 ARs with affinity values of 1.8 and 9.0 nM, 
respectively107. ASP-5854 turned out to be effective in a number of animal models of 
PD108,109, and it has shown beneficial effects in two models of cognition, the scopolamine-
induced memory deficits in the mouse Y-maze and the rat passive avoidance test110. On 
the contrary, the highly selective A2A antagonist KW-6002 showed minimal or no effect in 
the same models thus indicating that the A1 component could provide added benefit to 
PD patients. These data suggest that a dual A2A/A1 adenosine receptor antagonist may 
offer a unique and exciting approach to treating both the motor and the nonmotor 
disturbances of PD. 
A1 receptors play an active role in protecting astrocytes from damage and cell death111-113 
through the activation of PI3K and ERK 1/2 phosphorylation. A1ARs on microglial cells 
have been demonstrated to reduce excessive activation of microglial cells following 
immune activation114. Activation of these receptors may secondarily affect 
oligodendroglial cells114 and also astrocyte proliferation115, which emphasizes the 
possibility of an extended glial network of signaling. A1 receptors on neurons (especially 
at nerve terminals) are involved in mediating the dampening effect on neuronal activity 
mediated by adenosine generated from ATP released from astrocytes116,117.  
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1.3.5 A2A adenosine receptor 
 
 
Figure 5. Overview of A2AAR intracellular signaling pathways. A2AAR stimulation increases adenylate 
cyclase (AC) activity, cAMP production, protein kinase A (PKA), and cAMP-responsive element-binding 
protein (CREB) phosphorylation. AKT and mitogen- activated protein kinases p38, ERK1/ 2 and JNK1/2 are 
activated following by A2AAR recruitment.21 
 
The A2AAR subtype is localized both in the CNS and peripherally showing the greatest 
expression is in the striatum, olfactory tubercle and the immune system, while lower 
levels were observed in the cortex, hippocampus, heart, lung, and blood vessels. 
Furtheremore, A2AAR is expressed on both pre and postsynaptic neurons and in glial cells, 
astrocytes, microglia and oligodendrocytes, where it regulates several functions related 
to excitotoxicity, spanning neuronal glutamate release, glial reactivity, blood-brain barrier 
(BBB) permeability, and peripheral immune cell migration. The A2AAR subtype is also 
expressed in the immune system, in leukocytes, platelets, and the vasculature, where it 
mediates anti-inflammatory, antiaggregatory, and vasodilatory effects, respectively118. 
In the brain, A2AARs modulate the activation of a particular neuron-specific type of Gs 
protein, known as Golf, which is also linked to AC119. cAMP-dependent PKA is the most 
common effector raised by A2AAR activation; this phosphorylates and activates numerous 
proteins, including receptors, phosphodiesterases, cAMP-responsive element binding 
protein (CREB), and dopamine- and cAMP-regulated phosphoprotein (DARPP-32)120. 
Moreover, according to several literature reports on different cellular models, the A2AAR 
appears to be involved in the modulation of MAPK signaling121,122 (Figure 5). A2AAR may 
also interact with different accessory proteins, D2-dopamine receptors, α-actinin, ADP-
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ribosylation factor nucleotide site opener (ARNO), ubiquitin-specific protease (USP4), and 
translin associated protein X (TRAX) through the COOH terminus, which would explain the 
contrasting results found in terms of A2AAR-mediated effects121.  
 
1.3.5.1 A2AAR in neurological diseases 
 
➢ A2AAR in Parkinson’s disease 
A2ARs are highly expressed in the basal ganglia and depend on Gs and other interacting 
proteins for correct transduction of their signals123. The striatum is the anatomical region 
in mammals that most strongly expresses A2ARs, which have been established to play an 
important role in the regulation of dopaminergic transmission in the basal ganglia124. 
A2AAR are co-localized postsynaptically with D2Rs in GABAergic striatopallidal 
enkephalinergic MSNs. Stimulation of the A2AAR at this level counteracts the inhibitory 
modulation of NMDA receptor activity mediated by D2Rs, which includes regulating Ca2+ 
influx, transition to the firing “up” state and modulation of neuronal firing in the “up” 
state125,126 . This interaction is the main cause of most of the locomotor inhibition and 
activation induced by A2AR agonists and antagonists, respectively127. Adenosine A2AAR-
mediated activity is usually antagonistic to that mediated by D2R in MSNs and functional 
antagonism between A2A and D2 receptors was recently reported in striatal cholinergic 
interneurons128. Overall, adenosine-dopamine antagonism underlies the potential 
therapeutic benefits of A2AR-selective antagonists in PD. Related to this, blockade of A2A 
receptors showed beneficial effects in preclinical animal models of PD, showing 
potentiation of dopamine induced responses in dopamine 6-OHDA-treated129,130 animals 
and significant relief of parkinsonian symptoms in MPTP-treated131,132 nonhuman 
primates133-135. A2A antagonists facilitate dopamine receptor signaling thus normalizing 
motor function in animal models of dopamine dysregulation. Despite most of adenosine 
A2A receptors are located in the basal ganglia, some have been also found in other areas 
of the CNS such as the nucleus accumbens and olfactory tubercle. This suggests that 
adenosine A2A receptors might be actively involved in the neuropsychiatric nonmotor 
symptoms occurring in PD including anxiety, depression, and cognitive impairment. Only 
little investigation was carried out about of this possibility until recently but an association 
with A2A receptors had been demonstrated using A2A receptor knock-out mice and 
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pharmacological manipulation of A2A receptor function136,137. This is potentially important 
since the PD non-motor impairments, such as anxiety and depression, are not well 
controlled by classical antidepressant and anxiolytic drugs and changes in cognition only 
show a small improvement in response to cholinesterase inhibitors which can, in some 
cases, worsen motor features. Another issue to be investigated is the potential ability of 
A2A receptor antagonists to modify and slow the disease progression. At this regard, 
several epidemiological studies revealed that caffeine intake is related to a decrease risk 
of developing PD138. Among its many actions, caffeine also acts as an adenosine A2A 
receptor antagonist and this led to investigation of the potential of A2A receptor 
manipulation as a means of controlling disease progression in PD. 
 
➢ A2AAR in Alzheimer’s disease 
Limited data are available about the role of A2A in AD. An increased expression of A2A 
receptors in microglial cells in the hippocampus and cerebral cortex of AD patients has 
been found95. Modulation of A2A receptors could have neuroprotective effects in AD since 
they might interfere the pathogenesis of AD increasing the resistance of neuronal cells to 
insults. The main hypothesis underlyng the progressive neurodegeneration in AD is the 
neurotoxicity caused by Aβ139 and current evidence favors the idea that soluble Aβ plays 
the pivotal role in the pathogenesis of AD. Primary cultures of cerebellar granule cells with 
Aβ25-35 in the presence of adenosine receptor blockers revealed that the blockade of A2A 
receptors almost completely prevented Aβ-induced neurotoxicity140. So it appears that 
the presence of A2A receptor is essential for Aβ toxicity and inhibition of this receptor 
might counteract the Aβ induced neurotoxicity in AD. Nevertheless, the neuroprotective 
mechanism of A2A receptor antagonists against Aβ induced neurotoxicity is not well 
known. A possible explanation might be the A2AAR ability to modulate neuro-
inflammation by its anti-inflammatory properties141. Symptomatic relief from cognitive 
impairments in AD patients might be achieved by modulating A2A receptors, in fact, these 
receptors are able to positively modulate the neurophysiological mechanisms of learning 
and memory142,143. Furtheremore, severeal studies highlighted the efficacy of caffeine or 
selective A2A receptor antagonists in preventig delayed memory deficits induced by 
intracerebroventricular Aβ144. This result indicates that caffeine affords its beneficial 
effects through A2A receptors, which were found to be overexpressed in cortical regions 
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both in animal models101 as well as in cortical tissues of AD patients95, 100. The data 
collected from a recent report showed a reduction in memory loss induced by Aβ after 
the pharmacological blockade or genetic inactivation of A2A receptors142. Moreover, in A2A 
receptor knockout mice, administration of Aβ did not cause learning deficits or 
synaptotoxicity145, thus proving the important role of A2A receptors in cognitive function. 
The beneficial effects usually exerted by A2A receptor antagonists have also been found 
in different behavioral studies in vivo. 
 
➢ A2AAR in Huntington’s disease 
Several studies support the hypothesis146 that cortico-striatal glutamatergic deregulation 
should be involved in pathogenesis of HD. Indeed, mutated huntingtin induces 
glutamatergic dysfunctions such as the increased glutamate release and decreased 
astrocytic glutamate clearance147,148, as well as an overexpression and activation of NMDA 
receptors149 which are able to induce changes in NMDA receptor subunits150-152. A2AAR is 
mainly located postsynaptically in medium spiny neurons (MSNs)153 but it can also be found 
presynaptically on the cortico-striatal glutamatergic afferents154, where it modulate 
glutamate release155,156. Besides neurons, A2AR is also present in non-neuronal cells, such 
as endothelial and glial cells which allow a control of vasodilation and glial responses to 
injury and inflammation157-159. Several lines of evidence point towards a pathophysiologic 
role for adenosine A2AR in HD, since changes in A2AR gene expression, density and signaling, 
as well as early vulnerability of MSNs selectively expressing A2AR, has been observed160-163. 
Moreover, recent evidence indicates that a polymorphism of the A2AR gene (ADORA2A) can 
influence the age of onset of HD patients164. As reported above, continued exposure to 
glutamate and persistent opening of NMDA channels, make MSNs vulnerable to excitotoxic 
damage, in particular those expressing A2AR, which receive more glutamatergic inputs from 
the cortex165, further supporting a role for A2AR in HD physiopathology165. Neuroprotective 
effects attributed to A2AR antagonists correlate well with their ability to decrease glutamate 
levels by preventing166-169 or decreasing its release and enhancing its uptake by glial cells170-
173. A2AR in glutamatergic synapses is also able to control the activation/expression of 
NMDA receptors174,175, their subunit composition176 and plastic changes in cortical 
glutamatergic inputs. Whereas the presynaptic role of A2AR antagonists is increasingly 
accepted as neuroprotective, an effect mainly attributed to the modulation of 
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glutamatergic transmission, the postsynaptic and extra-synaptic effects of A2AR blockade 
have been speculative and most studies favor A2AR agonists, rather than antagonists as 
protective agents in the particular case of the degeneration of MSNs. These were attributed 
to the ability of A2AR antagonists to potentiate NMDA-mediated toxicity and to the ability 
of agonists to reduce NMDA currents in striatal MSNs168,169,174,177,178. Finally, A2AR blockade 
is generally accepted as a protective strategy in the control of neuroinflammation in several 
degenerative conditions, including HD. However, despite the established pathophysiologic 
role of A2AR in HD,further investigations areneeded to understandjjj if it is the activation or 
the blockade of A2AR that can bring about clinical benefits. The complexity of functions 
operated by A2AR in specific cellular and regional locations specifically in the striatum may 
suggest that neither stimulation nor blockade are beneficial or that both can be 
advantageous, depending on the time-frame of the disease taken into account. Thus, HD is 
a special case of a brain disorder where both A2AR agonists and antagonists have been 
shown to provide protection in animal models of HD.  
 
➢ A2AAR in cerebral ischemia 
The role of A2AR in ischemic brain damage was described in parallel by the group of John 
Phillis and that of Ennio Ongini at Schering-Plough; they first observed that the blockade 
of A2AR afforded protection against ischemic brain damage179-182. This effect was then 
confirmed in experiments carried out by Jiang-Fan Chen, showing that the genetic 
elimination of A2AR was effective in protecting from the ischemic brain damage183. 
Subsequent investigations in different brain preparations also confirmed that the 
pharmacological or genetic blockade of the A2AR consistently decreased the infarted area 
and/ or the outcome (neurological score) upon ischemic insults184-186. Although the 
collected data are consistent in indicating the important role for A2AR in counteracting 
ischemia-induced brain damage, there are still open questions before to consider this 
receptor as a concrete therapeutic target. In fact, is not yet known the exact time window 
in which the A2A AR manipulation might be beneficial and if its blockade might only be 
considered as a prophylactic strategy or if it might also have therapeutic utilities187. Also 
the comprehension of the mechanisms underlying the A2AR ability to control ischemic 
neuronal damage should be tackled to ensure a sustained translational rationale. In fact, 
several evidences in animal models have suggested the possible involvement of 
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mechanisms, either controlling glutamate release188,189, central inflammatory processes 
and glial reactivity190-192 or the permeability of the blood-brain barrier193,194 and 
infiltration of peripheral myeloid cells195. Recent studies highlighted also that caffeine 
improves both the stroke recovery196 and post-traumatic injury197 thus suggesting to 
further investigate the potential therapeutic effects of A2AR antagonists in the regulation 
of the post ischemic recovery of brain function.  
 
➢ A2AAR in cerebral glial cells  
Many functional measurements (such as cAMP levels and cytokine release) in association 
with pharmacological tools have clearly shown the presence and function of A2ARs in glial 
cells. Expression of this receptor in glial elements both the striatum and the solitary tract 
has been also confirmed by electron microscopic studies198. Under physiological 
conditions, the A2A AR expression in microglia and astrocyte is usually low and frequently 
below the detection limit of histological methods (i.e., immunohistochemistry, 
autoradiography, or in situ hybridization)116,199,200. On the contrary, A2ARs in glial cells is 
overexpressed following the brain insults as clearly shown by double 
immunohistochemistry analysis, in which, A2A AR expression is increased in microglial cells 
and astrocytes of mouse substantia nigra at 24 h after 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP) intoxication. The induction of glial A2ARs by brain insults and 
inflammatory signals, couple with local increase in adenosine and proinflammatory 
cytokine levels (such as IL-1b, which further induces A2AR expression) and take part to an 
important feed-forward mechanism to locally control neuroinflammatory responses in 
the brain. Moreover, A2A AR in glial cells might be involved in complex actions regulating 
neuronal cell death (both, potentially deleterious as well as neuroprotective) and possibly 
other functions such as modulation of synaptic transmission. In astrocytes, A2AAR 
stimulation by extracellular adenosine increases astrocyte proliferation and 
activation201,202, inhibits the expression of iNOS and the production of NO203, as well 
regulates glutamate efflux by astrocytes 170. Regarding the microglial cells, activation of 
A2AARs has mixed effects on their proliferation, but clearly shows facilitating effects on 
the release of cytokines, including upregulation of cyclooxygenase 2 and release of 
prostaglandin E2 (PGE2)204. The A2AR stimulation at this level was also observed to be 
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effective in increasing the nitric oxide synthase (NOS) activity and NO release205 as well as 
the nerve growth factor expression206. 
 
1.3.5.2 A2AAR in cardiovascular disorders 
A2AARs are largely involved in coronary vascular control due to their expression in the 
smooth muscle and endothelium, where they induce vasodilation. The A2AAR-mediated 
coronary response seems to involve PKA activation, and some studies have indicated the 
participation of p38 MAPK and IP3 signaling207,208. It has also been reported that 
adenosine induces the generation of large amounts of nitric oxide, a well-known 
vasodilator, through A2AAR-mediated activation of endothelial nitric oxide synthase209. 
The cardioprotective actions of A2AARs are also related to their potent anti-inflammatory 
effects, and it has been proposed that A2AAR stimulation results in cardioprotection by 
reducing neutrophil accumulation210. Furtheremore, A2AAR overexpression has been 
associated with spontaneous calcium release from the sarcoplasmic reticulum in atrial 
fibrillation patients, and blocking A2AARs results incalcium inhibition211. Moreover, 
stimulation of A2AARs in human atrial myocytes can induce beat-to-beat irregularities in 
the calcium transient, thus suggests a novel role for A2AAR antagonists in atrial fibrillation: 
maintaining uniform beat-to-beat responses at higher beating frequencies212.  
 
1.3.5.3 A2AAR in Inflammation 
A2A receptor is coupled to a Gs protein and its stimulation leads to increased intracellular 
cAMP levels213, which is a key regulator of immune and inflammatory responses. cAMP 
exerts its functions mainly through the protein kinase cAMP-dependent (PKA) that 
activates the nuclear substrate cAMP responsive element-binding protein (CREB) by 
phosphorylation at the level of Ser-133214. This latter binds to the nuclear co-factor CBP 
and to p300, and the complex in turn modulates the expression of many genes by binding 
to cAMP responsive elements in their promoter regions214. Importantly, CREB can 
indirectly regulate the transcription of many inflammatory genes competing with nuclear 
factor-κB (NF-κB)/p65 for CBP215. The latter is probably one of the major mechanisms by 
which A2AR stimulation inhibits the transcriptional activity of NF-κB in a PKA/CREB-
dependent manner, subsequently suppressing the expression of pro-inflammatory 
cytokines, such as tumour necrosis factor (TNF-α). cAMP can also activate other 
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substrates such as EPAC 1 (exchange protein directly activated by cAMP), altering 
proinflammatory genes expression216. Related to this, Sands and collaborators 
demonstrated that following A2AR stimulation, the accumulation of cAMP and the 
activation of EPAC1 in vascular endothelial cells might inhibit proinflammatory cytokines-
induced Janus kinases (JAKs) and signal transducer and activator of transcription (STAT) 
pathways, effect related to the suppressor of cytokine signaling-3 (SOCS-3)217,218. 
Furtheremore, expression of A2AR was increased by lipopolysaccharide (LPS) or by 
inflammatory cytokines such as TNF-α and IL-1β because of the presence of putative NF-
κB consensus sites in its promoter region219-222. Hence, during inflammatory conditions 
the overexpression of A2AR by inflammatory cytokines could imply an endogenous 
protective mechanism avoiding devastating effects. A2AR essentially suppress 
inflammatory and immune responses by reducing production of many pro-inflammatory 
cytokines from different cell types. One of the first pieces of evidence on this matter was 
shown by Sullivan et al who highlighted that CGS21680 inhibits TNF-α production from 
monocytes and macrophages in response to microbial products, such as endotoxin223.At 
this regard, CGS21680-mediated effects on accumulation of pro-inflammatory cytokines, 
such as TNF-α and IL-12, in macrophages activated via Toll-like receptor (TLR) agonists or 
by cytokines, is related to cAMP-mediated inhibition of NF-κB, via inhibition of IκB 
phosphorylation224. CGS21680 have been also observed to be capable in stimulating 
cycloxygenase-2 expression in neutrophils thus increasing the capacity of these cells to 
produce prostanglandins E2, that have potent anti-inflammatory activities on leukocytes 
and other inflammatory cells225-228. Interestingly, in human neutrophils stimulated with 
known inflammatory agents, it has been recently demonstrated  that CGS21680 and other 
c-AMP-elevating compounds could regulate the expression profile of many genes, 
encoding transcription factors, enzymes and regulatory proteins, as well as cytokines and 
chemokines involved in molecular signaling pathways associated with the resolution of 
inflammation229. 
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1.3.6 A2B adenosine receptor 
 
 
Figure 6. Overview of A2BAR intracellular signaling pathways. A2BAR stimulation increases adenylate 
cyclase (AC) activity, cAMP production, and protein kinase A (PKA) phosphorylation. A2BAR enrollement 
activates phospholipase C (PLC)-β and increases Ca2+. Mitogen-activated protein kinases p38, ERK1/2, and 
JNK1/2 phosphorylation are induced by A2BAR activation21. 
  
The A2BAR is highly expressed essentially in peripheral organs including bowel, bladder, 
lung, vas deferens, and different cell types such as fibroblasts, smooth muscle, 
endothelial, immune, alveolar epithelial, cells, and platelets. In the CNS are found in 
astrocytes, neurons, and microglia230-232. Its expression is upregulated in different 
injurious conditions such as hypoxia, inflammation, and cell stress. A2BAR signaling 
pathways involve AC activation through Gs proteins, leading to PKA phosphorylation and 
enrollment of different cAMP-dependent effectors like exchange proteins, which are 
directly activated by cAMP (Epac). Moreover, A2BARs can stimulate PLC through the Gq 
protein, resulting in Ca2+ mobilization, and can regulate ion channels through their βγ 
subunits (Figure 6). This subtype acts as stimulator of MAPK activation in several cell 
models in both central and peripheral systems233. In addition, A2BARs have multiple 
binding partners that modulate A2BAR responses and functions; these include netrin-1, 
E3KARPP-EZRIN-PKA, SNARE, NF-κB1/ P105, and α-actinin-1. Netrin-1, the neuronal 
guidance molecule, induced during hypoxia, reduces inflammation by activating A2BAR, 
which inhibit neutrophils migration234. Interestingly, binding of A2BAR to P105 inhibits NF-
κB activity, thereby explaining its anti-inflammatory effects235. Furthermore, α-actinin- 1 
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might favor A2AAR and A2BAR dimerization, thus inducing A2BAR expression on the cell 
surface236. 
 
1.3.6.1 A2BAR in neurological diseases 
A2BARs are located in the CNS and spinal cord in low concentrations, while higher levels 
have been observed in astrocytes, in which A2BAR expression is upregulated following 
lipopolysaccharide (LPS) and hypoxic stimulation237. It has been reported that A2BAR 
blockade in the brain inhibits the inflammatory cascade and neuronal injury following 
global cerebral ischemia by interfering with the p38 pathway238. Whatever the case, 
A2BARs may have a potential indirect role in hypoxia/ ischemia as a consequence of 
angiogenesis resulting from increased endothelial cell functions 239. Recently, it has been 
shown in two different chronic pain models that A2BARs on myeloid cells contribute to 
pain perception by stimulating IL-6 receptor signaling and promoting immune-neuronal 
interactions240. Even more recently, secretion of IL-6 and a consequent increase in cell 
proliferation mediated by A2BARs and a pathway involving p38 has been observed in 
microglial cells, suggesting that this subtype may have a proinflammatory role241. 
However, an anti-inflammatory effect, linked to IL-10 production and TNF-α inhibition, 
has also been observed following the A2BAR activation242,243. 
 
1.3.7 A3 adenosine receptor 
The A3AR subtype expression has been found in a variety of primary cells, tissues, and cell 
lines. Low levels have been reported in the brain, where it is located in the thalamus, 
hypothalamus, hippocampus, cortex, and retinal ganglion cells, as well as at motor nerve 
terminals and the pial and intercerebral arteries. A3ARs are also expressed in microglia 
and astrocytes, and the inhibition of a neuroinflammatory response in these cells has 
been associated with their induction of an analgesic effect244. Despite A3AR is also known 
to exert cardioprotective effects, and to be greatly expressed in the coronary and carotid 
artery, its precise location in the heart has not yet been reported. At the peripheral level, 
however, A3AR has been found in enteric neurons, as well as epithelial cells, colonic 
mucosa, lung parenchyma, and bronchi. Moreover, A3AR is widely expressed in 
inflammatory cells like mast cells, eosinophils, neutrophils, monocytes, macrophages, 
foam cells, dendritic cells, lymphocytes, bone marrow cells, lymph nodes, chondrocytes, 
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and osteoblasts, where it regulates anti-inflammatory effects74. Interestingly, A3AR is 
overexpressed in several cancer cells and tissues and is therefore likely to have an 
important antitumoral role245. 
 
 
Figure 7. Overview of A3AR intracellular signaling pathways. A3AR stimulation triggers decrease of 
adenylate cyclase (AC) activity and cAMP production, activation of glycogen synthase kinase-3β (GSK-3β), 
and consequent decrease of β-catenin, cyclin D1, and c-Myc. Increase induced by A3AR activation of 
phospholipase C (PLC)-β and Ca2+, as well as of RhoA and phospholipase D (PLD) is shown. Mitogen-activated 
protein kinases p38, ERK1/2, and JNK1/2 phosphorylation are induced by A3AR activation21. 
 
A3ARs activates a variety of intracellular signaling by preferentially coupling to Gi proteins, 
by which they inhibit AC, and, a high concentrations of A3AR agonists, to Gq proteins or Gβγ 
subunits, thereby inducing an increase in both PLC and calcium (Figure 7). A reduction in 
cAMP results in PKA inhibition, which leads to an increase in glycogen synthase kinase-3β 
(GSK-3β); downregulation of beta-catenin, cyclin D1, and c-Myc; and reduction of nuclear 
factor (NF)-κB DNA-binding ability246. A different pathway from GPCR signaling—involving 
monomeric G protein RhoA and phospholipase D—is important for A3AR-mediated neuro- 
and cardioprotection. A3ARs are also known to regulate MAPK, PI3K/Akt, and NF-κB 
signaling pathways, by which they exert anti-inflammatory effects. Stimulation or 
inhibition of HIF-1 has been also proved to have protumoral and neuromodulatory effects 
in cancer cells and astrocytes, respectively245.  
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1.3.7.1 A3AR in neurological diseases 
Despite the A3ARs expression in the brain is not abundant as in the periphery, these 
receptors are influential in some neuronal diseases. In cerebral ischemia, A3ARs play an 
initial protective role in synergy with A1ARs by inhibiting excitatory synaptic transmission. 
However, longer activation raises excitotoxicity and the risk of damage through the 
activation of PKC and consequent calcium increase. This suggests that the protective or 
deleterious role of A3ARs depends on the severity and duration of the ischemic episode247. 
In addition, plastic changes in A3ARs may occur following prolonged stimulation by both 
agonists and antagonists before and after ischemia/ hypoxia with similar results248. 
Specifically, A3ARs affect glial functions by regulating cell migration and TNF-α production 
in microglial cells249-251. In astrocytes, it has been demonstrated that A3 ARs decrease HIF-
1 expression in both normoxic and hypoxic conditions thus inhibiting proinflammatory 
genes including those for inducible nitric oxide synthse and A2BAR and suggesting an anti-
inflammatory role of this AR subtype in the CNS237. A3ARs involvement in pain conditions 
has also been investigated even if with mixed results. Despite some studies, performed 
with nonselective ligands as well as KO mice, have attributed them a pronociceptive 
function, several other studies have suggested A3ARs as an antinociceptive drug target252-
254 . In fact, A3ARs agonists show beneficial effects in neuropathic pain models by 
inhibiting the mechano-allodynia onset after chronic constriction injury and by increasing 
the potency of classical analgesic drugs such as morphine and gabapentin255,256. 
Interestingly, the antinociceptive activity of these agents has been demonstrated in 
neuropathic pain induced by chemotherapy in animal models of bone metastasis 
associated with breast cancer54,244,257,258.  
 
1.4. Adenosine receptors oligomerization 
For long time, adenosine receptors have been thought to exclusively exist in a monomeric 
state. Monomeric receptors are sufficient to induce signaling260-263. At least some studies 
suggest signaling via dimers occurs only at higher receptor densities263. However, several 
studies highlighted that adenosine receptors can form dimeric, multimeric or oligomeric 
structures. Through self-association, homo-oligomers (“homomers”) can be formed. 
Hetero-oligomerization leading to “heteromers” may be the consequence of the 
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association between adenosine receptors and preferred partners, preferably other 
GPCRs, including other adenosine receptor subtypes. This event has been observed 
through several experimental techniques, mostly in artificial cell lines. The use of 
overexpressed recombinant receptors may result in the creation of many more oligomers 
than naturally exist. Furthermore, GPCRs contain hydrophobic regions that can 
oligomerize, even after solubilization in SDS. Hence, receptor dimerization or 
oligomerization may occur after solubilization in detergent without being representative 
of receptor structure and organization in the membrane. 
 
1.4.1 Adenosine homomers 
 
Despite four homomeric pairs might be possible for adenosine receptors (A1-A1, A2A-A2A, 
A2B-A2B, and A3- A3) only experimental reports for the occurrence of A1-A1 and A2A-A2A 
homomers have been published. 
➢ A1-A1 
The existence of A1 receptor homomers were observed for the first time in 1995 by Ciruela 
263 and then by Yoshioka264  in 2002 by using (different) antibodies against the wild-type 
adenosine A1 receptor and observing after the immunoprecipitation experiments, 
analyzed with Western blotting, the presence of higher order bands in some instances 
(e.g., in HEK293 cells expressing the human adenosine A1 receptor, but also in brain 
tissues). In another study, A1-A1 homomers, predominantly located at the cell surface, has 
been identified with BiFC (Bimolecular Fluorescence Complementation) techniques in 
CHO cells expressing yellow fluorescent protein (YFP)-tagged receptors265. 
➢ A2A-A2A  
The first experimental evidence of the A2A-A2A homodimer existence was reported in 2004 
by Canals and coworkers. The authors used both FRET (Fluorescence Resonance Energy 
Transfer) and BRET (Bioluminescence Resonance Energy Transfer) techniques as well as 
immunoblotting to show that in transfected HEK293 cells, overexpressed recombinant 
adenosine A2A receptors exist as both homodimers and monomers. A2A receptor 
homodimerization was also demonstrated by Vidi (2008) with BiFC techniques 266, who 
also used a combination of FRET and BiFC techniques to demonstrate that recombinant 
adenosine A2A receptors exist as higher order oligomers, consisting of at least three 
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monomers, at the plasma membrane of differentiated neuronal cells267. In another study, 
recombinant A2A-A2A homodimers, mainly located intracellularly, were identified with 
BiFC techniques in CHO cells expressing YFP-tagged receptors265. 
 
1.4.2 Adenosine heteromers 
 
Available evidence points to the interaction of both adenosine A1 and A2A receptors with 
other GPCRs, no direct data have been reported for adenosine A2B and A3 subtypes. 
➢ A1-A2A 
Ciruela and coworkers155 in 2006 investigated the heteromerization of adenosine A1 and 
A2A receptors. The two receptors are colocalized in striatal glutamatergic terminals, both 
pre- and postsynaptically. This was demonstrated in immunogold blotting and, after 
detergent solubilization, coimmunoprecipitation experiments. In HEK293 cells 
transfected with suitably tagged adenosine A1 as well as A2A receptors, evidence in BRET 
and TR- FRET experiments was found for a direct interaction between the two 
recombinant receptors. The major receptor-receptor interaction found appears to be an 
A2AR agonist produced reduction of A1R affinity. Therefore, at high concentrations of 
adenosine, which can activate A2ARs, an increase of glutamate release is found.                         
In astrocytes a similar mechanism maybe found involving A1R-A2AR heteromers which via 
Gi/o and Gs proteins modulate GABA transport268,269.  
➢ D2-A2A 
The heteromeric couple of adenosine A2A and dopamine D2 receptor is probably the 
deeply studied combination. Hillion and coworkers performed double 
immunofluorescence experiments with confocal laser microscopy showing substantial 
colocalization of recombinant adenosine A2A and dopamine D2 receptors in cell 
membranes of SH-SY5Y human neuroblastoma cells stably transfected with human D2 
receptor as well as in cultured striatal cells (2002)270. Heteromerization between the two 
detergent-solubilized receptors was demonstrated in coimmunoprecipitation 
experiments, for which membrane preparations were used from D2 receptor-transfected 
SH-SY5Y cells and from mouse fibroblast Ltk_ cells stably transfected with the long form 
of the human D2 receptor. In the latter case, the A2A receptor (doubletagged with 
hemagglutinin) was transiently cotransfected. Similar studies were done by Kamiya et al. 
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(2003) in HEK293 cells271. Resonance energy transfer techniques (BRET and FRET) with 
suitably tagged receptors were used to demonstrate the same heteromerization in intact 
HEK293 cells271,272. Heteromerization seemed to be constitutive and not ligand-induced, 
and involved the long C-terminal tail of the adenosine A2A receptor273 , in contrast to A2A 
receptor homomerization. Related to PD, a large wide of evidence clearly showed the 
important role of the A2A-D2 heteroreceptor complex in modulation of motor activity. In 
fact, due the allosteric receptor-receptor interactions in this complex, adenosine reduces 
the affinity of agonists for the D2 receptor thus behaving as negative modulator of D2 
receptor-mediated neurotransmission52,230,274. In this scenario, A2A AR antagonists have 
demonstrated therapeutic value in the treatment of PD because they potentiate 
dopamine D2 receptor-mediated neurotransmission. 
 
1.5 Adenosine receptors ligands 
Several chemical methods have been applied to obtain selective agonists and antagonists 
for all four AR subtypes (A1, A2A, A2B, and A3). Availability of selective compounds has 
facilitated research on therapeutic applications of modulating ARs and in some cases has 
provided clinical candidates. The Prodrug approach have been also applied to improve 
the bioavailability of some compounds and minimize side-effects. The A2A agonist 
regadenoson (Lexiscan®), a diagnostic drug for myocardial perfusion imaging, was the first 
selective AR agonist to be approved. Other selective ligands (agonists and antagonists) 
are or were undergoing clinical trials for a broad range of therapeutic applications, 
including capadenoson and tecadenoson (A1 agonists) for atrial fibrillation, or paroxysmal 
supraventricular tachycardia, respectively, apadenoson and binodenoson (A2A agonists) 
for myocardial perfusion imaging, preladenant and tozadenant (A2A antagonists) for the 
treatment of Parkinson's disease, and CF101 and CF102 (A3 agonists) for inflammatory 
diseases and cancer, respectively. 
 
1.5.1 Adenosine receptor agonists 
The structure–activity relationship (SAR) of adenosine analogues as AR agonists has been 
deeply investigated and almost all are  purine nucleoside derivatives, either adenosine  or 
xanthosine. One exception to this role is represented by the class of 2-aminopyridine-3,5-
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dicarbonitrile derivatives that act as agonists at ARs with different degrees of subtype 
selectivity275-277. 
 
➢ A1AR selective agonists 
In general, substitution of adenosine at the N6 -position with a wide range of alkyl, 
cycloalkyl, and arylalkyl groups henances selectivity for the A1AR. In addition, any 
modification at the N6-position prevents the action of adenosine deaminase, which 
rapidly degrades adenosine itself, in vivo. N6-Cycloalkyl substitution has been the most 
successful and general means of achieving selectivity for the A1AR.                                                               
N6-Cyclopentyladenosine (CPA) and its 2-chloro analogue (CCPA) are the most potent and 
selective A1AR agonists in wide use as pharmacological agents. The bicyclic analogue S-
ENBA shows subnanomolar affinity at the A1AR with lower residual affinity than CPA or 
CCPA for other AR subtypes278. Bayer Co. (Germany) discovered 2-amino-3,5-
dicyanopyridine derivatives, e.g. capadenoson, as non-nucleoside-derived adenosine 
receptor agonists275,279 (Figure 8). Several A1-selective adenosine derivatives, including, 
selodenoson, capadenoson, NNC-21-0136 and others have been clinically investigated for 
various indications (Figure 8). 
 
 
 
Figure 8. A1 AR agonists.280 
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Diagnostic and therapeutic uses 
A1-selective (partial) agonists have been clinically investigated for therapeutic application 
in paroxysmal supraventricular tachycardia, atrial fibrillation, angina pectoris or 
neuropathic pain. In this sense, partial agonists are preferred to avoid receptor 
desensitization and to possibly achieve a certain tissue selectivity of the effects. A1AR 
agonists have antiischemic effects in the heart and brain. Recently, A1AR activation was 
shown to mediate neuroprotective effects through microglial cells281. Various A1AR 
agonists have been shown to be neuroprotective in ischemic and seizure models. 
However, the peripheral side effects of A1AR agonists could be severe. The A1AR agonist 
NNC-21-0136 was previously in clinical development for the treatment of stroke and 
other neurodegenerative conditions282. A1AR agonists are of interest for applications in 
treating cardiac arrhythmias, and recently was suggested that a partial agonist of this 
subtype would have advantages over a full agonist for this use283. The A1AR-selective 
agonist selodenoson (Figure 8) has been in clinic trials for treatment of acute and chronic 
control of tachycardia and topical treatment of diabetic foot ulcers (Aderis 
Pharmaceuticals). It was formulated for intravenous administration to control heart rate 
during acute attacks and for oral administration in the chronic management of atrial 
fibrillation. The non-nucleoside AR agonist BAY 68-4986 (capadenoson) is under 
investigation for atrial fibrillation and for the treatment of angina.  
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➢ A2AAR selective agonists 
 
 
Figure 9. A2A AR agonists280. 
 
Regarding the SARs for the A2AAR agonists, introduction of (thio)ethers, secondary 
amines, and alkynes groups at the 2-position of adenosine enhanced A2AAR selectivity in 
many synthetic analogues. The presence of a 5′-N-alkyluronamide modification, as found 
in the potent nonselective agonist NECA (5′-N-ethyluronamide), tends to maintain or 
enhance the selectivity for the A2AAR. Also, the 2-(2-phenylethyl)amino modification of 
adenosine was particularly advantageous in increasing the affinity at the A2AAR and is 
present in an extended chain in CGS21680 . In some cases also substitutions at the N6 -
position have been observed to increase the affinity at the A2AAR. An example of this is 
the class of N6 -(2,2-diphenylethyl)adenosine analogues, such as UK-432097. 
Regadenoson (Lexiscan™)284 has been introduced as a diagnostic for stress testing due to 
its vasodilatatory effects, and apadenoson was developed for the same application. 
Several A2A-selective agonists including UK-432097, sonedenoson, and binodenoson have 
been clinically evaluated. Unfortunately, their potent hypotensive effects following the 
systemic administration was the main problem associated to the application of A2A 
agonists as anti-inflammatory agents. Recently, efforts have been undertaken to obtain 
A2A agonists which show site-specific action. A2A agonists, such as UK-432097 have been 
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developed for the treatment of bronchial inflammation (constructive pulmonary disease, 
COPD) by inhalation with limited systemic exposure285. As an alternative, 5′-phosphate 
prodrugs (Figure 9) of A2A agonists have been prepared to obtain a selective cleveage and 
release of the A2A agonist at inflammation site where ecto-5′-nucleotidase (CD73) is highly 
expressed286. 
 
Diagnostic and therapeutic uses 
The 2-substituted A2AAR agonist apadenoson and other analogues (binodenoson and 
sonedenoson,  were investigated as cardiovascular clinical candidates287-289. Some 
agonists are of interest for use as vasodilatory agents in cardiac imaging (like adenosine 
itself, marketed as Adenoscan®) and in suppressing inflammation290. Regadenoson 
(Lexiscan®) is already approved for diagnostic imaging291. Two selective A2A agonists 
developed by Adenosine Therapeutics (now Clinical Data) were selected for clinical trials 
as therapeutic agents for acute inflammatory conditions (ATL-1222, structure not 
disclosed) and ophthalmic disease (ATL-313). 
 
1.5.2 Adenosine receptor antagonists 
The prototypical AR antagonists were alkylxanthine derivatives such as the natural 
products caffeine and theophylline that behave as weak and nonselective AR antagonists. 
The structure–activity relationship (SAR) of xanthine derivatives as AR antagonists has 
been exhaustively investigated. The effects on the receptor subtype selectivity of 
substitution at the 1-, 3-, 7-, and 8-positions have been explored in detail292. However, 
several new highly selective AR antagonists are chemically diverse than the xanthines and 
contain non purine heterocyclic scaffolds (Figure 10-11). 
 
➢ A1AR selective antagonists. 
Introduction of aryl or cycloalkyl groups at the 8-position of the xanthine core structure 
led to high affinity and selectivity for the A1AR. For example, the 8-cyclopentyl derivative 
DPCPX (CPX) (Figure 10) is highly selective and showed nanomolar affinity at the rat A1AR 
and is still selective, to a lesser degree, at the human A1AR. A bicycloalkyl group is present 
in the 8-(3-noradamantyl) group of rolofylline293 (KW-3902, NAX). Another 8-bicycloalkyl 
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xanthine analogue naxifylline (BG9719, Figure 10) was even more selective for the A1AR, 
with a Ki ratio human A2A /A1 of 2400 compared with a ratio of 150 for rolofylline  
 
 
 
Figure 10. A1 AR antagonists280. 
 
Diagnostic and therapeutic uses 
Various A1AR antagonists, xanthines and non-xanthines, have been or are currently being 
explored for clinical applications294 for heart failure, and for improving renal function and 
treatment of acute renal failure. The 8-cyclopentyl derivative DPCPX has been in clinical 
trials for cystic fibrosis through a non-AR related mechanism295 . The highly selective A1AR 
antagonist L-97-1 (Endacea Inc.) is relatively well water-soluble and in late preclinical 
development for the treatment of asthma and sepsis296 . Disappointedly the low water-
solubility and low bioavailability of DPCPX, rolofylline, naxifylline and others has always 
been a problem in the development of A1AR antagonists297,298; thus, A1AR antagonists 
such as toponafylline and L-97-1 endowed with good water solubility are better clinical 
candidates. Some nonxanthine A1AR antagonists including  SLV 320299 (Solvay 
Pharmaceuticals) have also been shown to have high receptor subtype selectivity. SLV 320 
has been selected for clinical trials as an intravenous treatment for acute decompensated 
heart failure with renal impairment. 
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➢ A2AAR selective antagonists 
 
 
 
Figure 11. A2A AR antagonists280. 
 
Recent discoveries led to the identification of new A2A antagonists300-302. Modification of 
xanthines at the 8-position with alkenes (notably styryl groups) henanced the selectivity 
for the A2AAR. The 8-styrylxanthine istradefylline was among the first A2AAR antagonists 
reported (Figure 11). The phosphate prodrug MSX-3 and the L-valine ester prodrug MSX-
4 have been synthesized to improve the water-solubility of the potent and selective A2A 
antagonist MSX-2303,304. Both are now broadly used as pharmacological tools in particular 
for in vivo studies305,306. Replacement of the xanthine core with various heterocyclic ring 
systems has led to exceptionally high affinity and selectivity at the A2AAR. The 
triazolotriazine ZM241385, the triazolopyrimidine vipadenant and the 
pyrazolotriazolopyrimidine SCH442416 (structure not reported) are examples of highly 
potent A2AAR antagonists of later generation. ZM241385, in both tritiated and iodinated 
form, has been employed as a radioligand at the A2AAR. SCH442416 related compounds 
include preladenant (SCH 420814). The latter proved to be effective in phase II clinical 
trials for the treatment of Parkinson’s disease but it was discontinuetd in may 2013 since 
it showed scarse efficacy than the Placebo in phase III clinical trials. Novel A2A antagonists, 
such as the benzothiazole derivative tozadenant (Figure 11) that are structurally neither 
related to xanthines nor to adenine have been identified by highthroughput screening.  
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Diagnostic and therapeutic uses 
The well-known regulation of motor control mediated by A2ARs under conditions of 
dopamine depletion is solid enough to merit the clinical trials currently underway, which 
aim to demonstrate the therapeutic efficacy of A2AR antagonists in PD. Thus far, several 
A2AAR antagonists have been developed and brought to the clinical arena. Istradefylline 
is the only drug that has been approved, but only in Japan, in combination with levodopa 
(L-DOPA), and is currently awaiting global approval following new clinical trials performed 
by Kyowa Hakko Kirin. Indeed, the American Food and Drug Administration (FDA) has thus 
far not approved this drug, due to its lack of efficacy with respect to L-DOPA. Similarly, 
another A2AAR antagonist, Preladenant, did not significantly decrease off-time in 
comparison with a placebo. Tozadenant appears more promising, and following positive 
results from phase IIb trials, a phase III clinical study has begun for this A2AR antagonist308. 
Furthermore, a functional link between A2AAR and α-synuclein (α-Syn) has recently been 
reported, which may open new avenues. Indeed, A2AAR knockout (KO) mice prevented α-
Syn-induced toxicity309, and α-Syn aggregation and associated toxicity were reduced by 
A2AAR blockade, suggesting a strong relationship between these two proteins, which are 
both harmful in PD310. More extensively, the involvement of aberrant A2AAR signaling has 
been found in the pathogenesis of synucleinopathy, as its genetic deletion reduces 
hippocampal pathological α-Syn aggregation311. 
 
1.6 Oxidative Stress and Neurodegenerative Disorders 
As widely known, oxygen plays a central role for the survival and normal functions of most 
eukaryotic organisms. Along the respiratory chain, oxygen is partially converted, at low 
ratio, into superoxide, a basic free radical that can generates other reactive oxygen 
species (ROS). Cell metabolism could generate other free radicals from nitrogen, classified 
into the family of reactive nitrogen species (RNS). ROS and RNS at physiological 
concentrations have recently been proved to regulate several normal functions, such as 
regulation of signal transduction, induction of mitogenic response, and involvement in 
defense against infectious agents, etc.312 
ROS levels are under the control of antioxidant systems which are responsible for keeping 
their level constant in living organisms. These antioxidant systems are both enzymatic and 
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non-enzymatic. Breaking the balance by over production of ROS and/or reduction of 
antioxidants can be deleterious, and is termed oxidative stress. Under these conditions, 
excessive free radicals could freely pass through the plasma membrane, damaging the cell 
membrane via lipid peroxidation, modifying signal and structural proteins to lead to 
misfolding and aggregation, and oxidizing RNA/DNA to interrupt transcription thus 
resulting in gene mutation.  
 
1.6.1 Reactive oxygen species (ROS) 
 
 
 
Figure 12. Overview of the reactions leading to the formation of ROS. Green arrows represent lipid 
peroxidation. Blue arrows represent the Haber–Weiss reactions and the red arrows represent the Fenton 
reactions. The bold letters represent radicals or molecules with the same behavior (H2O2). SOD refers to the 
enzyme superoxide dismutase and CAT refers to the enzyme catalase.313  
 
ROS principal production sites include mitochondria, endoplasmic reticulum (ER), plasma 
membrane and cytoplasm. During the aerobic metabolism, the 1–2% of electrons leak 
from the electron transport chain and form O2•− by cycling the ubiquinol in the inner 
mitochondrial membrane. In this sense, the NADH-ubiquinone oxidoreductase (Complex 
I) and ubiquinol-cytochrome c oxidoreductase (Complex III) are the two enzymatic 
sources for O2•− production314. O2•− is also produced by cytochrome P450-dependent 
oxygenases in the ER of the liver, lung and small intestine315,316 as well as by NADPH 
oxidase (Nox) of phagocytes cell membrane317,318. Xanthine oxidase (XO), instead, 
provides for the O2•− and H2O2 in the cytosol319. In addition, O2•− is generated non-
enzymatically by transferring a single electron to oxygen by reduced coenzymes, 
prosthetic groups (e.g., flavins or iron sulfur clusters) or previously reduced xenobiotics314. 
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O2•− is the precursor of most ROS and a mediator in oxidative chain reactions. It is 
spontaneously converted or catalyzed by superoxide dismutases (SOD) into H2O2, which 
is then partially reduced to •OH in the presence of Fe2+ by the Fenton reaction320. NO•, 
istead, is enzymatically synthesized from L-arginine by the family of nitric oxide synthases 
(NOS), including neuronal NOS (nNOS), endothelial NOS (eNOS) and inducible NOS (iNOS), 
which are all located in the cytosol. On the contrary, mitochondrial NOS (mtNOS) and α-
isoform ofnNOS, are localized in the mitochondria where NO and O2•− lead to the 
formation of ONOO−.NO− as the result of NO reaction with Heme-Fe2+ while a NO+ 
originates from a reaction of NO with Heme-Fe3+, 321,322. 
 
1.6.2 Antioxidant systems 
ROS over-accumulation is counteracted in the body thanks to enzymatic and non-
enzymatic systems. Enzymatic antioxidants are divided into primary and secondary 
enzymatic defences. Regarding the primary defence, it consists of three important 
enzymes:  
• Superoxide dismutase (SOD) 
• Glutathione peroxidase (GPx) 
• Thioredoxin reductase (TR)  
• Catalase (CAT) [10]  
SOD converts O2•− to O2 and H2O2 which is destroyed by GPx to form H2O in the presence 
of the tripeptide glutathione (GSH). Thioredoxin reductase (TR) is also essential for keeping 
low levels of H2O2 by converting it into H2O and O2 as well323,324. CAT, another enzyme that 
converts H2O2 to H2O and O2, is present in the cells. Despite their high efficiency, the 
enzymatic antioxidant systems does not suffice thus forcing the human body to use non 
enzymatic resources able to maintain free radical at low levels. These include, ascorbic acid 
(vitamin C), α-tocopherol (vitamin E), glutathione (GSH) and flavonoids325. Ascorbic acid is 
effective in scavenging the superoxide radical anion, hydrogen peroxide, hydroxyl radical, 
singlet oxygen and reactive nitrogen oxide326, while Vitamin E stops the lipid peroxidation 
by donating its phenolic hydrogen to the peroxyl radicals forming tocopheroxyl radicals 
that are unreactive and unable to continue the oxidative chain reaction. Vitamin E is the 
principal lipid-soluble antioxidant found in plasma, red cells and tissues, allowing it to 
protect the integrity of lipid structures, mainly membranes327. These two vitamins also 
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display a synergistic behavior with the regeneration of vitamin E through vitamin C from 
the tocopheroxyl radical to an intermediate form, therefore reinstating its antioxidant 
potential328.  Glutathione (GSH) is an endogenous tripeptide, which is the most abundant 
thiol in most tissues. It plays a crucial role in the cellular protection against oxidative stress 
(Figure 13) being active at various different levels. In particular, it acts as a direct free 
radical scavenger by hydrogen atom donation, and the resulting much less reactive radicals 
decay bimolecularly or through an oxygen-dependent mechanism forming in both cases 
the GSH disulphide329 (GSSG). Moreover, GSSG can quench radicals through electron 
donation by short living disulphide radical anions330. GSH also acts as as a hydrogen donor 
for several other endogenous antioxidants such as ascorbate, which in turr regenerates α -
TOC331. In this way, GSH can potentiate the protective efficacy of a wide range of 
endogenous mechanisms that are active against different reactive intermediates. 
Flavonoids constitute the most important single group of polyphenols, acting as 
antioxidants by terminating free radical chain reactions. Flavonoids stop the oxidation of 
lipids and other molecules by the rapid donation of hydrogen atoms to radicals, becoming 
the phenoxy radical intermediates by themselves. However, these intermediates are 
relatively stable, and thus do not initiate further radical reaction. Other non-enzymatic 
antioxidants in the body, such as selenium, carotenoids, lipoic acid, coenzyme Q and 
melatonin were also recognized as nicely reported in recent reviews 325, 332. 
 
 
 
Figure 13. The pathways of the antioxidants: glutathione (GSH), Lipoic acid (LA), and dihydrolipoic acid 
(DHLA). LA and DHLA increase the efficiency of the vitamin C cycle and activate the vitamin E cycle. 333 
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1.6.3 Other antioxidants 
➢ Lipoic acid 
 
 
 
Figure 14. Chemical structure of Lipoic acid (LA) and dihydrolipoc acid (DHLA). 
 
Lipoic acid (LA, Figure 14) is an endogen organosulfur compound that plays an essential 
role in the metabolism as a cofactor for several mitochondrial enzymes334,335. It can be 
synthesized by a enzymatic reaction from octanoic acid or ingested with food336,337.LA is 
better known than its reduce form, dihydrolipoic acid (DHLA) and both forms have been 
demostrated to exert antioxidant properties338-341. The chemical reactivity of LA is mainly 
conferred by its dithiolane ring. The oxidized (LA) and reduced (DHLA) forms create a 
potent redox couple, in fact, it has been reported that LA/DHLA has a redox potential of 
−320 mV while the redox potential of GSH/oxidized glutathione is −240 mV. This 
difference suggests that DHLA is more effective in protecting from oxidative damage than 
GSH. The LA/DHLA couple has been called “universal antioxidant” since it is able to 
regenerate several antioxidants333.  Furtheremore, differently from ascorbic acid DHLA is 
not destroyed while quenching free radicals and can be recycled from LA. Several studies 
higlighted that LA and DHLA are able to inactivate hydroxyl radicals, hypochlorous acid, 
and singlet oxygen339. Recently, LA and DHLA were also shown to react with peroxynitrite 
(ONOO−), a highly reactive oxidant species resulting from the rapid reaction of nitric oxide 
(•NO) with superoxide anion (O2•−), which is thought to be the main mediator of all the 
nitric oxide cytotoxic effects. However, Trujillo and Radi showed that the direct reaction 
between the LA/DHLA couple with peroxynitrite was not fast enough to be effective under 
in vivo conditions342. In addition to its ability to directly quench ROS in biological systems, 
LA also exerts antioxidant effects by acting on transition metal chelation. In fact, LA is a 
potent chelator of divalent metal ions in vitro, and forms stable complexes with Mn2+, 
Cu2+, Fe2+, and Zn2+. It has been demonstrated that LA had a profound dose-dependent 
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inhibitory effect upon Cu 2+ -catalyzed ascorbic acid oxidation343. LA also inhibited Cu2+ 
catalyzed liposomal peroxidation. Futhermore, have been also reported the protective 
effect of R- LA on cortical iron content in aged rats with lowering age-related oxidative 
stress344. DHLA-mediated chelation of iron and copper in the brain showed also a positive 
effect in the pathobiology of Alzheimer’s disease by lowering free radical damage345. 
Lipoic acid (LA), is used in combination with epalrestat in the treatment of diabetic 
peripheral neuropathy (DPN) Experimental evidences higlighted that LA enhances nerve 
blood flow, reduces oxidative stress, and improves distal nerve conduction346. A study 
revelead that intravenous (IV) administrations of LA (600 mg IV/day) ameliorated the 
symptoms of neuropathy after 3 weeks347, with i.v. therapy being more effective than oral 
treatment348 (SMD =−2.8 vs SMD =−1.8).Epalrestat is an aldose reductase inhibitor that 
relieves oxidative stress and suppresses the polyol pathway, which delays the progression 
of DPN and effectively and safely improves both diabetic neuropathy symptoms and the 
motor nerve conduction velocity349-351. Accumulating evidence has shown that LA 
combined with epalrestat may be a viable alternative for patients with DPN due to its 
marked beneficial effect on clinical symptoms and nerve conduction velocity352.  
 
1.6.4 Oxidative stress 
 
Figure 15. Targets of free radicals313. 
The equilibrium between production and neutralization of ROS is very delicate, and in the 
case this balance tends to a ROS overproduction, the cells start to suffer the consequences 
of oxidative stress353. Under normal conditions ROS mediate and regulate physiological 
functions of the body while in case of an over-accumulation they lead to severe 
deleterious effects for cells, tissues and organs. Oxidative stress and ROS accumulation 
are the result of several conditions including injury, inflammation, aging or chronic 
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diseases. Alternatively, their overproduction might originate from a diminished ability in 
the elimination of ROS. These compounds pass freely through cell and nucleus 
membranes, causing the oxidation of biomacromolecules such as lipids, proteins and 
nucleic acids (DNA and RNA) (Figure 15). The ROS-induced lipid peroxidation leads to 
membrane leakage354, while oxidation of amino acids (especially cysteine residues) 
results in the formation of protein-protein cross-links with dysfunction of these proteins. 
DNA peroxidation induced by ROS interrupts gene transcription and causes gene 
mutations, microsatellite instability, and effects on transcription binding factor355. RNA is 
even more vulnerable to oxidative stress than DNA due to its generally single-stranded 
state and accessibility to the oxidant-producing mitochondria. As a consequence of these 
processes, high levels of ROS cause damage to various cellular components and ultimately 
result in cell death. ROS overproduction results in a number of chronic diseases typified 
by neurodegenerative diseases and also mediate therapeutic side effects, such as 
chemotherapy-induced neuropaty. 
 
1.6.5 Oxidative stress and neurodegeneration 
A common feature in neurodegenerative disorders is the presence of specific protein(s) 
including Tau and beta-amyloid (Aβ) for Alzheimer’s disease (AD), alpha-synuclein (αSyn) 
for Parkinson’s disease, mutant huntingtin protein (mHtt) for Huntington’s disease, and 
TAR DNA binding protein (TDP-43) for Amyotrophic lateral sclerosis. ROS mediate 
neurotoxicity in each of these diseases through the oxidative modifications of the 
hallmark protein. It is well known that AD is characterized by the presence of intracellular 
neurofibrillary tangles (NFT) and extracellular Aβ deposits. NFT mainly consist in bundles 
of paired helical filaments (PHF), whose major component being the microtubule-
associated protein Tau. At this regard, hyperphosphorylation appears to be the critical 
event in leading the Tau protein to an abnormal aggregation and alterated function and 
in which ROS seem to be actively involved. In AD, ROS can also activate the c-Jun N-
terminal kinases (JNK), p38 and deactivate protein phosphatase 2A (PP2A). JNK and p38 
promote the expression of Tau, and stimulate AβPP cleaving enzyme 1 (BACE1), causing 
Aβ1-42 accumulation which leads to activation of NADPH oxidase (Nox) and producion of 
additional O2•−, and results in Ca2+ influx to elicit excitatory neurotoxicity. Once 
phosphorylated, Tau and other cytoskeletal proteins are subject of modification by 
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carbonyl products of oxidative stress356,357 and consequent aggregation into fibrils356. 
Furtheremore, Aβ presence in senile plaques is considered to have a causal role in AD and 
related to this H2O2 at 100–250 μM results in increased levels of intracellular Aβ in human 
neuroblastoma SH-SY5Y cells358. Oxidative stress have been also demonstrated to induce 
accumulation of potentially neurotoxic Aβ peptide by inducing the amyloidogenic process 
of AβPP and increasing the activity of β-secretase359,360. Cerebral amyloid angiopathy is 
associated with most cases of AD and characterized by Aβ deposits in brain vessels361. 
Oxidative stress is found triggering the amyloidogenic pathway in human vascular smooth 
muscle cells by up-regulation of AβPP cleaving enzyme 1 (BACE1) expression and 
secretion of Aβ1–40 and Aβ1–42 with mediation of c-Jun N-terminal Kinase and p38 
MAPK362. Oxidative stress plays also a central role in the protein aggregation mechanism 
in PD. Post translational modifications of the αSyn induced by oxidative stress, including 
those by 4-hydroxy-2-nonenal (HNE-αSyn), nitration (n-αSyn), and oxidation (o-αSyn), 
have been observed in αSyn oligomerization. Especially the HNE-αSyn and n-αSyn tend to 
be more inclined in forming oligomers than the unmodified one. The cellular toxicity of 
HNE-αSyn is significantly higher than other postranslationally modified species363. Related 
to HD, the mHtt aggregation is actively involved in the pathogenesis of the disease. The 
mHtt can aggregate at distinctive conformations that have different neurotoxicity, and 
different conformations of mHtt exist in different brain regions in HD mice364. Oxidative 
modification of the aggregated mHtt facilitates an increase in the size of aggregates and 
changes the conformation of aggregated mHtt365. Furtheremore, oxidative stimulations 
have been found to enhance the polyglutamine-expanded truncated N-terminal 
Huntingtin aggregation and mHtt-induced cell death366.  
 
1.6.6 Oxidative stress and neuropatic pain 
Neuropathic pain (NP) is a common and unique type of chronic pain. In developed 
countries, about the 3% of the population suffer from NP. It manifests as spontaneous 
burning, shooting pain, hyperalgesia and in most patients is usually chronic. This condition 
is the result of several factors with impairment in nerve function. The pathophysiology is 
relatively complex and involves both central and peripheral mechanisms with alteration 
in the ion channel expression, neurotransmitter release, and pain pathways are involved 
in the pathophysiology of pain367. Although infomations on molecular basis of the 
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neuropathy are insufficient, it has been reported that oxidative stress might contribute to 
the pathophysiology of NP368. In fact, in chronic constriction injury (CCI) model of rat 
neuropathic pain, heat hyperalgesia was reduced by systemically injections of 
antioxidants369,370. Another study, in spinal nerve ligation (SNL) model of neuropathic 
pain, showed that systemic administration of ROS scavenger phenyl-N-tert-butylnitrone 
(PBN) relieved mechanical allodynia371. Furthermore, increased levels of the antioxidant 
enzyme SOD together with a reduction in the concentration of the ROS-scavenger 
glutathione have also been observed in the CCI model of rat neuropathic pain372. In 
addition to this, beneficial effects in reliefing the hyperalgesia in CCI-induced neuropathic 
rats was demonstrated after the intraperitoneal administration of the antioxidant N-
acetyl-cysteine372.  
Neuropathy is a commonly found condition with the oxaliplatin anticancer treatment. In 
fact, patiens treated with oxaliplatin tend to develop a neuropathic syndrome with 
paresthesia, dysesthesia, and pain adversely affecting the quality of the daily life until 
suspension of the therapy373. At this regard, in a rat model of painful oxaliplatin-induced 
neuropathy an important component of oxidative stress have been observed374. 
Furtheremore, high levels levels of carbonylated protein and thiobarbituric acid reactive 
substances in the plasma of oxaliplatin-treated rats are index of the resultant protein 
oxidation and lipoperoxidation, respectively. The same pattern of oxidation was revealed 
also in the sciatic nerve, and in the spinal cord where the damage reached the DNA 
level374. Treatment with the antioxidant derivatives silibinin and α-tocopherol (100 mgkg 
-1 per os) proved to be effective in preventing oxidative damage and reducing oxaliplatin-
dependent pain induced by mechanical and thermal stimuli. These compounds have been 
also demostrated to improve motor coordination and reverse about 50% of the 
oxaliplatin-induced behavioral alterations374
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Adenosine elicits its physiological effects interacting with four receptor subtypes, whose 
activation mediate many physiophatological functions. Among adenosine receptors, the 
A2A subtype have attracted much interest as druggable target for therapeutic intervention 
in neurodegenerative diseases95,101,124,163. The A2AAR is widely expressed in the CNS and 
is involved in the control of motor activity, learning, memory90, 375-377 and in 
excitotoxicity176,378. Blockade of A2AARs may be useful in brain disorders such as 
Parkinson’s disease (PD)53,379, cerebral ischemia232,380,381, Huntington’s disease176,378(HD), 
or Alzheimer’s disease382,383 (AD) and also affords benefits in some psychiatric 
disorders142. Thus, identification of new A2A AR antagonists remains an attractive goal in 
drug discovery. Also the A2A/A1 AR dual targeted antagonism have emerged as promising 
therapeutic approach for the treatment of PD107,109,384. A1 ARs are presinaptically 
expressed on striatal dopaminergic neurons where they inhibit dopamine release385,386. 
Hence, A1/A2A AR antagonists would both facilitate dopamine release (A1) and potentiate 
the post-synaptic response to dopamine (A2A). A1 AR are also located in the hippocampus, 
neocortex and limbic system which are brain areas implicated in the control of cognitive 
and emotive functions6. Thus, A1 AR antagonists could ameliorate cognitive impairments 
associated to PD since they improve performance in animal model of learning and 
memory109,384.  
The research group I joined has been interested for years in the design, synthesis and 
pharmacological evaluation of heterocycle derivatives as adenosine receptor antagonists. 
In searching for a new byciclic chemotype to obtain selective hA2A AR antagonists, a 
molecular simplification approach was applied to the 1,2,4-triazolo[4,3-a]quinoxaline-1-
one scaffold (Figure 16), successfully employed in the past to synthesize potent and 
selective antagonists of A1, A2A and A3 ARs387-391. Thus, the 8-amino-1,2,4-triazolo[4,3-a]-
pyrazine-3-ones series was designed, also considering that its synthetic accessibility 
would have permitted to functionalize the 6 position with different moieties (methyl, aryl, 
arylalkyl, heteroaryl) and the 2 position with suitable aryl and benzyl groups. 
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Figure 16. Molecular simplification of 1,2,4-triazolo[4,3-a]quinoxaline-1-one scaffold to obtain the new      
8-amino-1,2,4-triazolo[4,3-a]-pyrazin-3-ones series. 
 
Hence, this PhD thesis focused on the identification of new compounds designed to target 
the hA2AAR, or both the hA1 and hA2A ARs, and based on the 8-amino-1,2,4-triazolo[4,3-
a]pyrazin-3-one scaffold (Figure 16). 
 
2.1 Preliminary structure-affinity relationship investigations: synthesis of 
8-amino-2-aryl-1,2,4-triazolo[4,3-a]pyrazin-3-ones 1-10 
The first aim of the work was the synthesis of compounds 1-10 (Figure 17) to carry out a 
preliminar SAR study. Hence, a methyl and the bulkier and more lipophilic phenyl moiety 
were appended at the 6-position (R6), while different small subtituents (R), endowed with 
different electronic and lipophilic properties, were placed on the 2-phenyl ring. The R 
groups were also selected as suggested by the affinity data of the TQX series387. 
Anticipating the obtained binding activities, it was observed that the phenyl was better 
than the methyl group for the 6-position, while the unsubstituted phenyl ring at position 
2 emerged as the best group for obtaining an efficient hA2A receptor interaction.  
 
Figure 17. Modifications performed on the 2-phenyl and at the 6-position of the 8-amino-1,2,4-
triazolo[4,3-a]-pyrazin-3-one scaffold. 
 
The 2,6-diphenyl substituted compound 2 was the most notable within the first set of 
synthesized compounds, possessing nanomolar for hA1, hA2A and hA3 ARs (Ki = 10-13 nM). 
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Based on these premises, in the subsequent derivatives, the 2-phenyl was maintained 
unmodified while structural changes were made at the 6-phenyl level. 
 
2.2 Structural modifications on the 6-phenyl ring: synthesis of 8-amino-6-
aryl-2-phenyl-1,2,4-triazolo[4,3-a]pyrazin-3-ones 11-39 
 
Figure 18. Modifications on the 6-phenyl ring of the 8-amino-2-phenyl -1,2,4-triazolo[4,3-a]-pyrazin-3-
one scaffold. 
 
The subsequent modifications were carried out on the 6 phenyl ring of derivative 2, where 
substituents with different lipophilicity, electronic and steric properties (OR1, NO2, NH2, 
Br, Cl, Me) were introduced at 2, 3 and 4 positions (Figure 18). In particular, several alkoxy 
moieties, containing either linear, unsaturated, branched or cyclic alkyl and benzyl chains 
(compounds 18-28) were investigated at position 3 and 4. Introduction of hindering 
moieties was performed taking into account the SARs of different series of hA2A AR 
antagonists with similar size and shape, indicating that the presence of bulky substituents 
at suitable positions was often profitable for an effective and selective recognition of the 
hA2A AR380. 
 
2.3 Structural modifications to improve drug-like properties: synthesis of 8-
amino-1,2,4-triazolo[4,3-a]pyrazin-3-ones 40-61 and 62-68  
To expand SAR studies and especially to ameliorate the drug-like properties of these AR 
antagonists, a third set of compounds was designed and synthesized by derivatization of 
the -NH2 and -OH functions of the previously obtained derivatives 16, 37-39.  
First, hydrophilic substituents were used to decorate some triazolopyrazines (40-51, 
Figure 19). In particular, substituted piperazine rings were introduced at the ortho, meta 
and para position of the 6-phenyl ring (compounds 40-45). Furthermore, substituted 
piperidine, pyrrolidine and morpholine moieties were appended at the para position of 
the 6-phenyl ring by using different length linkers (derivatives 52-61, Figure 19) endowed 
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with diverse flexibility. These basic moieties were selected since they are a common 
feature of known potent and selective hA2A AR antagonists380 and are known to improve 
the drug-like properties of the compounds.  
 
Figure 19. Introduction of hydrophilic and/or basic moieties at the 6-phenyl level to improve drug-like 
properties.  
 
Next, the 6-phenyl ring of compound 2 was replaced with heteroaryl groups (2-furyl, 2-
(5-methylfuryl), 2-thienyl and 2-pyridyl) which were thought to enhance compound 
solubility (compounds 62-65, Figure 20). Derivatives 66-68 (Figure 20) featuring a benzyl 
chain at position 2, combined with a phenyl, a 2-furyl and a 2-(5-methylfuryl) at position 
6, were synthesized because the benzyl pendant, being more flexible than the 2-phenyl 
moiety, was thought to improve the solubility of the compounds. Combination of a benzyl 
with a 2-furyl substituent was also suggested by the binding results previously obtained 
in our pyrazolopyrimidine series392 in which this type of decoration shifted affinity toward 
the hA2A AR.  
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Figure 20. Introduction of heterocyclic moieties at the 6-position and of a benzyl pendant at position -2 
of the 8-amino-1,2,4-triazolo[4,3-a]-pyrazin-3-one scaffold (compounds 62-68) 
 
2.4 Design of dual hA2A AR antagonists-antioxidants: synthesis of 8-amino-
6-aryl-2-phenyl-1,2,4-triazolo[4,3-a]pyrazin-3-ones 74-86.  
Finally, a set of triazolopyrazines bearing a potential antioxidant function (compounds 74-
86) were designed because we envisaged as an attractive aim to combine in the same 
molecule the ability of blocking the hA2A AR and that of counteracting oxidative stress and 
ROS formation, the latter processes being among the main causes of cellular and neuronal 
degeneration. The oxidative stress state is a condition in which antioxidant defenses are 
overwhelmed and not able to protect cells from oxidative damage. With this in mind, 
substituted phenolic residues were placed at the 6-position of the bicyclic scaffold 
(compounds 74-78, Figure 21). 
 
 
Figure 21. Newly synthesized 8-amino-2-phenyl-1,2,4-triazolo[4,3-a]-pyrazin-3-ones featuring 
substituted phenol moieties at the 6-position 
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The choice of these 6-substituents ensued from the evidence that substituted phenolic 
compounds, together with polyphenolic rings, are a common feature of both natural and 
synthetic antioxidant compounds. At this regard, the phenolic endogenous antioxidant α-
tocopherol (Vitamin E), as well as natural phenolic acids such as hydroxycinnamic and 
hydroxybenzoic acids, deserve to be mentioned. These latter exert antioxidant activity as 
chelators and free radical scavengers with special impact over hydroxyl and peroxyl 
radicals, superoxide anions and peroxynitrites393,394. As synthetic antioxidant compounds, 
butylhydroxytoluene (BHT), butylhydroxyanisole (BHA) and tert-butylhydroquinone 
(TBHQ) can be mentioned. With regard to BHT, it is a well known antioxidant used for 
several products including food, pharmaceuticals etc395. Moreover, several studies 
indicated that compounds containing di-tert-butylphenol groups exert several biological 
functions including antioxidant, anti-inflammatory, anticancer activities396-399.  
Other groups, thought to exert antioxidant properties, were selected and appended, 
directly or through spacers, to the para-OH and para-NH2 function of derivatives 16 and 
39, respectively, to provide compounds 79-86 (Figure 22).  
 
Figure 22. Introduction of potential antioxidant moieties at 6-phenyl level of the 8-amino-2-phenyl -1,2,4-
triazolo[4,3-a]-pyrazin-3-one scaffold. 
 
The antioxidant lipoic acid (LA) residue (compounds 80, 82, 84) was selected since LA 
turned out to be effective in scavenging free radicals in polar media by a one-electron 
transfer mechanism333 and also exerts antioxidant effects by acting on transition metal 
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chelation333. There are also evidences, from both in vitro and physiological studies, that 
LA increases or maintains cellular GSH levels by acting as a transcriptional inducer of genes 
governing GSH synthesis400 (see “Introduction”). 
The (S)-2-oxothiazolidine-4-carboxylic acid residue (OTC, derivative 79, 81), together with 
the 3,5-di-tert-butyl-4-hydroxybenzoic acid (compounds 83, 85) and the 5-methyl-1,2-
dihydro-3H-pyrazol-3-one (compound 86) moiety, were also chosen for the ibridization 
approach. OTC is a prodrug of cysteine which acts as antioxidant since it is able to 
inactivate the hydroxyl radicals401 or maintain free sulfhydryl groups402. Introduction of 
the 3,5-di-tert-butyl-4-hydroxybenzoic acid residue was undertaken due to its structural 
similarity to the butylhydroxytoluene (BHT, see above) which is able to break radical chain 
reactions through atom transfer403. Instead, the 5-methyl-1,2-dihydro-3H-pyrazol-3-one 
ring was selected since it plays a key role in the antioxidant mechanism of edaravone, an 
approved drug for brain ischemia404 which turned out to to be effective also in 
counteracting the myocardial ischemic insult405. Edaravone can exist in three tautomeric 
forms A, B, C406-408 (Figure 23) and it is currently accepted that the anionic form is very 
effective in scavenging free radicals in polar media by a one-electron transfer 
mechanism409 (Figure 23, pathway A). 
 
 
Figure 23. Edaravone antioxidant mechanism of action. 
All the synthesized 8-amino-1,2,4-triazolo[4,3-a]pyrazin-3-ones 1-86 were investigated 
for their affinity and selectivity at hARs. Based on the binding data, some of the 
compounds endowed with the highest affinities at the hA1 and hA2A subtypes (13, 31, 32, 
68, 47, 78, 82, 84 and 85) were selected to determine their antagonistic properties by 
evaluating their effect on cAMP production in CHO cells, stably expressing the hA1 and 
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hA2A ARs. The same derivatives were further pharmacologically profiled to evaluate their 
potential protective effects in vitro models of neuroprotection.
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Scheme 1. a) NaNO2, 2-Chloroacetoacetate, NaOAc, MeOH 0-5 °C; b) 33% aqueous NH3, 1,4-dioxane, r.t.; 
c) absolute EtOH, Ethyl 2-amino-2-thioxoacetate K2CO3, r.t.; d) for 99-102, Triphosgene, anhydrous THF, 
r.t.;410 for 103, Carbonyldiimidazole, dichloromethane, r.t.; e) R6-COCH2Br, K2CO3, DMF/acetonitrile, r.t.; f) 
NH4OAc, mw or conventional heating 130-190 °C sealed tube; g) POCl3, mw or conventional heating, 140-
180 °C; h) NH3, absolute EtOH, 130 °C. For R2 and R6 see Table 2. 
 
The new 8-amino-1,2,4-triazolopyrazin-3-one derivatives 1-6, 11-13, 17, 29-36, 62-73 
were prepared as depicted in Schemes 1. The starting ethyl 2-arylhydrazono-2-
chloroacetates 90-93393,411,412 were prepared by reacting the suitable aryldiazonium 
chloride with ethyl 2-chloroacetoacetate, in the presence of sodium acetate in MeOH. 
Compounds 94-97413,414 were prepared by reacting the ethyl 2-arylhydrazono-2-
chloroacetates 90-93 with 33 % aqueous ammonia solution in 1,4-dioxane at room 
temperature, while ethyl 2-amino-2-(2-benzyl-hydrazono)acetate 98 was obtained by 
reacting benzylhydrazine dihydrochloride with ethyl 2-amino-2-thioxoacetate in absolute 
ethanol and in the presence of potassium bicarbonate. Treatment of derivatives 94-97 
with triphosgene yielded the ethyl 1-phenyl-5-oxo-1H-1,2,4-triazole-3-carboxylates 99-
102410,415. The 1-benzyl-substituted derivative 103, instead, was obtained by reacting 
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ethyl 2-amino-2-(2-benzyl-hydrazono)acetate 98 with carbonyldiimidazole in methylene 
chloride at room temperature416. N4-alkylation of 99-103 with commercial or properly 
synthesized α-aloketones in DMF/CH3CN, in the presence of potassium carbonate, 
afforded the ethyl 1-aryl-5-oxo-1,2,4-triazole-3-carboxylates 104-133 whose cyclization 
with ammonium acetate, performed by conventional heating or under microwave 
irradiation, gave the 1,2,4-triazolo[4,3-a]pyrazine-3,8-dione derivatives 134-163. The 
latter were chlorinated with phosphorus oxychloride, under microwave irradiation, to 
obtain the related 8-chloro derivatives 164-193 which were allowed to react with a 
saturated solution of ammonia, in absolute ethanol, to afford the desired 8-amino-1,2,4-
triazolo[4,3-a]pyrazine-3-one derivatives 1-6, 11-13, 17, 29-36, 62-73. 
 
 
Demethylation of the (methoxyphenyl) derivatives 3, 4, 6, 11-13 with 1M solution of BBr3 
in methylene chloride gave the corresponding (hydroxyphenyl)-substituted compounds 
7-9, 14-16 (Scheme 2). 
    Table 2. R6 R2  R6 R2 
104, 134, 164, 1 
105, 135, 165, 2 
106, 136, 166, 3 
107, 137, 167, 4 
108, 138, 168, 5 
109, 139, 169, 6 
110, 140, 170, 11 
111, 141, 171, 12 
112, 142, 172, 13 
113, 143, 173, 17 
114, 144, 174, 29 
115, 145, 175, 30 
116, 146, 176, 31 
117, 147, 177, 32 
118, 148, 178, 33 
           Me 
            Ph 
           Me 
            Ph 
            Ph 
            Ph 
    C6H4-2-OMe 
    C6H4-3-OMe 
    C6H4-4-OMe 
    C6H4-4-Me 
C6H4-3,4-OCH2O 
      C6H4-3-Br 
      C6H4-4-Br 
      C6H4-3-Cl 
      C6H4-4-Cl 
        Ph 
        Ph 
C6H4-4-OMe 
C6H4-4-OMe 
C6H4-4-NO2 
C6H4-2-OMe 
        Ph 
        Ph 
        Ph 
        Ph 
        Ph 
        Ph 
        Ph  
        Ph 
        Ph 
119, 149, 179, 34 
120, 150 ,180, 35 
121, 151, 181, 36 
122, 152, 182, 62 
123, 153, 183, 63 
124, 154, 184, 64 
125, 155, 185, 65 
126, 156, 186, 66 
127, 157, 187, 67 
128, 158, 188, 68 
129, 159, 189, 69 
130, 160, 190, 70 
131, 161, 191, 71 
132, 162, 192, 72 
133, 163, 193, 73 
C6H4-2-NO2 
C6H4-3-NO2 
C6H4-4-NO2 
2-furan 
2-(5-methylfuryl) 
2-thienyl 
2-pyridyl 
Ph 
2-furan 
2-(5-methylfuryl) 
C6H4-2,4-diOCH3 
C6H4-3,4-diOCH3 
C6H4-3,4-triOCH3 
C6H4-4-OCH3-3,5-diCH3 
C6H4-4-OCH3-3,5-di-t-but 
   Ph 
   Ph 
   Ph 
   Ph 
   Ph 
   Ph 
   Ph 
CH2Ph 
CH2Ph 
CH2Ph 
   Ph 
   Ph 
   Ph 
   Ph 
   Ph 
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Scheme 2. a) BBr3 1M in dichloromethane, anhydrous dichloromethane, 0 °C, r.t. 
 
Finally, the (nitrophenyl) derivatives 5, 34-36 were reduced (H2, Pd/C) in a Parr apparatus 
to yield the corresponding (aminophenyl) derivatives 10, 37-39 (Scheme 3). 
 
 
Scheme 3. a) H2, Pd/C, DMF, Parr apparatus, 40 psi, r.t. 
 
The 6-(alkoxyphenyl) compounds 18−28 (Table 3) were synthesized as outlined in Scheme 
4, i.e. by alkylation of the 6-(hydroxyphenyl) derivatives 15 or 16 with the suitable alkyl 
bromides in refluxing 2-butanone and in the presence of potassium carbonate. 
 
Scheme 4. a) Alkyl bromide, K2CO3, 2-Butanone, reflux. 
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           Table 3.  
 
 
 
 
It has to be pointed out that the 6-aminophenyl substituted compounds 37-39 and the 6-
(4-hydroxyphenyl) derivative 16 were employed as key intermediates for the synthesis of 
the new sets of compounds 40-61 and 79-86. 
The 2-phenyl-triazolopyrazines 40-61, bearing, on the 6-phenyl ring, substituents which 
were thought to enhance water solubility and drug-like properties, were synthesized as 
depicted in Scheme 5-9. Compounds 40-42, featuring a piperazine residue at the three 
positions of 6-phenyl moiety, were achieved as described in Scheme 5. The piperazine 
ring was constructed by alkylation of the aromatic amino group of derivatives 37-39 with 
bis(2-chloroethyl)amine in sulfolane at 150 °C. Reaction of the 6-(3-piperazin-1-yl)-
substituted compound 41 with methyl iodide gave rise to the N,N-dimethylpiperazinium 
salt 43 while allowing to react compounds 41 and 42 with benzyl bromide, the respective 
N-benzylpiperazin-1-yl-derivatives 44 and 45 were obtained. 
 
Scheme 5. a) Bis(2-chloroethyl)amine hydrochloride, sulfolane, 150 °C; b) From 41, CH3I, anhydrous DMF, 
r.t.; c) From 41 and 42, Benzyl bromide, Et3N, anhydrous 1,4-dioxane, reflux. 
Derivatives 46-50, featuring small hydrophilic chains on the para position of the 6-phenyl 
ring, were synthesized as outlined in Scheme 6. Reaction of the 6-(4-hydroxyphenyl)-
 R  R 
18 3-O-propargyl 24 4-O-iC3H7 
19 4-O-propargyl 25 4-OCH2-iC3H7 
20 3-OCH2Ph 26 4-OCH2cC3H5 
21 4-OCH2Ph 27 4-OCH2cC4H7 
22 4-OC2H5 28 4-OCH2-CH=CH2 
23 4-O-nC3H7  
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derivative 16 with suitable alkyl halides and in presence potassium carbonate in 
anhydrous acetone, afforded the desired 6-(4-O-alkylated) compounds 46 and 47. 
Reduction of the nitrile 47 with lithium aluminium hydride in anhydrous THF at room 
temperature gave the corresponding 6-(4-(2-aminoethoxy)phenyl compound 48. 
Compounds 49 and 50 were achieved by reacting the 6-(4-hydroxyphenyl) intermediate 
16 with ethylene carbonate, in presence of potassium carbonate and in anhydrous DMF 
at 110 °C, (compound 49) or with 3-chloropropane-1,2-diol in anhydrous acetonitrile at 
room temperature (compound 50). 
 
 
Scheme 6. a) Chloroacetamide (for compd. 46) or Chloroacetonitrile (for compd. 47), K2CO3, anhydrous 
acetone, r.t.; b) from 47, LiAlH4, anhydrous THF, 0 °C; c) Ethylene carbonate, K2CO3, anhydrous DMF, 110 
°C; d) 3-Chloropropane-1,2-diol, K2CO3, anhydrous Acetonitrile, r.t. 
 
Other basic hydrophilic functions were appended, by suitable spacers on the para-
position of the 6-phenyl ring (Schemes 7, 8 and 9). Reaction of the 6-(4-aminophenyl)-
derivative 39  with 3-chloropropionic acid in presence of EDCI hydrochloride,                                                                                    
DIPEA in anhydrous DMF, gave the N-(4-(8-amino-3-oxo-2-phenyl-2,3-dihydro-
[1,2,4]triazolo[4,3-a]pyrazin-6-yl)phenyl)acrylamide 194 which was treated with a 
saturated ammonia solution at 130 °C in absolute ethanol to afford 3-amino-N-(4-(8-
amino-3-oxo-2-phenyl-2,3-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-6 
yl)phenyl)propanamide 51. Instead, the 8-amino-1,2,4-triazolopyrazin-3-one derivatives 
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52-55, bearing in the side chain cyclic amines, were achieved by refluxing the 
intermediate 194 with the suitable amine in anhydrous THF (Scheme 7). 
 
 
Scheme 7. a) 3-Chloropropionic acid, EDCI.HCl, DIPEA, anhydrous DMF, r.t.; b) NH3, absolute EtOH, 130 
°C; c) Cyclic amine, anhydrous THF, reflux. 
 
Reaction of the 6-(4-(2-hydroxyethoxy)phenyl) derivative 49 with thionyl chloride in 
anhydrous toluene, and in presence of pyridine, afforded the 6-(4-(2-
chloroethoxy)phenyl) derivative 195 which was reacted with suitable cyclic amines in 
presence of potassium carbonate, and catalytic amount of potassium iodide, in anhydrous 
DMF at 110 °C, to yield the desired final compounds 56-59 (Scheme 8).  
 
 
 
Scheme 8. a) SOCl2, pyridine, anhydrous toluene, reflux; b) Cyclic amines, K2CO3, KI, anhydrous DMF, 110 
°C. 
 
Treatment of the 6-(4-hydroxyphenyl)-derivative 16 with epichlorohydrin, potassium 
carbonate in anhydrous acetonitrile at 85 °C, afforded the 6-(oxiran-2-ylmethoxy)phenyl 
substituted derivative 196 which was reacted with piperidine or morpholine, in boiling 
ethanol and in presence of potassium carbonate, to yield the desired triazolopyrazines 
60-61 (Scheme 9). 
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Scheme 9. a) Epichlorohydrin, K2CO3, anhydrous acetonitrile, reflux; b) Cyclic amines, K2CO3, absolute 
EtOH, reflux. 
 
Finally, a set of 8-amino-1,2,4-triazolopyrazin-3-one derivatives 74-86, containing 
moieties which were thought to confer antioxidant properties were synthesized (Scheme 
10-14). Compounds 74-77, bearing substituted phenolic rings at position 6, were obtained 
by reacting the corresponding methoxy derivatives 69-72 with BBr3 1M dichloromethane 
solution in anhydrous methylene chloride at room temperature. This conditions did not 
work to demethylate the 3,5-di-tert-butyl-4-methoxyphenyl-derivative 73, due to the 
steric hindrance of the two tert-butyl groups. More drastic conditions, i.e. 48% aqueous 
HBr in boiling acetic acid, permitted demethylation of 73, but also caused elimination of 
one tert-butyl group, thus affording the 3-(tert-butyl)-4-hydroxyphenyl derivative 78 
(Scheme 10).  
 
Scheme 10. a)  from 69-72, BBr3 1M in dichloromethane, anhydrous dichloromethane, r.t.; b) from 73, 
48% HBr, acetic acid, reflux. 
The set of 8-amino-1,2,4-triazolopyrazin-3-one derivatives 79-86, featuring different 
possible antioxidant groups on 6-phenyl ring, were synthesized as depicted in Schemes 
11-14. Compounds 79, 80 were prepared as shown in Scheme 11, i.e. starting from the 6-
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(4-aminophenyl)-derivative 39 which was reacted at room temperature with (S)-2-
oxothiazolidine-4-carboxylic acid (compound 79) or racemic lipoic acid (compound 80) 
and EDCI hydrochloride, 1-hydroxybenzotriazole hydrate, DIPEA, in anhydrous DMF. 
 
Scheme 11. a) (R) Oxothiazolidine-4-carboxylic acid, EDCI.HCl, DIPEA, HOBt.H2O, anhydrous DMF, r.t.;                
b) (R, S) Lipoic acid, EDCI.HCl, DIPEA, HOBt.H2O, anhydrous DMF, r.t. 
 
Compounds 81-83 were synthesized by reacting the 4-(2-aminoethoxy)phenyl derivative 
48 with the suitable carboxylic acids and in the same experimental conditions described 
above to prepare 79 and 80 from 39 (Scheme 12).  
 
Scheme 12. a) (R) Oxothiazolidine-4-carboxylic acid, EDCI.HCl, DIPEA, HOBt.H2O, anhydrous DMF, r.t.; b) 
(R, S) Lipoic acid, EDCI.HCl, DIPEA, HOBt.H2O, anhydrous DMF, r.t.; b) 3,5-Di-tert-butyl-4-hydroxy-benzoic 
acid, EDCI.HCl, DIPEA, HOBt. H2O, anhydrous DMF, r.t.                                                                                                                                                                                   
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The same procedure was employed to prepare the novel 8-amino-1,2,4-triazolo[4,3-
a]pyrazin-3-ones 84 and 85 (Scheme 13) starting from the amino derivative 51.  
 
Scheme 13. a) (R, S) Lipoic acid, EDCI.HCl, DIPEA, HOBt.H2O, anhydrous DMF, r.t.; b) 3,5-Di-tert-butyl-4-
hydroxy-benzoic acid, EDCI.HCl, DIPEA, HOBt.H2O, anhydrous DMF, r.t.  
 
Compound 86, bearing the 5-methyl-1,2-dihydro-3H-pyrazol-3-one ring on the lateral 
chain, was obtained starting from intermediate 194 which was reacted with hydrazine 
monohydrate in anhydrous THF at reflux to give the corresponding 3-
hydrazinylpropanamide 197. Cyclization of the latter with ethyl acetoacetate in ethanol 
at 60°C afforded the desired final compound (Scheme 14).  
 
Scheme 14. a) Hydrazine.hydrate, anhydrous THF, reflux; b) Ethyl acetoacetate, EtOH, 60 °C
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4. RESULTS AND DISCUSSION 
The 8-amino-1,2,4-triazolo[4,3-a]pyrazin-3-ones 1-86 were evaluated for their affinity to 
hA1, hA2A, and hA3 ARs, stably transfected in Chinese hamster ovary (CHO) cells, and were 
also tested at the hA2B AR subtype by measuring their inhibitory effects on 5′-(N-ethyl-
carboxamido)adenosine (NECA)-stimulated cAMP levels in hA2B CHO cells. These studies 
were performed in collaboration with the group of Professor R. Volpini, from the 
University of Camerino. With the aim to rationalize the results obtained from 
pharmacological assays, the synthesized compounds were subjected to a molecular 
modeling investigation at the A2AAR crystal structure. These studies were performed by 
the group of Professor Dal Ben, from the University of Camerino. As previously discussed 
in the “Aim of the Work”, the synthesized compounds have been subdivided into four sets 
which reflect the different phases of the work. The same division was applied to SAR 
discussion. 
 
4.1. Preliminary structure-affinity relationship investigations of 8-amino-2-
aryl-1,2,4-triazolo[4,3-a]pyrazin-3-ones 1-10  
 
                 Table 4                                                           
 
Binding experiments 
Ki (nM)a 
cAMP assays 
IC50 (nM)a 
 R6 R2 hA1b hA2Ac hA3d hA2Be 
1 CH3 H 67 ± 8 485 ± 39 4370 ± 355 >30000 
2 C6H5 H 13 ± 1 10 ± 3 11 ± 2 >30000 
3 CH3 4-OCH3 1743 ± 514 1038 ± 271 255 ± 21 >30000 
4 C6H5 4-OCH3 20 ± 5 78 ± 18 117 ± 26 >30000 
5 C6H5 4-NO2 8.1 ± 2.5 402 ± 91 >30000 >30000 
6 C6H5 2-OCH3 247 ± 31 309 ± 37 392 ± 60 >30000 
7 CH3 4-OH 1000 ± 128 1319 ± 184 5159 ± 752 >30000 
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aData (n = 3−5) are expressed as means ± standard errors. bDisplacement of specific [3H]-CCPA binding at 
hA1 AR expressed in CHO cells. cDisplacement of specific [3H]-NECA binding at hA2A AR expressed in CHO 
cells. dDisplacement of specific [3H]-HEMADO binding at hA3 AR expressed in CHO cells. eIC50 values of the 
inhibition of NECA-stimulated adenylyl cyclase activity in CHO cells expressing hA2BAR. fKi values (nM) from 
radioligand binding assays, for DPCPX417, for NECA418 and CCPA. gEC50 value (nM) of the stimulation of 
adenylyl cyclase activity in CHO cells expressing hA2B AR. 
 
As anticipated above, the first purpose of the work was to perform a preliminary 
investigation of the SARs of this new series and to identify new hA2A AR antagonists. In 
the early stage of the project, structural modifications were carried out to evaluate which 
group, between the methyl and the phenyl, was the better for the 6 position. Analyzing 
the binding data of the 8-amino-2-phenyl-1,2,4-triazolo[4,3-a]pyrazin-3-ones 1-10, the 
2,6-diphenyl-substituted derivative 2 turned out to be notable, showing high and 
comparable affinities at hA1, hA2A and hA3 ARs (Ki = 10-13 nM). The 6-methyl-2-phenyl 
derivative 1 instead (Ki = 67-4370 nM) was significantly less active, in particular for the 
targeted hA2A AR. The para-hydroxy substituent inserted on the 2-phenyl ring of 1 and 2 
was chosen because in the TQX series388 it was profitable for A2A AR affinity. The 2-(4-
hydroxyphenyl)-substituted derivatives 7 and 8 were less active at the hA2AAR than the 
unsubstituted compounds 1 and 2 and also than their methoxy substituted synthetic 
precursors 3 and 4. The last two derivatives showed, on the whole, lower affinities for 
both hA1 and hA2A ARs than their parent compounds 1 and 2. The comparison of AR 
affinity data for the 6-phenyl derivatives 2 (Ki hA2A = 10 nM), 4 (Ki hA2A = 78 nM) and 8 (Ki 
hA2A = 138 nM) with those of the corresponding 6-methyl derivatives 1 (Ki h A2A = 485 
nM), 3 (Ki hA2A 1038  = nM) and 7 (Ki hA2A = 1319 nM) highlighted that the 6-phenyl moiety 
is more advantageous than the methyl one, probably due to its higher lipophilicity and/or 
capability to enhance the structural complementarity of the whole molecule with the 
receptor binding site. Thus, subsequent investigations were carried out on the 6 phenyl 
8 C6H5 4-OH 18 ± 2 138 ± 28 429 ± 89 >30000 
9 C6H5 2-OH 47 ± 9 232 ± 47 1558 ± 393 >30000 
10 C6H5 4-NH2 8.9 ± 1.1 3480 ± 398 650 ± 143 >30000 
 DPCPX  2.8 ± 0.5 125 ± 21 3850 ± 762  989 ± 22g 
73.24 ±2.0f 
 NECA  4.6 ± 0.8 16 ± 3 12.8 ± 2.5 1510 ± 210g 
1890f 
 CCPA  1.2 ± 0.2 2050 ± 400 26 ± 5 16850 ± 320g 
18800f 
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substituted compound 2 which was modified by introducing a para-amino group 
(compound 10), as suggested by affinity data for the TQX series388. Compound 10 (Ki hA2A 
= 3480 nM), as well as its synthetic precursor 2-(4-nitrophenyl) derivative 5 (Ki hA2A = 402 
nM) did not show enhanced affinity for the hA2A AR with respect to the lead 2. On the 
contrary, hA1 AR affinities of 5 and 10 were very high (Ki = 8.1 and 8.9 nM) and similar to 
that of 2 (Ki hA1 = 13 nM). The presence of a methoxy or hydroxy group at the ortho 
position of the 2-phenyl ring proved to be disadvantageous for the recognition of both 
hA2A and hA1 ARs. In fact, compounds 6 (Ki hA2A = 309 nM) and 9 (Ki hA2A = 232 nM) are 
significantly less active than 2 (Ki hA2A = 10 nM). 
 
4.1.1. Molecular modeling studies 
The binding mode of the synthesized compounds at the hA2A AR cavity was simulated with 
docking analysis by using the Molecular Operating Environment (MOE, 2014.09) docking 
tool and Gold and Autodock software419-422. For the docking tasks, two crystal structures 
of the hA2A AR in complex with the antagonist/inverse agonist ZM241385 were employed 
(PDB 3EML, 2.6 Å resolution, and PDB 4EIY, 1.8 Å resolution)423-425. The MOE software 
analysis was made by selecting the induced fit docking and optimization protocol 
(schematically, a preliminary docking analysis provides a set of ligand conformations that 
are energy minimized, including inthis step the side chains of the receptor residues in 
proximity). The docking analysis was performed with different docking tools and two 
different crystal structures of the target to get an average prediction of the binding mode 
of the synthesized compounds at the binding cavity. The docking results at the hA2A AR 
show that the molecules could bind to the pocket of this receptor with a preferred 
orientation (“type-one” conformations), presenting the substituent at the 2-position 
located in the depth of the cavity and the R6 group at the entrance of the binding site 
(Figure 24, A).  
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Figure 24. (A) General binding mode of the synthesized compounds atthe hA2A AR (pdb 4EIY) binding 
cavity, with indication of some key receptor residues. (B) Schematic description of the ligand−target 
interaction (built with MOE software). 
 
The scaffold adopts a position that makes it able to interact with Asn 2536.55 and Glu169 
(EL2) through H-bond contacts, while a π−π interaction is present between the phenyl 
ring of Phe168 (EL2) and the bicyclic core of the compounds (Figure 24, B). This interaction 
is very similar to the one given by the cocrystallized hA2A AR antagonist ZM241385423-425 
and by other structural classes of hA2A AR ligands previously described393,426. A second 
binding mode (“type-two” conformations) simulated by docking experiments presents 
the scaffold oriented in the opposite way with respect to the conformations described 
above, the 6-substituent being located in the depth of the cavity and the 2-substituent 
pointing toward the extracellular environment. This second binding mode is generally not 
preferred at the hA2A AR, being associated with lower docking scores than those of the 
above-described docking conformations, except for derivatives presenting ortho-
substituent on the 2-phenyl ring (see below). Compound 2 can be considered the 
reference ligand of the series, as it bears two unsubstituted phenyl rings at the 2 and 6 
positions. This derivative showed good affinity at the hA1 AR, hA2A AR, and hA3 AR, and 
this makes it a sort of passe-partout for the three ARs. Docking results of compound 2 at 
the three AR structures showed that it may be inserted in the receptor cavities with the 
two binding modes, both associated with good docking scores (the “type-one” generally 
preferred). The possibility of making more than one complex with the same receptor 
could result in good affinity, and this feature could be applied at the three ARs. The 
substituents inserted on the 2-phenyl group modulate the interaction with the binding 
pocket. In detail, the presence of small groups at the para-position generally affords 
decreased hA2A AR affinity with respect to the corresponding analogues with an 
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unsubstituted 2-phenyl ring (compare derivatives 3 and 7 with 1 and compounds 4, 5, 8, 
and 10 with 2). This result was interpreted considering various parameters. The first is the 
topological complementarity of the ligand with the binding pocket (Figure 25, A). 
The presence of a para-substituent on the 2-phenyl ring seems to cause a slight 
displacement of the ligand that decreases its ability in establishing some crucial 
interactions with the receptor (i.e., H-bonds with Asn2536.55 and Glu169) with respect to 
the compounds with an unsubstituted 2-phenyl ring. Second, hA2A AR affinities may be 
rationalized by docking results also considering that the depth of the binding cavity is 
mainly hydrophobic. Hence, a nonpolar group at the paraposition of the 2-phenyl ring, 
such as the methoxy group of 4 (Ki = 78 nM), would afford a slightly better interaction 
with the target when compared to a more polar group at the same position such as the 
OH group of 8 (Ki = 138 nM). On this basis, we conclude that a para-substituent on the 2-
phenyl ring is fairly allowed for these compounds and, if present, should be a small 
hydrophobic function. Introduction of a substituent (OMe, OH) at the ortho position of 
the 2-phenyl ring of compound 2 afforded derivatives 6 and 9, endowed with 20−30-fold 
reduced hA2AAR affinity. Docking results suggest that these compounds preferentially 
adopt the “type-two” orientation with the 2-aryl pendant located at the entrance of the 
cavity and the R6 group positioned in the depth of the pocket (Figure 25, B). In this way, 
the ortho-hydroxy group of derivative 9 could give some polar interaction with Glu169 
(EL2). 
  
Figure 25. (A) Molecular surface representation of the A2A hAR binding cavity (yellow) and the bound 
ligand (red) indicating the topological complementarity of the ligand and the cavity in the depth of the 
binding pocket. (B) Alternative binding mode of the synthesized compounds at the hA2A AR (pdb 4EIY) 
binding cavity, with indication of some key receptor residues. This binding mode was particularly 
observed for compounds presenting an ortho-substituted phenyl ring at position 2. 
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4.2 Structural modifications on the 6-phenyl ring: 8-amino-6-aryl-2-phenyl-
1,2,4-triazolo[4,3-a]pyrazin-3-ones 11-39  
 
Table 5. Binding experiments 
Ki (nM)a 
cAMP assays IC50 
(nM)a 
 R6 hA1b hA2Ac hA3d hA2Be 
2 C6H5 13 ± 1 10 ± 3 11 ± 2 >30000 
11 2-OCH3 40.8 ±7.1 2.0 ± 0.2 51.5 ± 3.5 >30000 
12 3-OCH3 44 ± 7 6.8 ± 0.7 42 ± 10 >30000 
13 4-OCH3 >30000 7.2 ± 1.8   >30000 >30000 
14 2-OH 16.3 ± 0.3 2.4 ± 0.5 44.5±8.3 > 30000 
15 3-OH 14 ± 2 3.5 ± 0.6 134 ± 13 >30000 
16 4-OH 45 ± 10 45 ± 12 53 ± 13 >30000 
17 4-CH3 >30000 >30000 >30000 >30000 
18 3-O-propargyl 45 ± 10 5.1 ± 1.5 67 ± 9 >30000 
19 4-O-propargyl >30000 10.6 ± 1.3 >30000 >30000 
20 3-OCH2Ph >30000 >30000 >30000 >30000 
21 4-OCH2Ph 3704 ± 495 708 ± 160 >30000 >30000 
22 4-OC2H5 >30000 2.9 ± 0.5  >30000 >30000 
23 4-O-nC3H7 >30000 NDf >30000 >30000 
24 4-O-iC3H7 >30000 7.4 ± 0.9 >30000 >30000 
25 4-OCH2-iC3H7 NDf NDf NDf >30000 
26 4-OCH2cC3H5 >30000 >30000 >30000 NDf 
27 4-OCH2cC4H7 >30000 >30000 >30000 >30000 
28 4-OCH2-CH=CH2 NDf NDf NDf >30000 
29 3,4-OCH2O 13 ± 2.5 7.4 ± 0.9 38 ± 6.7 >30000 
30 3-Br 11±2 8±2.1 >30000 > 30000 
31 4-Br >30000 10.6 ± 2.5 705.4 ± 139.5 > 30000 
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aData (n = 3−5) are expressed as means ± standard errors. bDisplacement of specific [3H]-CCPA binding at 
hA1 AR expressed in CHO cells. cDisplacement of specific [3H]-NECA binding at hA2A AR expressed in CHO 
cells. dDisplacement of specific [3H]-HEMADO binding at hA3 AR expressed in CHO cells. eIC50 values of the 
inhibition of NECA-stimulated adenylyl cyclase activity in CHO cells expressing hA2B AR. fNot determined. 
 
Affinity data of the first set of triazolopyrazines (1-10) indicated the unsubstituted phenyl 
ring as the best group for the 2-position. Thus, to enhance affinity and selectivity for the 
hA2AAR and enlarge SAR studies, new derivatives (11-39) were synthesized by 
introduction of various substituents with different lipophilicity, electronic and steric 
properties (OR1, NO2, NH2, Br, Cl, Me) at the 2, 3 and 4 positions of the 6-phenyl ring. The 
obtained results show that some of the probed substituents, such as para-alkoxy residues 
(derivatives 13, 19, 22, 24), the para-bromo (compound 31) and the para-nitro groups 
(compound 36), afforded high hA2A AR affinities and selectivities, the best group being the 
4-ethoxy residue (22, Ki = 2.9 nM). Other compounds (15, 30, 32, 33, 38, 39) bind 
efficiently both hA2A and hA1 ARs. This result makes these derivatives interesting as well, 
because dual hA1/A2A AR antagonists have emerged as promising agents for the treatment 
of PD107,109,384 since they are able to both relieve motor symptoms and ameliorate 
cognitive impairments associated to PD. In fact, hA1 receptor antagonists facilitate DA 
release in the striatum and potentiates, like hA2A AR antagonists, the DA-mediated 
responses. hA1AR antagonists are also able to improve performance in an animal model 
of learning and memory109,384 due to the high hA1AR expression in brain areas 
(hippocamus, neocortex, limbic system) implicated in the control of cognitive and 
emotive functions. Analizing the affinity data in detail, introduction of a methoxy and 
hydroxy group at the ortho (11 and 14), meta (12 and 15) and para (13 and 16) positions 
on the 6-phenyl moiety achieved notable results, the most relevant being the 
32 3-Cl 4.7 ± 1.1 6.3 ± 1 >30000 > 30000 
33 4-Cl 14.3 ± 3.6 10.9 ± 2.7 >30000 > 30000 
34 2-NO2 95 ± 18 43 ± 2.4 180 ± 34 >30000 
35 3-NO2 35.9 ± 7.8 NDf 38.6 ± 7.9 >30000 
36 4-NO2 7834 ± 597 7.2± 1.6 16421 ± 3505 > 30000 
37 2-NH2 191 ± 28 19.5 ± 1 321 ± 63 > 30000 
38 3-NH2 15.0 ± 3.0 10.9± 2.3 169 ± 13.5 > 30000 
39 4-NH2 33.5 ± 6.7 22.9 ± 0.2 253.7 ±67.6 > 30000 
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identification of the 6-(4 methoxyphenyl) derivative 13 possessing nanomolar affinity (Ki 
= 7.2 nM) and a complete selectivity for the hA2A AR. Very interestingly, demethylation of 
compound 13 led to a completely change in the the affinity profile since the hydroxy 
derivative 16 shows a 6-fold reduced hA2A AR affinity (Ki = 45 nM) and, above all, null 
selectivity, being able to bind also hA1 and hA3 ARs with similar Ki values. Moving the 
methoxy substituent from the para to the ortho (derivative 11) or the meta position 
(derivative 12) maintained a high hA2A AR affinity (Ki = 2.0 and 6.8 nM) but lost selectivity 
since 11 and 12 displayed considerable and comparable affinity both for hA1 AR (Ki = 40.8 
and 44 nM) and hA3 ARs (Ki = 51.5 and 42 nM). Demethylation of compounds 11 and 12 
to the corresponding hydroxy derivatives 14 and 15 did not modify the affinity profile 
much, although they showed a higher affinity both to the hA1 (Ki = 16.3 and 14 nM) and 
hA2A ARs (Ki = 2.4 and 3.5 nM) and a quite good one to the hA3 AR (Ki = 44.5 and 134 nM). 
On the contrary, replacement of the 4-methoxy group with a methyl elicited a detrimental 
effect, which was difficult to explain, since compound 17 being totally inactive. With the 
aim of enhancing the hA2A AR affinity, compounds 12 and 13 were modified by replacing 
the 3- and 4-methoxy groups with the hindered propargiloxy (compound 18 and 19) and 
benzyloxy moieties (compound 20 and 21). In fact, it is well known that long and bulky 
side chain increase affinity and selectivity at the hA2A AR.380 Similarly, to the methoxy-
substituted compounds 12 and 13, the propargyloxy substituted derivatives 18 and 19 
showed nanomolar affinity for the hA2A AR (Ki = 5.1 and 10.6 nM) and 19 was also totally 
selective. On the contrary, the benzyloxy derivatives 20 (ki hA2A > 30000 nM) and 21 (ki h 
A2A = 708 nM) were significantly less active than 12 and 13, in particular, the 3-benzyloxy 
derivative 20 was completely devoid of affinity for all the ARs. Other structural 
modifications were carried out by replacing the 4-methoxy group with small alchoxy 
residues containing either linear, unsaturated, branched or cyclic alkyl chains (derivatives 
22-28). Within this new set of ligands, the 4-ethoxyphenyl derivative 22 (Ki hA2A = 2.9 nM) 
and the 4-isopropoxyphenyl derivative 24 (Ki hA2A = 7.4 nM), bearing the smallest alkyl 
groups resulted in potent and completely selective hA2A AR antagonists. Differently, 
compounds 26 and 27, bearing the cyclopropylmethoxy and cyclobutylmethoxy moieties, 
were inactive at the hA2A AR as well as at the other ARs. Disappointendly, no biological 
data are available for derivatives 25 and 28 since we met some difficulties in testing them, 
probably due to their scarce solubility in the assay medium. The same applies to 23 for 
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the assays at the hA2A AR. Interestingly, the presence at 6 level of the 3,4-
(methylendioxy)phenyl ring, (compound 29), led to a potent and non selective hA1 (Ki= 13 
nM), hA2A (Ki= 7.4 nM) and hA3 (Ki= 38 nM) AR ligand.  
To continue SAR investigations, other small substituents with different electronic, 
lipophilic and steric properties (Cl, Br, NO2, NH2) were probed on 6-phenyl ring 
(compounds 30-39). Introduction of a 4-bromo and 4-nitro substituent resulted in potent 
and selective hA2AAR ligands (compounds 31 and 36, respectively, Ki= 10.6 and 7.2 nM). 
Insertion of the nitro group at the ortho position (derivative 34) yielded to moderate 
affinity for the hA1, hA2A and hA3 ARs. Good hA1 and hA3 AR affinities were achieved for 
the meta nitro-substituted derivative 35 (Ki= 35.9 and 38.6 nM, respectively) while it was 
not possible to obtain the hA2A data. Its low solubility in the assay medium did not allow 
to test high enough concentrations to obtain the dose-response curve. Introduction of 
the lipophilic 3-bromo (30), 3-chloro (32) and 4-chloro (33) substituents on the 6-phenyl 
moiety led to dual potent hA1 (Ki= 4.7-14.3 nM) and hA2A ligands (Ki= 6.3-10.9 nM). The 
hydrophilic amino group inserted either in meta (38) or para (39) position gave 
compounds able to bind efficiently (Ki= 10.9-33.5 nM) both hA1 and hA2A ARs while the 
same group at the ortho position (37) preserved the hA2A affinity (Ki= 19.5 nM) but 
worsened the hA1 one (Ki= 191 nM). All the three amino-substituted compounds 37-39 
showed also some ability to bind the hA3 receptor subtype.  
Concerning the hA2B AR, all the compounds 11-39 were inactive (IC50> 30000 nM) in 
inhibiting the NECA-stimulated cAMP levels in hA2B CHO cells, thus suggesting that they 
lack affinity for the hA2B AR.Derivative 32, able to bind both hA1 and hA2A ARs with 
nanomolar affinity, and compounds 13, 22 and 31, highly selective for the hA2A subtype, 
were selected to determine their antagonistic properties by evaluating their effect on 
cAMP production in CHO cells, stably expressing the hA1 and hA2A ARs. The obtained 
results (Table 6) showed that the compounds behaved as antagonists being able to 
counteract NECA-inhibited (A1) or NECA-stimulated (A2A) cAMP accumulation.  
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Table 6. Potencies of compounds 13, 22, 31 and 32 at hA1 and hA2A ARs. 
 
 
 
 
 
aIC50 values obtained counteracting the NECA-induced decrease of cAMP accumulation in CHO cells 
expressing hA1R. bIC50 values obtained by inhibition of NECA-stimulated adenylyl cyclase activity in CHO cells 
expressing hA2AR. cNot determined. 
 
4.2.1. Molecular modeling studies  
Docking results of compounds bearing an unsubstituted 2-phenyl ring and various aryl 
substituents at the R6 position (11−39) again show a preferential binding mode with the               
2- group located in the depths of the cavity and the 6-substituent pointing toward the 
external environment. Hence, the substituents on the 6-phenyl ring are generally located 
at the entrance of the cavity, providing different degrees of interaction with the receptor 
residues in proximity and modulating the affinity for the three ARs subtypes. The 
compounds featuring a small ortho-substituent (11, 14, 34, 37) are generally endowed 
with low nanomolar hA2A AR affinity. This substituent is oriented toward the N7 atom and 
in proximity of Glu169 (EL2) residue, with possibility to give polar interaction with the 
nitrogen atom of the compound scaffold or with the backbone or sidechain atoms of the 
above cited receptor residue (Figure 26).  
 
Figure 26. (A) The type-one docking conformation of the synthesized compounds at the hA2A AR cavity, 
representing the preferred binding mode according to docking-scoring results; compound 11 is represented 
and key receptor residues are indicated. (B) Schematic description of the ligand-target interaction (built 
within MOE software). 
 
hA1  
IC50 (nM)a 
hA2A  
IC50 (nM)b 
13 NDc 180 ± 34 
22 NDc 98 ± 19 
31 NDc 694 ± 74 
32 298 ± 58 374 ± 52 
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However, the precence of a nitro group at the ortho position of the 6-phenyl ring (34) 
affords a lower hA2A AR affinity, mainly due to higher hindrance of the substituent and 
consequent lower ability of the compound to maintain the co-planarity of the 6-phenyl 
ring with the heterocyclic scaffold. An electronic repulsion with the Glu169 (EL2) side 
chain is an additional factor at the basis of the lower affinity of this compound. According 
to the binding data, the presence of small substituent at the meta or para position of the 
6-phenyl ring leads, excepting for 17, 26 and 27, to a high hA2AAR affinity. Even these 
compounds appear to exclusively bind this receptor with the “type-one” docking 
conformation. These groups get located in proximity of H-bond donor functions of the 
receptor, such as the backbone NH groups of Phe168 and Glu169 (EL2) and the hydroxyl 
group of Tyr2717.36. Even the side chains of (EL2) and Leu267 (EL3) are in proximity to 
these compound substituents, allowing non-polar interaction. Considering the effects of 
substituents at the para-position of the 6-phenyl ring, the introduction of a polar hydroxyl 
group led to a decrease in hA2A AR affinity (16, Ki = 45 nM) with respect to the 
unsubstituted analogue 2. Docking results suggest that this hydroxy group is inserted 
within a set of hydrophobic amino acid residues, such as Leu167 (EL2), Leu267 (EL3), and 
Tyr2717.36, thus helping to explain the nonoptimal interaction of the 6-(4-phenol) group 
(16) with the receptor site with respect to the phenyl ring (2). On the same basis, we may 
interpret why the introduction of nonpolar groups at the para-position of the 6- phenyl 
ring is generally well tolerated, leading to compounds (13, 19, 22, and 24) with similar 
affinity with respect to the corresponding analogue 2, lacking a substituent on the 6-
phenyl ring.  
 
Figure 27. hA2A AR residues located at the entrance of the binding cavity (pdb 4EIY) and able to provide 
interaction with substituents on the R6 aryl ring. 
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Figure 27 shows the binding mode of compound 22 with a focus on the residues located 
in proximity of the R6 substituent. The para-ethoxy substituent of 22 appears inserted 
among the above cited hydrophobic residues Leu167 (EL2), Leu267 (EL3), and Tyr2717.36. 
In the case of derivatives with substituents at the meta position of the 6-phenyl ring, the 
affinity data show that the nature of the substituent does not significantly influence the 
receptor−ligand interaction because the presence of a polar hydroxyl group (15) or 
nonpolar functions, such as methoxy or propargyloxy groups (12, and 18, respectively), 
leads to analogue affinities at the hA2A AR. Figure 27 shows the presence on the receptor 
of nonpolar groups (i.e., the alkyl chain of Ile662.64) as well as polar functions (i.e., the 
carbonyl groups of Ile662.64 and Ser672.65) in proximity with the meta position of the 6-
phenyl ring.  
 
4.3. Structural refinement aimed at improving drug-like properties:                         
8-amino-6-(hetero)aryl-1,2,4-triazolo[4,3-a]pyrazin-3-ones 40-61 and 62-
68  
 
40-61 
Table 7 Binding experiments 
Ki (nM) a 
cAMP assays 
IC50 (nM) a 
 R6 hA1b hA2Ac hA3d hA2Be 
40 2-(piperazin-1-yl) 1640 ± 237 1528 ± 100 4465 ± 653 > 30000 
41 3-(piperazin-1-yl) 36.1 ± 8.4 NDf 410.1 ± 89.2 >30000 
42 4-(piperazin-1-yl) 265.1 ± 14.4 90.4 ± 8 1905 ± 314 > 30000 
43 3-(N-dimethyl+-
piperazin-1-yl) 
57.1 ± 2.9 89.8 ± 2.8 3783 ± 667 > 30000 
44 3-(4-benzylpiperazin-1-
il)- 
235.7 ± 39.9 32.3± 7.5 298.1 ± 49.8 > 30000 
45 4-(4-benzylpiperazin-1-
yl)- 
121 ± 28 29 ± 1.5 >30000 > 30000 
46 C6H4-4-OCH2-CONH2 391.7 ± 104 26 ± 1.7 604 ± 94 > 30000 
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aData (n = 3−5) are expressed as means ± standard errors. bDisplacement of specific [3H]-CCPA binding at 
hA1 AR expressed in CHO cells. cDisplacement of specific [3H]-NECA binding at hA2A AR expressed in CHO 
cells. dDisplacement of specific [3H]-HEMADO binding at hA3 AR expressed in CHO cells. eIC50 values of the 
inhibition of NECA-stimulated adenylyl cyclase activity in CHO cells expressing hA2B AR. 
 
The set of triazolopyrazines 40-68 (Tables 7 and 8) was designed to obtain derivatives 
endowed with enhanced water solubility and drug-like properties with respect to the 
compounds synthesized in the previuos phases of the work. Hence, the 6-phenyl ring was 
decorated with hydrophilic functions, some of which (substituted piperazines, 
morpholine, piperidine and pyrrolidine) are a common feature of known potent and 
selective hA2A AR antagonists, structurally correlated to our series380. The selected 
substituents were attached both directly on the 6-phenyl ring (compounds 40-45) or 
47 C6H4-4-OCH2-CN > 30000 8.2 ± 2.3 > 30000 > 30000 
48 C6H4-4-O-(CH2)2-NH2 288.7 ± 54 14.94 ± 0.1 2131 ± 173.5 > 30000 
49 C6H4-4-O-(CH2)2-OH 510 ± 0.2 250 ± 24 >30000 >30000 
50  
363.7 ± 58 355 ± 93 1774 ± 362 >30000 
51 C6H4-4-NHCO-(CH2)2-NH2 479.2 ± 89 0.59 ± 0.17 509 ± 90 9658 ± 1431 
52 
 
 
296 ± 36 4.31 ± 0.5 1016 ± 165 >30000 
53  
614.1 ± 145 5 ± 1.3 1169 ± 85 >30000 
54  
586 ± 164 3.6 ±1.1 1023 ± 76.7 >30000 
55  
662.8 ± 178 1 ± 2.5 3104 ± 924 >30000 
56  
873.5 ± 171 230 ± 50 4303 ±968 >30000 
57  
363.3 ± 52.8 45.4 ± 1.5 1062 ± 138 >30000 
58  
363.2 ± 61 174.4 ± 16 >30000 >30000 
59  
510.3 ± 86 85.2 ± 18 368.7 ± 90 >30000 
60  
336.1 ± 87 91.7 ± 15 495 ± 112 >30000 
61  
571 ± 47 197 ± 49 780 ± 149 >30000 
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through small alkoxy (derivatives 46-50, 56-61) and amide (derivatives 51-55) chains, both 
linked to the para position of the ring. 
Analyzing the binding data, it can be observed that some derivatives (46-48, 51-55) are 
endowed with high affinity (Ki hA2A = 0.59-26 nM) and good selectivity for the A2A AR. The 
most relevant outcomes included derivatives 51-55 which showed hA2A AR affinity values 
in the range 0.59-5 nM.  
Compounds bearing piperazine moieties on the 6-phenyl group (40-45) did not showed 
the expected affinities. Insertion of an unsubstituted piperazine at the ortho position 
made the compound (40) a very weak ligand at all ARs, instead its presence at the para 
position (42) permit a quite good and selective interaction with the hA2A AR (Ki= 90 nM). 
Unfortunately, we were not able to determine the hA2A AR affinity of the meta- piperazine 
derivative 41, for the problems described above for compounds 23, 25, 28 and 35. Also 
the N,N-dimethylation of the meta-piperazine group afforded a quite good affinity for the 
hA2A AR (43), and an even better substitution was the N-benzylation of the meta- (44) or 
para- (45) piperazine, giving rise to low nanomolar affinities at this receptor. In the 
subsequent modifications, small chains containing CONH2 (46), CN (47), NH2 (48, 51) or 
OH (49, 50) as terminal group groups were inserted at the para position of the 6-phenyl 
ring by an –O- or NHCO linker. Very interestingly, compounds 46-48 and 51 were endowed 
with high affinity (Ki= 0.59-26 nM) and selectivity for the hA2A AR, the most active being 
derivatives 47 (Ki= 8.2 nM) and 51 (Ki= 0.59 nM). On the contrary, compounds 49 and 50, 
bearing, respectively, the 6-(4-(2-hydroxyethoxy)phenyl and 6-(4-(2,3-
dihydroxypropoxy)phenyl pendants, emerged as weak hA1 and hA2A AR ligands. 
Concerning the set of compounds bearing cyclic amines (piperidine, pyrrolidine, 
morpholine or substituted piperazines) in the side chain (derivatives 52-61), it can be 
observed that compounds 52-55 are highly potent (Ki = 3.6-11 nM) and selective hA2AAR 
ligands while compounds 56-59 (Ki = 45-230 nM) are less active at the hA2A subtype, as 
well as the other ARs. These data highlight that the propanamide linker is more profitable 
than the ethoxy or propoxy chain for hA2A receptor-ligand interaction.  
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aData (n = 3−5) are expressed as means ± standard errors. bDisplacement of specific [3H]-CCPA binding at 
hA1 AR expressed in CHO cells. cDisplacement of specific [3H]-NECA binding at hA2A AR expressed in CHO 
cells. dDisplacement of specific [3H]-HEMADO binding at hA3 AR expressed in CHO cells. eIC50 values of the 
inhibition of NECA-stimulated adenylyl cyclase activity in CHO cells expressing hA2B AR. 
 
Other structural modifications, supposed to be advantageus for improving drug-like 
properties, were made by replacing the 6-phenyl ring of the reference ligand 2 with a 
heterocyclic moiety (2-furyl, 2-(5-methylfuryl), 2-thienyl, 2-pyridinyl). Compounds 62-65 
maintained a high affinity for both hA1 and hA2A ARs (Ki= 8.4-13.2 nM) while showing an 
enhanced selectivity versus the hA3 subtype (Table 8). Furthermore, derivatives bearing a 
benzyl chain at position 2, combined with a phenyl, 2-furyl and a 2-(5-methylfuryl) at 
position 6 (compounds 66-68, Table 8), were synthesized because the 2-benzyl pendant, 
being more flexible than the 2-phenyl moiety, was thought to enhance the solubility of 
the compounds. This type of decoration was also suggested by the binding results 
previously obtained in our pyrazolopyrimidine series393 in which combination of a benzyl 
moiety with a 2-furyl substituent shifted affinity toward the hA2A AR. In the 
triazolopyrazine series, this modification enhanced both hA1 and hA2A AR affinities 
(compare the 2-benzyl derivative 66-68 with the relative 2-phenyl derivatives 2, 62, 63) 
Table 8 Binding experiments 
Ki (nM) a 
cAMP 
assays 
IC50 (nM) a 
 R6 R2 hA1b hA2Ac hA3d hA2Be 
62 2-furyl Ph 13 ± 2 8.4 ± 0.9 120 ± 18 > 30000 
63 2-(5-methylfuryl) Ph 10 ± 2.8 11 ± 1 77 ± 6.5 > 30000 
64 2-thienyl Ph 14.1 ± 3.2 9.0 ± 2.2 42 ± 10.2 > 30000 
65 2-pyridyl Ph 77.4 ± 5.2 13.2 ± 3.8 131.1 ± 30 > 30000 
66 Ph CH2Ph 2.4 ± 0.5 4.4 ± 0.1 223.7 ± 4.8 > 30000 
67 2-furyl CH2Ph 13.7 ± 0.3 2 ± 0.1 1131 ± 132 > 30000 
68 2-(5-methylfuryl) CH2Ph 3.7 ± 0.2 4.6 ± 1.3 112 ± 2 > 30000 
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while reducing ability to bind the hA3 AR. Compounds 66-68 are indeed dually potent hA1 
(Ki =2-4.6 nM) and hA2A ligands (Ki= 2.4-13 nM). 
Derivative 68, able to bind both hA1 (Ki= 3.7 nM) and hA2A (Ki= 4.6 nM) ARs with nanomolar 
affinity, was selected to evaluate its antagonistic profile by measauring the effect on 
cAMP production in CHO cells, stably expressing hA1 and hA2A ARs. The obtained results 
(Table 9) showed that the compound behaved as antagonist being able to counteract 
NECA-inhibited (A1) or NECA-stimulated (A2A) cAMP accumulation.  
Table 9. Potencies of compound 68 at hA1 and hA2A ARs. 
 
 
 
 
aIC50 values obtained counteracting the NECA-induced decrease of cAMP accumulation in CHO cells 
expressing hA1R. bIC50 values obtained by inhibition of NECA-stimulated adenylyl cyclase activity in CHO cells 
expressing hA2AR.  
 
To verify if the performed modifications are effective or not in improving solubility and 
physicochemical properties of the compounds, further investigations are needed.  
However, we are confident about the successful outcome since for most of derivatives 
40-68, lower melting points (200-270 °C), a better solubility in the most common organic 
solvents (methanol, ethanol, nitromethane etc.), as well as less drastic recrystallization 
conditions, have been observed. 
 
4.3.1. Molecular modeling studies 
Molecular docking studies at the A2AAR crystal structure were carried out on compounds 
42-45 (Table 7) to depict their hypothetical binding mode. The obtained results 
highlighted that derivatives 43 and 44 bearing large substituents at the meta position of 
the 6-phenyl ring adopt the “type-one” docking conformation, presenting the 2-phenyl-
ring located in the depth of the cavity and the 6-aryl group at the entrance of the binding 
site. Compounds 42 and 45, featuring a large substituent at the para position of the same 
ring, were also investigated, showing an upside-down conformation, where the 2-phenyl 
ring was inserted in the depth of the cavity while the scaffold was oppositely oriented 
with the 3-carbonyl group pointing toward the Asn2536.55 amide function (Figure 28).  
 
hA1  
IC50 (nM)a 
hA2A 
IC50 (nM)b 
68 675 ± 123 521 ± 79 
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Figure 28. Alternative binding mode of the synthesized compounds presenting a large substituent in the 
para-position of the 6-phenyl ring (compound 45 is shown). The key ligand-target polar interaction is 
between the 3-carbonyl group of the compound and the Asn2536.55 amide function. 
 
Compounds 62-65, bearing a heterocyclic moiety at the 6-position and a phenyl ring at 
the 2-position, may adopt both type-one and type-two docking conformations, like 
compound 2, with a fair preference for the type-two conformation (the one pointing the 
2-phenyl ring toward the extracellular environment). This behaviour may explain the high 
affinity of these derivatives for the hA2A AR binding cavity, analogously to the reference 
compound 2. When the 2-phenyl ring is replaced by a benzyl moiety and a heterocyclic 
ring is inserted at the 6-position (66-68), the compounds preferentially adopt a type-two 
docking conformation pointing the 2-substituent toward the extracellular environment. 
For both these sets (62-65 and 66-68) the steric and chemical-physical profile of the 6 
substituent modulates the hA2A AR affinity, with the 2-furyl providing the highest affinity 
data within each set, as expected.  
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4.4 Design of dual A2A AR antagonist-antioxidant triazolopyrazines:                   
8-amino-6-aryl-2-phenyl-1,2,4-triazolo[4,3-a]pyrazin-3-ones 69-86  
 
Table 10 Binding experiments 
Ki (nM) a 
cAMP assays 
IC50 (nM) a 
 R6 hA1b hA2Ac hA3d hA2Be 
69 C6H4-2,4-diOCH3 28 ± 0.26 2.4 ± 0.48 118 ± 6.6 >30000 
70 C6H4-3,4-diOCH3 59.0 ± 12.7 5.68 ± 0.78 80.1±15.8 >30000 
71 C6H4-3,4,5-triOCH3 55 ± 16 3.5 ± 0.8 214 ± 4.4 >30000 
72 C6H4-4-OCH3-3,5-diCH3 4.5 ± 1.4 0.17 ± 0.0046 8.6 ± 1.7 >30000 
73 C6H4-4-OCH3-3,5-ditBu 108.5 ± 17 141.6 ± 34 >30000 >30000 
74 C6H4-2-OCH3-4-OH 29.8 ± 1.6 16.8 ± 0.87 11130 ± 975 > 30000 
75 C6H4-3,4-diOH 42.6 ±9.6 5.21 ± 0.5 950±200.4 >30000 
76 C6H4-3,4,5-triOH 175.5 ± 3 94.5± 21 5575±989 17.330±3365 
77 C6H4-4-OH-3,5-diCH3 21.3 ± 7 2.5 ± 0.78 100 ± 0.7 >30000 
78 C6H4-4-OH-3-tBu >30000 8.47 ± 1.4 >30000 >30000 
79 
 
504 ± 129 8.1 ± 0.83 1140 ± 167 >30000 
80 
 
8.4 ± 0.39 5 ± 0.62 >30000 >30000 
81 
 
173.4 ± 37 1.7±1.4 868±169 >30000 
82 
 
378.6 2.4±0.3 >30000 4097±812 
83 
 
13670 ± 275 14750 ± 270      >30000      >30000 
84 
 
1359 ± 284 36.4 ± 8.2 >30000 >30000 
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aData (n = 3−5) are expressed as means ± standard errors. bDisplacement of specific [3H]-CCPA binding at 
hA1 AR expressed in CHO cells. cDisplacement of specific [3H]-NECA binding at hA2A AR expressed in CHO 
cells. dDisplacement of specific [3H]-HEMADO binding at hA3 AR expressed in CHO cells. eIC50 values of the 
inhibition of NECA-stimulated adenylyl cyclase activity in CHO cells expressing hA2B AR. 
 
Finally, a new set of 8-amino-1,2,4-triazolo[4,3-a]pyrazin-3-ones (74-86, Table 10) bearing 
potential antioxidant moieties at the 6-position were synthesized and pharmacologically 
evaluated. These compounds can be divided into two sets: derivatives 74-78, featuring 
substituted phenol rings at the 6-position, and compounds 79-86, bearing antioxidant 
moieties on the lateral chain linked to the para position of the 6-phenyl ring. The affinity 
data, reported in Table 10, indicate that the presence of differently substituted phenols 
(compounds 74-78) at the 6-position shifted affinity towards both the hA1 (Ki = 21.3-175 
nM) and A2A (Ki = 2.5-94 nM) ARs. Within this set of compounds, the 6-(3-(tert-butyl)-4-
hydroxyphenyl derivative 78 turned out to be a highly potent (Ki = 8.47 nM) and selective 
hA2A AR ligand while compounds 74, 75 and 77 bind both hA1 (Ki = 21.3-42.6 nM) and hA2A 
(Ki = 2.5-16.8 nM) ARs with nanomolar affinity and different degrees of selectivity versus 
the hA3 subtype. Among the latter derivatives, the best in terms of hA2A affinity were 75 
and 77, displaying Ki values in the range of 2.5-5.21 nM. The methoxy derivatives 69-73, 
synthetic precursors of the desired phenols 74-78, were also tested to evaluate their 
affinity at ARs. The obtained binding data for this subset indicated that the contemporary 
presence of two or three methoxy groups on the 6-phenyl ring led to compounds (69-71) 
possessing high affinity for both hA1 (Ki = 28-59 nM) and hA2A (Ki = 2.4-5.68 nM) ARs, and 
also able to bind to the hA3 AR subtype (Ki = 80.1-214 nM). Compound 72, instead, bearing 
the 6-(3,5-dimethyl-4-methoxyphenyl) residue, showed subnanomolar hA2A AR affinity (Ki 
= 0.17 nM) and was also able to bind efficiently the hA1 and hA3 ARs with Ki values of 4.5 
and 8.6 nM respectively. Replacement of the methyl groups of 72 with t-butyl moieties 
(compound 73) completely changed the affinity profile. In fact, the 6-(3,5-ditert-butyl-4-
methoxyphenyl) derivative 73 shows a marked reduced affinity for both hA1 (Ki = 108.5 
nM) and hA2A (Ki = 141.6 nM) ARs and completely lacks activity at the A3 AR subtype. Other 
85 
 
    >30000    54.5 ± 7.1     >30000      >30000 
86   
581.4±40.3 
 
91±8.5 
 
>30000 
 
>30000 
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groups supposed to exert antioxidant properties (see “Aim of the work”) were introduced, 
by suitable spacers, at the para position of 6-phenyl ring. The (S)-2-oxothiazolidine-4-
carboxylic acid (OTC) residue achieved good results since the triazolopyrazines 79, 81 
were endowed with high affinity (Ki = 8.1 and 1.7 nM respectively) and selectivity at the 
hA2A AR. Also the lipoic acid residue, either directly appended on the para-amino function 
(compound 80) or spaced by a chain (compounds 82, 84) was well tolerated by the hA2A 
AR.  In fact, compounds 82 and 84 emerged as highly potent and selective hA2A AR ligands 
(Ki = 2.4 and 36.4 nM respectively) and derivative 80 also efficiently binds the hA2A AR (Ki 
= 5 nM), even though showing high hA1 AR affinity (Ki = 8.4 nM). It is worth noting that the 
presence of the ethoxy or propanamide spacer shifted the selectivity toward the A2A AR 
(compounds 82 and 84).  
The presence of the 3,5-di-tert-butyl-4-hydroxybenzoic acid residue on the lateral chain 
of derivatives 83 and 85 led to opposite results in terms of AR affinity depending on the 
linker, -O- and -NHCO-, binding the chain to the 6-phenyl ring. The amide linker might 
confer more rigidity to the moiety, thus, probably, stabilizing the proper binding 
conformation of the triazolopyrazine 85, which showed high affinity (Ki = 54 nM) and 
selectivity at the hA2AAR. In contrast, compound 83, featuring a more flexible pendant 
due to the –O- linker, completely lacks affinity towards all the ARs. Molecular docking 
studies are in progress to interpret these affinity data. The 5-methyl-1,2-dihydro-3H-
pyrazol-3-one ring, appended on compound 86, was chosen as potential antioxidant 
moiety because it plays a key role in the antioxidant mechanism of action410 of edaravone, 
an approved anti-cerebral ischemia drug. This modification turned out to be 
advantageous since derivative 86 possesses good nanomolar affinity (Ki = 91 nM) toward 
the hA2AAR and is also able to bind the hA1 AR subtype with a 6-fold reduced activity. 
 
The triazolopyrazines 75-80, 82, bearing potential antioxidant functions, and endowed 
with high hA2AAR affinity, were selected to evaluate their stability in human plasma, and 
in tris(hydroxymethyl)aminomethane/HCl (Tris/HCl) and phosphate buffer solutions 
(PBS). These tests are being performed by the research group of Prof. Gianluca Bartolucci, 
at the NEUROFARBA Department – Pharmaceutical and Nutraceutical Section, of the 
University of Florence. Preliminary results suggested that the tested compounds are, on 
the whole, stable in the assayed conditions (data not shown). 
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4.4.1 Molecular modeling studies 
Molecular docking studies on compound 79 and 80 (Table 10), bearing antioxidant 
residues at 6-phenyl level, were carried out to determine the hypothetical binding mode 
at the A2AAR crystal structure (PDB: 4EIY) and to gain useful information for the design of 
new hA2A AR antagonists. The obtained results showed that these molecules bind to the 
receptor binding pocket with the preferred “type one” arrangement. The 
triazolopyrazinone scaffold has been demonstrated to be able to interact with Asn2536.55 
and Glu169 (EL2) through H-bond contacts and with the phenyl ring of Phe168 (EL2) 
through a π-π interaction410. Moreover, π-π interaction between Phe168 and the bicyclic 
core were evidenced, as well as hydrophobic interaction between Leu167, 267 and the 
lipoic and the (S)-2-oxothiazolidine-4-carboxylic acid moieties (Figure 29). 
 
 
 
 
 
 
 
 
 
Figure 29. Schematic description of ligand−target interaction of derivatives 79 (A) and 80 (B) in the hA2A 
AR (built with MOE software).  
 
 
4.5 Pharmacological studies 
Based on their affinity and selectivity profile at ARs, some of the synthesized compounds 
(13, 31, 32 and 68) indentified in the second phase of the work (see “Aim of the work”) 
were selected to investigate their in vitro neuroprotective properties in PD and AD 
models. The 6-(4-methoxyphenyl)-2-phenyl-triazolopyrazine derivative 13, showing high 
affinity (Ki = 7.2 nM) and selectivity at the hA2A AR, was evaluated for its ability in 
counteracting the MPP+ induced neurotoxicity in cultured human neuroblastoma SH-SY5Y 
cell lines, a widely used cellular PD model427,428. Compound 31, highly selective at the hA2A 
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subtype, and derivatives 32 and 68, able to bind both hA1 and hA2A ARs with nanomolar 
affinity, were profiled for their neuroprotective effect against the -amyloid peptide (Aβ)-
induced toxicity429.  
 
4.5.1 Neuroprotection Studies in MPP+-induced toxicity in SH-SY5Y Cell Lines 
As reported above (see “Introduction”), interest in the use of A2A AR antagonists in PD has 
increased because they proved to be beneficial both in relieving motor symptoms and 
neuropsychiatric impairments of the disease430,431 but, more importantly, because they 
might be helpful in counteracting neurodegeneration190,432. In fact, animal models of PD 
highlighted the A2A AR antagonist ability to protect nigral dopaminergic neurons from 
death induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)190, thus slowing 
the deterioration of dopamine-producing cells and modifying the disease progression. 
Related to this, the A2A AR antagonist protective effect against the MPTP-induced toxicity 
is probably associated to a mechanism counteracting neuroinflammation and involving 
A2A AR on glial cells190,433. The aim of the herein reported study was to examine the 
efficacy of compound 13 in counteracting the 1-methyl-4-phenyl-pyridinium (MPP+) 
induced neurotoxicity on SH-SY5Y cells in an in vitro model of PD. A large wide of evidence 
indicates that SH-SY5Y cells possess many features of dopaminergic neurons and have 
been widely employed for the study of neuroprotection against PD-related neurotoxins. 
MPP+ is a well-recognized dopaminergic neurotoxin resulting from the metabolic 
transformation of MPTP and able to induce cell death through a series of processes such 
as oxidation, hydrogen peroxide formation, and direct inhibition of the mitochondrial 
respiratory chain434. These studies were carried out in collaboration with Dr. Teresa De 
Vita, from the Italian Institute of Technology (IIT) of Genova. First, a pilot study was 
conducted to evaluate the neurotoxic effect produced by MPP+ on SH-SY5Y cells. Cells 
were treated for 24 h with increasing doses of MPP+ (50 μM to 3 mM). 
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Figure 30. Dose dependency of MPP+ in SH-SY5Y cells. Cellular viability was carried out after 24 h of MPP+. 
Effect of MPP+ on cell viability was measured by CellTiter-Glo luminescent assay. Data are expressed as 
mean of three independent experiments. **P < 0.01 compared with control; ***P < 0.001 compared with 
control 
 
The results in Figure 30 show that MPP+ produced a significant and concentration-
dependent neurotoxic effect in this cell line. The dose of 1.5 mM, which caused 50% of 
cell death, was chosen for the subsequent neuroprotection studies. Compound 13, when 
administered alone, did not modify cell viability (Figure 31, A) while at the concentration 
of 15 nM it was able to partially counteract MPP+-induced neurotoxicity (Figure 31, B).  
 
 
Figure 31. SH-SY5Y cells were treated for 24 h with different concentrations of compound 13 from 0.5 to 
30 nM, alone (A) and inthe presence of MPP+ 1.5 mM (B). Compound 13 proved not to be toxic and 
neuroprotective against MPP+ in SH-SY5Y cells after CellTiter-Glo luminescent cell viability assay. Data are 
expressed asmean of three independent experiments. ***P < 0.001 compared withcontrol, ###P < 0.001 
compared to MPP+ 1.5 mM. 
 
To verify that the protective effect of 13 was due to the selective blockade of the A2A AR, 
we compared the effects of the compound with those of the well-known selective hA2A 
4.RESULTS AND DISCUSSION 
 
85 
AR antagonist 4-(2-[7-amino- 2-(2-furyl[1,2,4]-triazolo[2,3-a][1,3,5]triazin-
5ylamino]ethyl)- phenol ZM241385435 and we evaluated the effects of 13 in the presence 
of the selective hA2A AR agonist 2-[p-(2-carboxyethyl)phenethylamino]-5′-N-
ethylcarboxamido adenosine CGS21680436. As shown in Figure 32 A, the hA2A AR 
antagonist ZM241385, used at the concentration of 0.5 nM427, presented a 
neuroprotective effect on SH-SY5Y cells, thus counteracting MPP+ toxicity. To validate the 
involvement of the A2A AR in the neuroprotective activity of 13 against MPP+ toxicity, we 
evaluated the ability of the hA2A AR agonist CGS21680 to reverse the effects of compound 
13. SH-SY5Y cells were treated with 13 (15 nM) in the presence of different CGS21680 
concentrations ranging from 10 to 100 nM. As shown in Figure 32 B, the hA2A agonist 
CGS21680 was able to suppress the protective effects of 13, thus confirming that the its 
effects may be attributed to the selective blockade of the A2A AR.  
 
Figure 32. Reference hA2A antagonist ZM241385-induced neuroprotection against MPP+ toxicity in SH-
SY5Y cells (A). Neuroprotection inducedby the hA2A antagonist 13 is lost by the coadministration of the 
selective hA2A agonist CGS21680. SH-SY5Y cells were treated for 24 h with 1.5 mM MPP+ in absence and in 
the presence of 15 nM of compound 13 and different concentrations of the agonist CGS21680, from 10 to 
100 nM (B). Cell viability was evaluated by using CellTiter-Glo luminescent assay. Data are expressed as 
mean of three independent experiments. ***P <0.001 compared with control, ###P < 0.001 compared to 
MPP+ 1.5mM, §§§P < 0.001 compared with MPP+ 1.5 mM + 13 15 nM. 
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4.5.2 Neuroprotection studies in β-amyloid peptide (Aβ)-induced toxicity in SH-SY5Y 
cells 
In the last decade, several human studies highlighted the beneficial effects of caffeine, a 
non-selective A1 and A2A AR antagonist, in reducing the risk of developing AD and PD437-
440. The caffeine protective effect was also investigated in animal models of AD and PD 
turning out to be related, among other pathways, to antagonism of the A2A AR 
subtype140,441. Moreover, in AD models, both caffeine and the potent A2A AR antagonist 
ZM241385 proved to be effective in preventing cell death after exposure of rat cultured 
cerebellar granule neurons to Aβ-amyloid peptide (25-35)140. Recently, also the A1 AR 
antagonism was recognized to afford neuroprotection in a model of combined 
neurotoxicity, in fact, the protective effect of dual A1 and A2A AR blockade in counteracting 
β-amyloid toxicity in neuroblastoma cells exposed to aluminium chloride has been 
demonstrated429. Within the synthesized compounds, the highly potent and selective 
hA2A AR antagonist 31 togheter with the dual potent hA1/A2A AR ligands 32 and 68 were 
chosen to evaluate their ability in counteracting β-amyloid peptide (Aβ)-induced toxicity. 
For this purpose we used the neuronal cell line SH-SY5Y a widely emplyed 
catecholaminergic in vitro model for studies on pathologies or toxicities affecting the 
nervous system429, 442-444. The 25-35 aminoacids Aβ fragment was used for setting up a 
model of neurotoxicity429. It was previously incubated (at 2 and 10 µM) at 37 °C to allow 
peptide aggregation, 3 and 7 days were evaluated to establish the optimal timepoint. The 
obtained aggregates were incubated with cells for increasing times (24, 48 and 72 h), 
subsequently cell viability was assessed via the MTT assay. Results are shown in Table 11, 
we chose 48 h incubation with 7 days aggregated-Aβ as the most suitable, concentration-
dependent condition for screening the new synthesized compounds (cell viability of 
control was arbitrarily set to 100%).  
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Table 11. Toxic effect induced by β-amyloid protein (Aβ fragment 25-35 aa)a 
 Cell viability % 
Time of 
incubation with 
cells 
 Time of preventive 
aggregation of Aβ 25-35 
 
2
4
 h
 
  3 days 7 days 
Control 100 ± 4.2   
Aβ 25-35, 2 µM  92.8 ± 1.9 69.6 ± 2.9** 
Aβ 25-35, 10 µM  80.3 ± 4.5* 64.4 ± 3.8** 
 
4
8
 h
 
  3 days 7 days 
Control 100 ± 7.2   
Aβ 25-35, 2 µM  80.5 ± 7.6 73.3 ± 2.1* 
Aβ 25-35, 10 µM  69.8 ± 5.4** 63.2 ± 4.6** 
 
7
2
 h
 
  3 days 7 days 
Control 100 ± 8.9   
Aβ 25-35, 2 µM  95.5 ± 15.1 108.1 ± 16.3 
Aβ 25-35, 10 µM  83.0 ± 11.4 68.7 ± 8.7** 
 
aAggregation of β-amyloid protein (Aβ fragment 25-35 aa; 2 and 10 µM) was allowed for 3 and 7 days at 
37°C. The so obtained different proteins aggregates were tested in SH-SY5Y cell (1x104 cell/well) to 
evaluate the cytotoxic effect. Incubation was performed for increasing times (24, 48 and 72 h), 
subsequently cell viability was assessed via the MTT assay. Viability is expressed as % in comparison to 
the control cells (arbitrarily set 100 % of viable cells). Data are presented as mean ± SEM of 3 different 
experiments performed in quintuplicate. One-way ANOVA with a Bonferroni post-hoc test was used to 
compare different treatments. *P<0.05 and **P<0.01 versus control. 
 
Derivatives 31, 32 and 68 (0.1–1 µM) were co-incubated with SH-SY5Y cells (1x104 
cell/well) for 48 h in the presence of Aβ 25-35 (2 and 10 µM). Figure 33 shows the 
decrease of cell viability induced by 2 µM Aβ up to 73.3 ± 2.1%. Compound 68 is able to 
significantly prevent Aβ toxicity starting from concentration 0.1 µM restoring the cell 
viability till to control level at 0.3 µM. Compound 31, instead, proved to be effective in 
counteracting the Aβ induced neurotoxicity starting from 0.3 µM concetration. On the 
other hand, higher concentration of Aβ 25-35 (10 µM, previously aggregated for 7 days) 
decrease cell vitality to 63.2 ± 4.6% (Figure 34). Compound 31 was protective when co-
incubated at 0.3 µM whereas 68 was able to significantly prevent cell mortality from 0.1 
µM (Figure 34). In the concentration range 0.1-3 µM, caffeine was ineffective. These 
4.RESULTS AND DISCUSSION 
                                                                                                                                                                           88 
studies were performed by Dr. Lorenzo Di Cesare Mannelli at the NEUROFARBA 
Department – Pharmacology and Toxicology section, of the University of Florence. 
  
 
Figure 33. SH-SY5Y cell (1x104 cell/well) were incubated 48 h with compounds 31, 32 and 68 (0.1, 0.3 and 
3 µM) in the presence Aβ-amyloid peptide (Aβ fragment 25-35 aa; 2 µM following 7 days of 37 °C 
aggregation). Caffeine was used as reference compound. Cell vitality was assessed via MTT assay. Viability 
is expressed as % in comparison to the control cells (arbitrarily set 100 % of viable cells). Dashed lines 
represent values of control and Aβ-treated samples. Data are presented as mean ± SEM of 3 different 
experiments performed in quintuplicate. One-way ANOVA with a Bonferroni post-hoc test was used to 
compare different treatments. ^P<0.05 and ^^P<0.01 versus β-amyloid effect. 
 
 
Figure 34. SH-SY5Y cell (1x104 cell/well) were incubated 48 h with compounds 31, 32 and 68 (0.1, 0.3 and 
3 µM) in the presence Aβ-amyloid peptide (Aβ fragment 25-35 aa; 10 µM following 7 days of 37 °C 
aggregation). Caffeine was used as reference compound. Cell vitality was assessed via MTT assay. Viability 
is expressed as % in comparison to the control cells (arbitrarily set 100 % of viable cells). Dashed lines 
represent values of control and Aβ-treated samples. Data are presented as mean ± SEM of 3 different 
experiments performed in quintuplicate. One-way ANOVA with a Bonferroni post-hoc test was used to 
compare different treatments. ^P<0.05 and ^^P<0.01 versus β-amyloid effect. 
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4.5.3 Neuroprotection studies in oxaliplatin-induced neurotoxicity in microglia cells 
As previously reported in the “Introduction”, the anticancer drug oxaliplatin leads to the 
development of neuropathic syndrome with paresthesia, dysesthesia, and pain. Despite 
informations about the molecular basis underlyng the neuropathy are unclear, some 
experimental evidences point toward a correlation between oxidative stress damage and 
neuropatic pain (NP) onset374,445. The aim of the current study was to determine the 
potential protective effects of the novel triazolopyrazines 47, 78, 82, 84 and 85 against 
the oxaliplatin-induced neurotoxicity in rat microglia cells. These compounds were chosen 
taking into account their high affinity and selectivity toward the hA2AAR but also for the 
presence, in some of them (78, 82, 84 and 85), of antioxidant moieties which were 
envisaged to counteract the oxidative stress-neurotoxicity. Before to perform these 
studies, the antagonistic properties of the derivatives were preliminarly demonstrated in 
functional cAMP assays (data not shown).  
Primary rat microglia cells have been obtained then they were treated with oxaliplatin in 
the absence or in the presence of the tested compounds. Oxaliplatin damage was 
evaluated as cell viability and oxidative stress as previously described as a main damage 
evoked by oxaliplatin374,445. The new synthesized compounds were tested at 10 μM, the 
maximum soluble concentration. Oxaliplatin, concentration-dependently, strongly 
reduced microglia viability (MTT test) after 24 h incubation (33% and 19% viability with 
10 and 30 μM, respectively, in comparison to 100% of control condition).  
This oxaliplatin-induced neurotoxicity assay was performed by Dr. Lorenzo Di Cesare 
Mannelli at the NEUROFARBA Department – Pharmacology and Toxicology section, of the 
University of Florence.  The obtained results showed that derivative 82 was the most 
active in prevent the oxaliplatin damage also when incubated at the high concentration 
while 47 was effective against 10 μM oxaliplatin. With regard to the other tested 
compounds, only a partial activity has been observed for derivatives 78 and 85 whereas 
84, contrary to our expectations, turned out to be ineffective (Table 12). 
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Table 12 Cell viability (%)a 
 Oxa 0 μM Oxa 10 μM Oxa 30 μM 
Control 100.0 ± 7 33.2 ± 1.3** 19.1 ± 0.8** 
DMSO 0.75% 90.9 ± 8   
47 10 μM  48.7 ± 0.8^^ 23.0 ± 0.9 
78 10 μM  46.4 ± 1.4^^ 28.6 ± 1.21^ 
82 10 μM  54.5 ± 1.9^^ 34.2 ± 0.60^ 
84 10 μM  38.9 ± 1.6 18.3 ± 0.3 
85 10 μM  43.5 ± 1.8^ 30.6 ± 2.2^ 
 
aCell viability. Primary rat microglia cells were plated 4000 cells/well and 24 hours later cells were treated 
with oxaliplatin 10 and 30 μM in presence of 47, 78, 82, 84, 85 at 10 μM for 24 hours. Cell vitality was 
assessed via MTT assay. Viability is expressed as % in comparison to the control cells (arbitrarily set 100 % 
of viable cells). Data are presented as mean ± SEM. *P<0.05 and **P<0.01 versus control; ^P<0.05 and 
^^P<0.01 versus oxaliplatin. 
 
Further investigations were carried out these compounds by evaluating their ability to 
prevent the oxaliplatin-dependent increase of the SOD-inhibitable superoxide anion 
(cytochrome C assay). According to the obtained data, compounds 82 and 85 proved to 
be effective in significantly decrease the oxygen free radical level thus suggesting a direct 
antioxidant activity or, hypothetically, a protective property against mitochondrion 
(Figure 35).  
 
Figure 35. SOD-inhibitable O2.− concentrations. Microglia cells (5×105 cells/well) were exposed to 100 μM 
oxaliplatin for 4 h in the absence or presence of tested compounds (10 μM). O2.− concentration was 
evaluated by cytochrome c assay. The nonspecific absorbance was measured in the presence of SOD 
(300 mU/ml) and subtracted from the total value. Values are expressed as the mean ± SEM of three 
experiments. *P<0.05 and **P<0.01 versus control; ^P<0.05 and ^^P<0.01 versus oxaliplatin.  
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The activity of the detoxifying enzyme catalase was also measured to study the potential 
effect of new compounds on peroxisomes, the other intracellular organelle involved in 
the redox balance. As shown in Figure 36, oxaliplatin impaired peroxisome functionality 
reducing catalase activity while 82 and 85 significantly prevented the damage. 
 
 
Figure 36.  Activity of catalase. Microglia cells (5·105 cells/well) were treated with oxaliplatin (10 µM) in 
the absence or in the presence of new compounds (10 µM). Activity was measured after 24h incubations. 
Values are expressed as the mean ± S.E.M. percent of control of three experiments. Control condition was 
arbitrarily set as 100%. *P<0.05 and **P<0.01 versus control; ^P<0.05 and ^^P<0.01 versus oxaliplatin. 
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5. CONCLUSIONS 
The research activity accomplished in this PhD thesis led to the identification of the new 
and versatile 8-amino-1,2,4-triazolo[4,3-a]pyrazin-3-one scaffold which was successfully 
employed to obtain highly potent and selective antagonists for the hA2A AR and 
compounds able to bind with high affinity both the hA1 and the hA2A ARs. These type of 
AR antagonists have attracted our attention for their therapeutic potential in 
neurodegenerative disorders, such as PD and AD.  
Different sets of triazolopyrazines were designed and synthesized with diverse aims.  
 
The first set of compounds (1-10) was prepared to carry out a preliminary SAR study, and 
point out the basic structural requirements to target the A2A AR. The 2,6-diphenyl 
substituted compound 2 was the most notable within this set of ligands, possessing 
nanomolar affinity for hA1, hA2A and hA3 ARs (Ki = 10-13 nM). 
In the subsequent phase of the work a structural refinement was performed to enhance 
hA2A AR affinity and selectivity and expand the SAR study. Within this set of AR ligands 
(11-39), some derivatives (13, 19, 22, 24, 31 and 36) turned out to be highly potent and 
selective hA2A AR ligands (Ki = 2.9- 10.6 nM) while others (15, 30, 32, 33, 38 and 39) were 
able to efficiently bind both the hA1 (Ki = 4.7-33.5 nM) and hA2A ARs (Ki = 3.5-22.9 nM). 
Selected derivatives (13, 31 and 32), proved to be potent A2A AR antagonists, were further 
investigated for their in vitro neuroprotective effects. Compound 13, at 15 nM 
concentration, showed protective effect against the MPP+ induced-neurotoxicity in         
SH-SY5Y cells, a widely used cellular PD model. Derivative 31, at 0,3 μM concentration, 
demonstrated ability in counteracting the Aβ-amyloid peptide-induced toxicity in an AD 
model.  
The set including the triazolopyrazines 40-68 was designed to improve the drug-like 
properties of the compounds. Within this set of ligands, compounds 46-48, 51-55 
emerged as potent and highly selective hA2AAR antagonists (Ki = 0.59-26 nM) while 
derivatives 66-68 turned out to be dual potent hA1 (Ki =2-4.6 nM) and hA2A ligands (Ki= 
2.4-13 nM). Derivative 68 was selected to be tested for the potential neuroprotective 
effect in the same in vitro model of AD used for 31 and 32. The obtained results showed 
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that 68 was effective in preventing the cell mortality starting from concentration 0.1 µM 
and restoring the cell viability till to control level at 0.3 µM. 
Further investigations are currently ongoing to understand if these structural 
modifications have been effective in improving the drug-like properties of these 
compounds.  
The last purpose of the work was the synthesis of triazolopyrazines bearing, at position 6 
of the scaffold, potential antioxidant functions (compounds 74-86). These modifications 
were succesfull since compounds 78, 79, 81, 82, 84 and 85 showed high affinity and 
selectivity toward the hA2A AR (Ki = 1.7-54.5 nM) while 74 and 80 were able to bind 
efficiently both the hA1 (Ki = 8.4-29.8 nM) and hA2A (Ki = 5-16.8 nM) ARs. The selected 
derivatives 78, 82, 84 and 85 were tested for their potential protective effects in microglia 
cells against oxaliplatin-induced neurotoxicity. The obtained results highlighted that 
compound 82 was effective in preventing the oxaliplatin damage at 10 and 30 μM 
concentrations whereas only a partial activity has been observed for derivatives 78 and 
85. 
Further investigations are ongoing to confirm the stability of derivatives 75-80, 82 in 
human plasma, and in Tris/HCl and phosphate buffer solutions (PBS). These tests are 
being performed by the research group of Prof. Gianluca Bartolucci, at the NEUROFARBA 
Department – Pharmaceutical and Nutraceutical Section, of the University of Florence 
 
Molecular modeling investigations were carried out on the synthesized compounds to 
gain informations about their hypothetical binding mode at the A2AAR crystal structure 
and to provide useful indications for the design of new 8-amino-triazolo[4,3-a]pyrazin-3-
one derivatives as hA2A AR antagonists. 
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6. EXPERIMENTAL SECTION 
The microwave-assisted syntheses were performed using an Initiator EXP Microwave 
Biotage instrument (frequency of irradiation: 2.45 GHz). Silica gel 60 (Merck, 70-230 
mesh) was used for analytical TLC, and for column chromatog raphy, respectively. All 
melting points were determined on a Gallenkamp melting point apparatus and are 
uncorrected. Elemental analyses were performed with a Flash E1112 Thermofinnigan 
elemental analyzer for C, H, N and the results were within 0.4% of the theoretical values. 
All final compounds revealed purity not less than 95%. The IR spectra were recorded with 
a Perkin-Elmer Spectrum RX I spectrometer in Nujol mulls and are expressed in cm-1. NMR 
spectra were recorded on a Bruker Avance 400 spectrometer (400 MHz). The chemical 
shifts are reported in δ (ppm) and are relative to the central peak of the solvent which 
was CDCl3, MeOD or DMSO-d6. The following abbreviations are used: s= singlet, d= 
doublet, dd = doublet of doublets, t= triplet, q= quartet, m= multiplet, br= broad and ar= 
aromatic protons. The following abbreviation are used for solvents and reactive products: 
AcOH = Acetic acid, CDCl3 = Deuterated chloroform, CHCl3 = Chloroform, DCM = 
Dichloromethane, DIPEA = N,N-Diisopropylethylamine, DMF = Dimethylformamide, 
DMSO-d6 = Deuterated dimethyl sulfoxide, EtOAc = Ethyl acetate,  EDCI.HCl = N-(3-
Dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride,   Et2O = Diethyl ether, EtOH = 
Ethanol, HCl = Hydrochloric acid, HOBt = Hydroxybenzotriazole, MeOD = Deuterated 
methanol, MeOH = Methanol, THF = Tetrahydrofuran. 
 
General procedure for the synthesis of Ethyl 2-amino-2-arylhydrazonoacetates (94-97). 
 
2-amino-2-arylhydrazonoacetates 95 (R2= 4-OMe), 96 (R2= 4-NO2) and 97 (R2= 2-OMe)414 
were prepared as previously described for 94 (R= H)413 i.e. from the corresponding 2-
chloro derivatives 90-93.392,411,412 Briefly, 33% aqueous ammonia (3 mL) in dioxane (5 mL) 
was added dropwise to a solution of the suitable chloro derivative 90-93 (13.3 mmol) in 
dioxane (15 mL) and the reaction mixture was stirred for 4 h at room temperature. The 
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white solid was filtered off and the mother liquor was concentrated at reduced pressure. 
The obtained precipitate was collected by filtration, washed with water (30 mL), dried and 
recristallized. The crude compound 51 was obtained as an oil residue which was purified 
on silica gel column chromatography (eluent Cyclohexane 7/EtOAc 3). 
Ethyl 2-amino-2-(phenylhydrazono)acetate (94). Yield 73% m.p. 129-130 °C (lit413 128 °C) 
(Cyclohexane/EtOAc). 1H NMR (DMSO-d6) 1.28 (t, 3H, ar, J = 7.1 Hz), 4.23 (q, 2H, CH2, J = 
7.1 Hz), 5.88 (br s, 2H, NH2), 6.72 (t, 1H, ar, J = 7.3 Hz), 7.01 (d, 2H, ar, J = 7.6 Hz), 7.18 (t, 
1H, ar, J = 8.2 Hz), 8.66 (br s, 1H, NH). Anal. Calcd. for C10H13N3O2 
Ethyl 2-amino-2-(4-methoxyphenylhydrazono)acetate (95). Yield 55% brownish oil; 1H 
NMR (CDCl3) 1.42 (t, 3H, CH3, J= 7.1 Hz), 3.87 (s, 3H, OCH3), 4.38 (q, 2H, CH2, J= 7.1 Hz), 
4.69 (br s, 2H, NH2), 6.45 (br s, 1H, NH), 6.88 (d, 2H, ar, J= 9.0 Hz), 7.11 (d, 2H, ar, J= 9.0 
Hz), 8.27 (s, 1H, NH). Anal. Calcd. For C11H15N3O3. 
Ethyl 2-amino-2-(4-nitrophenylhydrazono)acetate (96). Yield 65 % m.p. 192-193 °C 
(EtOH) (lit414 190-191 °C). 1H NMR (DMSO-d6) 1.29 (t, 3H, CH3, J= 7.2 Hz), 4.27 (q, 2H, CH2, 
J= 7.2 Hz), 6.39 (br,s, 2H, NH2), 7.07 (d, 2H, ar, J= 9.2 Hz), 8.20 (d, 2H, ar, J= 9.2 Hz), 9.66 
(br s, 1H, NH). Anal. Calcd. For C10H12N4O4. 
Ethyl 2-amino-2-(2-methoxyphenylhydrazono)acetate (97). Yield 95% m.p. 99-101 °C 
(Cyclohexane/EtOAc). 1H- NMR (DMSO-d6) 1.28 (t, 3H, ar, J= 7.1 Hz), 3.82 (s, 3H, OCH3), 
4.23 (q, 2H, CH2, J= 7.1 Hz), 6.15 (br s, 2H, NH2), 6.73 (t, 1H, ar, J= 7.6 Hz), 6.84-6.92 (m, 
2H, ar), 7.28 (d, 1H, ar, J= 7.9 Hz), 7.86 (s, 1H, NH). Anal. Calcd. for C11H15N3O3.  
 
Synthesis of ethyl (Z)-2-amino-2-(2-benzylhydrazono)acetate (98). 
 
Ethyl thiooxamate (3.7 mmol) was added to a mixture of benzylhydrazine hydrochloride 
(3.7 mmol) and K2CO3 (3.7 mmol) in absolute ethanol (15 mL). The suspension was stirred 
at 25° C for 15 h then was treated with NaHCO3 saturated solution (40 mL) and extracted 
with EtOAc (30 mL x 3). The organic layer was washed with brine (30 mL x 3), anhydrified 
(Na2SO4) and evaporated under reduced pressure to give a brown solid which was used 
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for the next step without further purification. Yield 88%. 1H NMR (DMSO-d6) 1.22 (t, 3H, 
CH3, J = 7.1 Hz), 4.16 (q, 2H, CH2, J = 7. 1 Hz), 4.25 (d, 2H, CH2, J = 5.1 Hz), 5.49 (br s, 2H, 
NH2), 5.88 (t, 1H, NH, J = 5.1 Hz), 7.24-7.35 (m, 5H, ar). Anal. Calcd. For C11H15N3O2. 
 
General procedure for the synthesis of Ethyl 5-oxo-1-aryl-4,5-dihydro-1H-1,2,4-triazole-
3-carboxylates (99-102). 
 
A solution of triphosgene (4.2 mmol) in anhydrous THF (10 mL) was added dropwise to a 
stirred solution of ethyl 2-amino-2-(arylhydrazono)acetate derivatives 94-97 (4.6 mmol) 
in anhydrous THF (15 mL) at 0 °C. After the addition was completed, the mixture was 
stirred 2-3 h at room temperature. Then, most of the solvent was removed at reduced 
pressure and water (20 mL) was added to the residue to give a solid wich was collected 
by filtration, washed with water (20 mL), dried and recrystallized. 
Ethyl 5-oxo-1-phenyl-4,5-dihydro-1H-1,2,4-triazole-3-carboxylate (99). Yield 62%. m.p. 
200-202 °C (lit.415 193-194 °C) (Cyclohexane/EtOAc). 1H NMR (DMSO-d6) 1.33 (t, 3H, CH3, 
J = 7.1 Hz), 4.38 (q, 2H, CH2, J = 7.1 Hz), 7.30 (t, 1H, ar, J = 7.4 Hz), 7.49 (t, 2H, ar, J = 7.4 
Hz), 7.89 (d, 2H, ar, J = 7.6 Hz), 7.90 (s, 1H, H-9), 12.99 (br s, 1H, NH). Anal. Calcd. for 
C11H11N3O3. 
Ethyl 1-(4-methoxyphenyl)-5-oxo-4,5-dihydro-1H-1,2,4-triazole-3-carboxylate (100). 
Yield 42%. m.p. 186-187 °C (lit415 179 °C) (EtOH). 1H NMR (CDCl3) 1.48 (t, 3H, CH3, J= 7.2 
Hz), 3.80 (s, 3H, OCH3),4.50 (q, 2H, CH2, J= 7.2 Hz), 6.98 (d, 2H, ar, J= 9.1 Hz), 7.87 (d, 2H, 
ar, J= 9.1 Hz), 10.65 (br s, 1H, NH). Anal. Calcd. for C12H13N3O4.  
Ethyl 1-(4-nitrophenyl)-5-oxo-4,5-dihydro-1H-1,2,4-triazole-3-carboxylate (101). Yield 
65%. m.p. 241-242 °C (Cyclohexane/EtOAc). 1H NMR (CDCl3) 1.50 (t, 3H, CH3, J= 7.1 Hz,), 
4.55 (q, 2H, CH2, J= 7.1 Hz), 8.29-8.37 (m, 4H, ar), 10.31 (br s, 1H, NH). IR 3369, 1755, 1698, 
1513, 1375. Anal. Calcd. for C11H10N4O5.  
Ethyl 1-(2-methoxyphenyl)-5-oxo-4,5-dihydro-1H-1,2,4-triazole-3-carboxylate (102). 
Yield 79%. m.p. 131-133 °C (EtOAc). 1H NMR (DMSO-d6) 1.30 (t, 3H, CH3, J = 7.1 Hz), 3.78 
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(s, 3H, OCH3), 4.34 (q, 2H, CH2, J= 7.1 Hz), 7.06 (t, 1H, ar, J= 7.6 Hz), 7.21 (d, 1H, ar, J= 8.3 
Hz), 7.36 (d, 1H, J= 7.6 Hz), 7.49 (t, 1H, J= 7.6 Hz), 12.69 (br s, 1H, NH). Anal. Calcd. for 
C12H13N3O4. 
 
Synthesis of Ethyl 5-oxo-1-benzyl-4,5-dihydro-1H-1,2,4-triazole-3-carboxylate (103). 
 
Carbonyldiimidazole (5.4 mmol) was portion wise added to a cold (T= 0° C) suspension of 
ethyl (Z)-2-amino-2-(2-benzylhydrazono)acetate 98 (2.7 mmol) in anhydrous DCM (20 
mL). The mixture was stirred at room temperature for 15 h then was treated with a NH4Cl 
saturated solution (30 mL) and extracted with DCM (30 mL x 3). The organic phase was 
anhydrified (Na2SO4) and the solvent evaporated under reduced pressure to afford a 
yellow solid which was purified by column chromatography (Cyclohexane 6/EtOAc 
4/MeOH 1). Yield 35%. mp 154-156 °C. 1H NMR (DMSO-d6) 1.27 (t, 3H, CH3, J = 7.1 Hz), 
4.31 (q, 2H, CH2, J = 7.1 Hz), 4.95 (s, 2H, CH2), 7.26-7.38 (m, 5H, ar), 12.67 (br s, 1H, NH). 
Anal. Calc. for C12H13N3O3. 
 
General procedure for the synthesis of ethyl 1-aryl- and 1-benzyl-substituted 5-oxo-4-
(2-(hetero)aryl-2-oxoalkyl)-4,5-dihydro-1H-1,2,4-triazole-3-carboxylate derivatives 
(104-133). 
 
A solution of chloroacetone (1.2 mmol) or the suitable α-bromoketone (1.2 mmol), was 
added to a mixture of ethyl 1-aryl-5-oxo-1,2,4-triazole-3-carboxylate derivatives (99-103) 
(1 mmol) and potassium carbonate (2 mmol) in a mixture of DMF/acetonitrile (1:9, 10 
mL). The suspension was stirred at room temperature until the disappearance of the 
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starting material (TLC monitoring, 2-24 h). The solvent was removed at reduced pressure 
and the residue was treated with water (50-70 mL). The precipitate was collected by 
filtration, washed with water (20 mL), then with Et2O (10 mL). The crude compounds were 
purified by recrystallization except compound 129 which was purified by liquid 
chromatography.  
 
Ethyl 5-oxo-4-(2-oxopropyl)-1-phenyl-4,5-dihydro-1H-1,2,4-triazole-3-carboxylate 
(104). Yield 58% m.p. 104-105 °C (EtOH). 1H NMR (DMSO-d6) 1.31 (t, 3H, CH3, J = 7.1 Hz), 
2.28 (s, 3H, CH3), 4.35 (q, 2H, CH2, J = 7.1 Hz), 4.92 (s, 2H, CH2), 7.35 (t, 1H, ar, J = 7.4 Hz), 
7.54 (t, 2H, ar, J = 7.4 Hz), 7.91 (d, 2H, ar, J = 7.7 Hz). Anal. Calc. for C14H15N3O4.  
Ethyl 5-oxo-4-(2-oxo-2-phenylethyl)-1-phenyl-4,5-dihydro-1H-1,2,4-triazole-3-
carboxylate (105). Yield 75%. m.p. 157-159 °C (EtOAc/EtOH). 1H NMR (DMSO-d6) 1.21 (t, 
3H, ar, J = 7.1 Hz), 4.29 (q, 2H, CH2, J = 7.1 Hz), 5.59 (s, 2H, CH2), 7.37 (t, 1H, ar, J = 7.4 Hz), 
7.55 (t, 2H, ar, J = 7.6 Hz), 7.63 (t, 2H, ar, J = 7.7 Hz), 7.76 (t, 1H, ar, J = 7.4 Hz), 7.95 (d, 2H, 
ar, J = 7.7 Hz), 8.11 (d, 2H, ar, J = 7.8 Hz). Anal. Calc. for C19H17N3O4. 
Ethyl 1-(4-methoxyphenyl)-5-oxo-4-(2-oxopropyl)-4,5-dihydro-1H-1,2,4-triazole-3-
carboxylate (106). Yield 92%. m.p. 98-100 °C (EtOH). 1H NMR (DMSO-d6) 1.30 (t, 3H, CH3, 
J = 7.1 Hz), 3.80 (s, 3H, OMe), 4.34 (q, 2H, CH2, J = 7.1 Hz), 4.91 (s, 2H, CH2), 7.08 (d, 2H, 
ar, J = 9.1 Hz), 7.76 (d, 2H, ar, J = 9.1 Hz). Anal. Calc. for C15H17N3O5. 
Ethyl 1-(4-methoxyphenyl)-5-oxo-4-(2-oxo-2-phenylethyl)-4,5-dihydro-1H-1,2,4-
triazole-3-carboxylate (107). Yield 58%. m.p. 127-128 °C (Cyclohexane/EtOAc). 1H NMR 
(CDCl3) 1.38 (t, 3H, CH3, J= 7.1), 3.86 (s, 3H, OCH3), 4.40 (q, 2H, CH2, J= 7.1 Hz), 5.57 (s, 2H, 
CH2), 6.99 (d, 2H, ar, J= 9.1 Hz), 7.55 (t, 2H, ar, J = 7.5 Hz), 7.68 (t, 1H, ar, J = 7.4 Hz), 7.88 
(d, 2H, ar, J = 9.1 Hz), 8.03 (d, 2H, ar, J = 7.4 Hz). IR 1732, 1711, 1694. Anal. Calc. for 
C20H19N3O5.  
Ethyl 1-(4-nitrophenyl)-5-oxo-4-(2-oxo-2-phenylethyl)-4,5-dihydro-1H-1,2,4-triazole-3-
carboxylate (108). Yield 92%. m.p. 147-148 °C (MeOH). 1H NMR (CDCl3) 1.40 (t, 3H, CH3, 
J= 7.2 Hz), 4.44 (q, 2H, CH2, J= 7.2 Hz), 5.59 (s, 2H, CH2), 7.58 (t, 2H, ar, J = 7.2 Hz), 7.70 (t, 
1H, ar, J = 8.4 Hz), 8.04 (d, 2H, ar, J = 7.2 Hz), 8.35-8.38 (m, 4H, ar). IR 1736, 1725, 1700, 
1463, 1375. Anal. Calc. for C19H16N4O6.  
Ethyl 1-(2-methoxyphenyl)-5-oxo-4-(2-oxo-2-phenylethyl)-4,5-dihydro-1H-1,2,4-
triazole-3-carboxylate (109). Yield 65%. m.p. 88-90 °C (Cyclohexane/EtOAc). 1H NMR 
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(DMSO-d6) 1.18 (t, 3H, CH3, J =  7.1 Hz), 3.81 (s, 3H, OMe), 4.24 (q, 2H, CH2, J = 7.1 Hz), 
5.55 (s, 2H, CH2), 7.04-7.09 (m, 2H, ar), 7.42-7.48 (m, 2H, ar), 7.57 (t, 2H, ar, J = 7.5 Hz), 
7.67 (t, 1H, ar, J = 7.4 Hz), 8.04 (d, 2H, ar, J = 7.1 Hz). Anal. Calc. for C20H19N3O5. 
.Ethyl 4-[2-(2-methoxyphenyl)-2-oxoethyl]-5-oxo-1-phenyl-4,5-dihydro-1H-1,2,4-
triazole-3-carboxylate (110). Yield 53%. m.p. 155-157 °C (EtOH). 1H NMR (DMSO-d6) 1.21 
(t, 3H, CH3, J = 7.1 Hz), 4.02 (q, 2H, CH2, J = 7.1 Hz), 4.31 (s, 3H, OCH3), 5.37 (s, 2H, CH2), 
7.12 (t, 1H, ar, J = 7.5 Hz), 7.30 (d, 1H, ar, J = 8.6 Hz), 7.36 (t, 1H, ar, J = 7.4 Hz), 7.55 (t, 2H, 
ar, J = 7.6 Hz), 7.70 (t, 1H, ar, J = 7.8 Hz), 7.79 (d, 1H, ar, J = 7.8 Hz), 7.9 (d, 2H, ar, 7.9 Hz). 
C20H19N3O5 
Ethyl 4-[2-(3-methoxyphenyl)-2-oxoethyl]-5-oxo-1-phenyl-4,5-dihydro-1H-1,2,4-
triazole-3-carboxylate (111). Yield 80%. m.p. 123-125 °C (EtOH). 1H NMR (DMSO-d6) 1.20 
(t, 3H, ar, J = 7.1 Hz), 3.86 (s, 3H, OCH3), 4.29 (q, 2H, CH2, J = 7.1 Hz), 5.59 (s, 2H, CH2), 
7.34-7.38 (m, 2H, ar), 7.52-7.57 (m, 4H, ar), 7.71 (d, 1H, ar, J = 7.7 Hz), 7.94 (d, 2H, ar, J = 
8.0 Hz). Anal. Calc. for C20H19N3O5.  
Ethyl 4-[2-(4-methoxyphenyl)-2-oxoethyl]-5-oxo-1-phenyl-4,5-dihydro-1H-1,2,4-
triazole-3-carboxylate (112). Yield 85%. m.p. 149-151 °C (Cyclohexane/EtOAc). 1H NMR 
(CDCl3) 1.38 (t, 3H, CH3, J = 6.9 Hz), 3.93 (s, 3H, CH3), 4.41 (q, 2H, CH2, J = 6.9 Hz), 5.53 (s, 
2H, CH2), 7.02 (d, 2H, CH2, J = 7.6 Hz), 7.31 (t, 1H, ar, J = 7.4 Hz), 7.48 (t, 2H, ar, J = 7.4 Hz), 
8.01-8.05 (m, 4H, ar). Anal. Calc. for C20H19N3O5. 
Ethyl 4-[2-(4-methylphenyl)-2-oxoethyl]-5-oxo-1-phenyl-4,5-dihydro-1H-1,2,4-triazole-
3-carboxylate (113). Yield 60%. m.p. 189-190 °C (EtOH). 1H NMR (DMSO-d6) 1.19 (t, 3H, 
CH3, J = 6.9 Hz), 2.43 (s, 3H, CH3) 4.28 (q, 2H, CH2, J = 7.1 Hz), 5.55 (s, 2H, CH2), 7.37 (t, 1H, 
ar, J = 7.4 Hz), 7.43 (d, 2H, ar, J = 7.7 Hz), 7.55 (t, 2H, ar, J = 7.7 Hz), 7.94 (d, 2H, ar., J = 8.3 
Hz), 8.01 (d, 2H, ar, J = 7.6 Hz). Anal. Calc. for C20H19N3O4. 
Ethyl 4-[2-(3,4-methylendioxyphenyl)-2-oxoethyl]-5-oxo-1-phenyl-4,5-dihydro-1H-
1,2,4-triazole-3-carboxylate (114) Yield 77%. m.p. 179-181 °C (Cyclohexane/EtOAc). 1H 
NMR (CDCl3) 1.39 (t, 3H, CH3, J = 7.1 Hz), 4.42 (q, 2H, CH2, J = 7.1 Hz), 5.50 (s, 2H, CH2), 
6.11 (s, 2H, CH2), 6.94 (d, 1H, ar, J = 8.2 Hz), 7.31 (t, 1H, ar, J =  7.6 Hz),  7.48 (t, 3H, ar, J = 
8.0 Hz), 7.65 (d, 1H, ar, J = 8.2 Hz), 8.03 (d, 1H, ar, J = 8.0 Hz). Anal. Calc. for C20H17N3O6. 
Ethyl 4-[2-(3-bromophenyl)-2-oxoethyl]-5-oxo-1-phenyl-4,5-dihydro-1H-1,2,4-triazole-
3-carboxylate (115). Yield 62%. m.p. 200-202 °C (EtOH). 1H NMR (CDCl3) 1.40 (t, 3H, CH3, 
J = 7.1 Hz), 4.42 (q, 2H, CH2, J = 7.1 Hz), 5.54 (s, 2H, CH2 ), 7.32 (t, 1H, ar, J = 7.5 Hz), 7.43-
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7.5 (m, 3H, ar), 7.81 (d, 1H, ar, J = 8 Hz), 7.96 (d, 1H, ar, J = 7.8 Hz), 8.02 (d, 2H, ar, J = 8.2 
Hz), 8.16 (t, 1H, ar, J = 1.8 Hz). Anal. Calc. for C19H16BrN3O4. 
 Ethyl 4-[2-(4-bromophenyl)-2-oxoethyl]-ethyl-5-oxo-1-phenyl-4,5-dihydro-1H-1,2,4-
triazole-3-carboxylate (116). Yield 77%. m.p. 167-169 °C (EtOH). 1H NMR (CDCl3) 1.39 (t, 
3H, CH3, J = 7.1 Hz), 4.42 (q, 2H, CH2, J = 7.1 Hz), 5.53 (s, 2H, CH2 ), 7.32 (t, 1H, ar, J = 7.5 
Hz), 7.48 (t, 2H, ar, J = 8.4) Hz), 7.71 (d, 2H, ar, J = 6.7 Hz), 7.9 (d, 2H, ar, J = 8.6 Hz), 8.02 
(d, 2H, ar, J = 7.8 Hz). Anal. Calc. for C19H16BrN3O4. 
Ethyl 4-[2-(3-chlorophenyl)-2-oxoethyl]-5-oxo-1-phenyl-4,5-dihydro-1H-1,2,4-triazole-
3-carboxylate (117). Yield 47%. m.p. 141-143 °C (EtOH). 1H NMR (DMSO-d6) 1.20 (t, 3H, 
CH3, J = 7.1 Hz), 4.30 (q, 2H, CH2, J = 7.1 Hz), 5.61 (s, 2H, CH2 ), 7.37 (t, 1H, ar, J = 7.6 Hz), 
7.56 (t, 2H, ar, J = 7.6 Hz), 7.67 (t, 1H, ar, J = 7.9 Hz), 7.83-7.85 (dd, 1H, ar, J = 1.2 Hz, J = 
6.7 Hz), 7.94 (d, 2H, ar, J = 7.7 Hz), 8.08 (d, 1H, ar, J = 7. 8 Hz), 8.14 (t, 1H, ar, J = 1.8 Hz) 
(C, H, N). Anal.Calc. for C19H16ClN3O4. 
Ethyl 4-[2-(4-chlorophenyl)-2-oxoethyl]-ethyl-5-oxo-1-phenyl-4,5-dihydro-1H-1,2,4-
triazole-3-carboxylate (118). Yield 60%. m.p. 194-196 °C (MeOH). 1H NMR (DMSO-d6) 
1.20 (t, 3H, CH3, J = 7.1 Hz), 4.30 (q, 2H, CH2, J = 7.1 Hz), 5.59 (s, 2H, CH2), 7.37 (t, 1H, ar, J 
= 7. 4 Hz), 7.55 (t, 2H, ar, J = 7.5 Hz), 7.70 (d, 2H, ar, J = 8.6 Hz), 7.94 (d, 2H, ar, J = 7.9 Hz), 
8.13 (d, 2H, ar, J = 8.7 Hz). Anal. Calc. for C19H16ClN3O4. 
Ethyl 4-[2-(2-nitrophenyl)-2-oxoethyl]-5-oxo-1-phenyl-4,5-dihydro-1H-1,2,4-triazole-3-
carboxylate (119). Yield 92%. m.p. 171-173 °C (EtOH). 1H NMR (CDCl3) 1.49 (t, 3H, CH3, J 
= 7.1 Hz), 4.52 (q, 2H, CH2, J = 7.1 Hz), 5.44 (s, 2H, CH2 ), 7.32 (t, 1H, ar, J = 7.4 Hz), 7.48 (t, 
2H, ar, J = 7.8 Hz), 7.70-7.77 (m, 2H, ar), 7.84 (t, 1H, ar, J = 7.3 Hz ), 8.04 (d, 2H, ar, J = 7.9 
Hz), 8.22 (d, 1H, ar, J = 8.2 Hz). Anal. Calc. for C19H16N4O6. 
Ethyl 4-[2-(3-nitrophenyl)-2-oxoethyl]-5-oxo-1-phenyl-4,5-dihydro-1H-1,2,4-triazole-3-
carboxylate (120). Yield 89%. m.p. 134-136 °C (Cyclohexane/EtOAc). 1H NMR (DMSO-d6) 
1.20 (t, 3H, CH3, J = 7.1 Hz), 4.30 (q, 2H, CH2, J = 7.3 Hz), 5.71 (s, 2H, CH2 ), 7.39 (t, 1H, ar, 
J = 7.4 Hz), 7.56 (t, 2H, ar, J =  8.1 Hz), 7.91-7.95 (m, 3H, ar), 8.57 (t, 2H, ar, J = 8. 6 Hz ), 
8.78 (s, 1H, ar). Anal. Calc. for C19H16N4O6. 
Ethyl-4-[2-(4-nitrophenyl)-2-oxoethyl]-5-oxo-1-phenyl-4,5-dihydro-1H-1,2,4-triazole-3-
carboxylate (121). Yield 97%. m.p. 180-182 °C (EtOH/Nitromethane). 1H NMR (DMSO-d6) 
1.21 (t, 3H, CH3, J = 7.1 Hz), 4.30 (q, 2H, CH2, J = 7.1 Hz), 5.67 (s, 2H, CH2 ), 7.37 (t, 1H, ar, 
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J = 7.5 Hz), 7.56 (t, 2H, ar, J = 8.3 Hz), 7.94 (d, 2H, ar, J = 7.8 Hz), 8.35 (d, 2H, ar, J = 8.8 Hz), 
8.43 (d, 2H, ar, J = 8.8 Hz). Anal. Calc. for C19H16N4O6. 
Ethyl 4-[2-(furan-2-yl)-2-oxoethyl]-5-oxo-1-phenyl-4,5-dihydro-1H-1,2,4-triazole-3-
carboxylate (122). Yield 72%. m.p. 170-172 °C (EtOH). 1H NMR (DMSO-d6) 1.22 (t, 3H, CH3, 
J= 7.1 Hz), 4.31 (q, 2H, CH2, J= 7.1 Hz), 5.37 (s, 2H, CH2), 6.84 (d, 1H, furan proton, J= 2.0 
Hz),7.35-7.38 (m, 1H, ar), 7.53-7.57 (m, 2H, ar),7.75 (d, 1H, furan proton, J= 2.0 Hz), 7.93 
(d, 2H, ar, J= 7.4 Hz), 8.15 (m, 1H, furan proton). Anal. Calc. for C17H15N3O5. 
Ethyl 4-[2-(5-methylfuran-2-yl)-2-oxoethyl]-5-oxo-1-phenyl-4,5-dihydro-1H-1,2,4-
triazole-3-carboxylate (123). Yield 58%. m.p. 142-144 °C (Cyclohexane/AcOEt). 1H NMR 
(CDCl3) 1.40 (t, 3H, CH3, J = 7.1 Hz), 2.46 (s, 3H, CH3), 4.42 (q, 2H, CH2, J = 7.1 Hz), 5.40 (s, 
2H, CH2), 6.26 (d, 1H, furan proton, J = 2.8 Hz), 7.31-7.33 (m, 2H, 1 ar, 1 furan proton), 7.47 
(t, 2H, ar, J = 7.7 Hz), 8.03 (d, 2H, ar, J = 8.4 Hz). Anal. Calc. for C18H17N3O5. 
Ethyl 4-[2-(thiophen-2-yl)-2-oxoethyl]-5-oxo-1-phenyl-4,5-dihydro-1H-1,2,4-triazole-3-
carboxylate (124). Yield 80%. m.p. 167-168 °C (EtOH). 1H-NMR (DMSO-d6) 1.21 (t, 3H, CH3, 
J = 7.1 Hz), 4.31 (q, 2H, CH2, J = 7.1 Hz), 5.52 (s, 2H, CH2), 7.35-7.39 (m, 2H, CH2), 7.55 (t, 
2H, ar, J = 7.8 Hz), 7.94 (d, 2H, ar, J = 7.7 Hz), 8.18 (d, 1H, ar, J = 4.0 Hz), 8.28 (d, 1H, ar, J = 
2.9 Hz). Anal. Calc. for C17H15N3O4S. 
 Ethyl 4-[2-(pyrid-2-yl)-2-oxoethyl]-5-oxo-1-phenyl-4,5-dihydro-1H-1,2,4-triazole-3-
carboxylate (125). Yield 30%. m.p. 153-155 °C (EtOH). 1H-NMR (DMSO-d6) 1.29 (t, 3H, CH3, 
J = 7.0 Hz), 4.29 (q, 2H, CH2, J = 7.0 Hz), 5.67 (s, 2H, CH2), 7.37 (t, 1H, ar, J = 7.4 Hz), 7.55 
(t, 2H, ar, J = 7.8 Hz), 7.80 (t, 1H, ar, J = 3.1 Hz), 7.82 (d, 1H, ar, J = 4.8 Hz), 7.95 (d, 1H, ar, J 
= 8.5 Hz), 8.05 (d, 1H, ar, J = 7.8 Hz), 8.11 (t, 1H, ar, J = 7.7 Hz), 8.85 (d, 1H, ar, J = 4.7 Hz). 
Anal. Calc. for C18H16N4O4. 
Ethyl 1-benzyl-5-oxo-4-[2-oxo-2-phenylethyl]-4,5-dihydro-1H-1,2,4-triazole-3-
carboxylate (126). Yield 34%. m.p. 90-92 °C. 1H NMR (CDCl3) 1.34 (t, 3H, CH3, J = 7.1 Hz), 
4.36 (q, 2H, CH2, J = 7.1 Hz), 5.15 (s, 2H. CH2), 5.51 (s, 2H. CH2), 7.32-7.42 (m, 5H, ar), 7.54 
(t, 2H, ar, J = 7.7 Hz), 7.67 (t, 1H, ar, J = 7.5 Hz), 8.01 (d, 2H, J =7.7 Hz). Anal. Calc. for 
C20H19N3O4. 
Ethyl 1-benzyl-4-[2-(furan-2-yl)-2-oxoethyl]-5-oxo-4,5-dihydro-1H-1,2,4-triazole-3-
carboxylate (127). Yield 68%. m.p. 104-106 °C. 1H NMR (CDCl3) 1.34 (t, 3H, CH3, J = 7.1 
Hz), 4.36 (q, 2H, CH2, J = 7.1 Hz), 5.13 (s, 2H. CH2), 5.37 (s, 2H. CH2), 6.63 (dd, 1H, furan 
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proton, J = 1.6 Hz, J = 1.9 Hz), 7.32-7.41 (m, 6H, 5ar + 1 furan proton), 7.67 (s, 1H, furan 
proton). Anal. Calc. for C18H17N3O5. 
Ethyl 1-benzyl-4-[2-(5-methylfuran-2-yl)-2-oxoethyl]-5-oxo-4,5-dihydro-1H-1,2,4-
triazole-3-carboxylate (128). Yield 93%. Oily compound. 1H NMR (CDCl3) 1.35 (t, 3H, CH3, 
J = 7.1 Hz), 2.44 (s, 3H, CH3), 4.37 (q, 2H, CH2, J = 7.1 Hz), 5.13 (s, 2H, CH2), 5.33 (s, 2H, 
CH2), 6.24 (d, 1H, furan proton, J = 3.3 Hz), 7.25 (d, 1H, 1 furan proton, J = 3.4 Hz), 7.41-
7.31 (m, 5H, ar). C19H19N3O5. 
Ethyl 4-[2-(2,4-dimethoxyphenyl)-2-oxoethyl]-5-oxo-1-phenyl-4,5-dihydro-1H-1,2,4-
triazole-3-carboxylate (129). Yield 85%. m.p. 150-152 °C. Purified by column 
chromatography (Cyclohexane 6/EtOAc 4). 1H NMR (CDCl3-d6) 1.38 (t, 3H, CH3, J = 7.1 Hz), 
3.96 (s, 3H, CH3 ), 3.98 (s, 3H, CH3 ), 4.41 (q, 2H, CH2, J = 7.1 Hz), 5.45 (s, 2H, CH2 ),  6.53 (d, 
1H, ar, J = 1.8 Hz), 6.61 (dd, 1H, ar, J = 1.9 Hz, J = 6.8 Hz), 7.30 (t, 1H, ar, J = 7.3 Hz), 7.47 
(t, 2H, ar, J = 7.8 Hz), 7.99-8.07 (m, 3H, ar). Anal. Calc. for C22H23N3O6. 
Ethyl 4-[2-(3,4-dimethoxyphenyl)-2-oxoethyl]-5-oxo-1-phenyl-4,5-dihydro-1H-1,2,4-
triazole-3-carboxylate (130). Yield 76%. m.p. 159-161 °C (EtOH). 1H NMR (CDCl3) 1.39 (t, 
3H, CH3, J= 7.1 Hz), 3.96 (s, 3H, OCH3), 4.00 (s, 3H, OCH3), 5.55 (s, 2H, CH2), 6.97 (d, 1H, ar, 
J= 8.4 Hz), 7.31 (t, 1H, ar, J= 7.4 Hz), 7.48 (t, 2H, ar, J= 8.3 Hz), 7.54 (d, 1H, J= 1.7 Hz), 7.68 
(d, 1H, ar, J= 8.4 Hz), 8.02 (d, 2H, ar, J= 8.2 Hz). Anal. Calc. for C21H21N3O6. C22H23N3O6. 
Ethyl 4-[2-(3,4,5-trimethoxyphenyl)-2-oxoethyl]-5-oxo-1-phenyl-4,5-dihydro-1H-1,2,4-
triazole-3-carboxylate (131). Yield 95%. m.p. 131-133 °C (Cyclohexane/EtOAc). 1H NMR 
(CDCl3) 1.41 (t, 3H, CH3, J = 7.1 Hz), 4.43 (q, 2H, CH2, J = 7.1 Hz), 5.55 (s, 2H, CH2), 7.27-
7.34 (m, 4H, ar), 7.49 (t, 2H, ar, J = 7.4 Hz), 8.04 (d, 2H, ar, J = 8.6 Hz). Anal. Calc. for 
C23H25N3O7 
Ethyl 4-(2-(4-methoxy-3,5-dimethylphenyl)-2-oxoethyl)-5-oxo-1-phenyl-4,5-dihydro-
1H-1,2,4-triazole-3-carboxylate (132). Yield 70%. m.p. 140-142 °C (EtOH). 1H-NMR (CDCl3) 
1.39 (t, 3H, CH3, J = 7.1 Hz), 2.38 (s, 6H, CH3),  3.81 (s, 3H, CH3),  4.41 (q, 2H, CH2, J = 7.1 
Hz),  5.52 (s, 2H, CH2),  7.31 (t, 1H, ar, J = 7.2 Hz),  7.48 (t, 2H, ar, J = 7.9 Hz), 7.71 (s, 2H, 
ar), 8.04 (d, 2H, ar, J = 8.1 Hz). Anal. Calc. for C23H25N3O5. 
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Ethyl 4-(2-(3,5-di-tert-butyl-4-methoxyphenyl)-2-oxoethyl)-5-oxo-1-phenyl-4,5-dihydro-
1H-1,2,4-triazole-3-carboxylate (133). Yield 60%. m.p. 196-198 °C (EtOH). 1H-NMR 
(CDCl3-d)  1.40 (t, 3H, CH3, J = 7.1 Hz), 1.48 (s, 18H, (CH3)3), 3.76 (s, 3H, CH3), 4.42 (q, 2H, 
CH2, J = 7.1 Hz), 5.56 (s, 2H, CH2), 7.32 (t, 1H, ar, J = 7.5 Hz ), 7.48 (t, 2H, ar, J = 7.7 Hz ), 
7.94 (s, 2H, ar), 8.04 (d, 2H, ar, J = 7.8 Hz ). Anal. Calc. for C29H37N3O5. 
 
General procedure for the synthesis of 1,2,4-triazolo[4,3-a]pyrazine-3,8(2H,7H)-dione 
derivatives (134-163). 
 
A mixture of the suitable ethyl 1,2,4-triazole-3-carboxylate derivatives 104-133 (0.87 
mmol) and ammonium acetate (3.48 mmol) was heated under microwave irradiation at 
140 °C otherwise in a sealed tube at 130°C (compound 139) or 190 °C (compounds 136, 
137) until the disappearance of starting material (TLC monitoring, 3-24 h). The residue 
was taken up with EtOH (1 mL) and Et2O (5 mL), collected by filtration and washed with 
water (20 mL). All the crude compounds were purified by recrystallization. 
6-Methyl-2-phenyl-1,2,4-triazolo[4,3-a]pyrazine-3,8(2H,7H)-dione (134). Yield 85%. 
m.p. 288-289 °C (2-Methoxyethanol). 1H NMR (DMSO-d6) 2.04 (s, 3H, CH3), 6.88 (s, 1H, H-
5), 7.34 (t, 1H, ar, J = 7.4 Hz), 7.54 (t, 2H, ar, J = 7.8 Hz), 7.98 (d, 2H, ar, J = 8.3 Hz), 11.32 
(br s, 1H, NH). Anal. Calc. for C12H10N4O2.  
2,6-Diphenyl-1,2,4-triazolo[4,3-a]pyrazine-3,8(2H,7H)-dione (135). Yield 65%. m.p. 290-
291 °C (2-Methoxyethanol). 1H NMR (DMSO-d6) 7.28 (s, 1H, H-5), 7.37 (t, 1H, ar, J = 7.4 
Hz), 7.46-7.51 (m, 2H, ar,), 7.57 (t, 2H, ar, J = 7.7 Hz), 7.72 (d, 2H, ar, J = 8.0 Hz), 8.02 (d, 
2H, ar, J = 7.9 Hz), 11.63 (br s, 1H, NH). Anal. Calc. for C17H12N4O2.  
6-Methyl-2-(4-methoxyphenyl)-1,2,4-triazolo[4,3-a]pyrazine-3,8(2H,7H)-dione (136). 
Yield 78%. m.p. > 300 °C (DMF). 1H NMR (DMSO-d6) 2.04 (s, 3H, CH3), 3.80 (s, 3H, OCH3), 
6.87 (s, 1H, H-5), 7.09 (d, 2H, ar, J= 9.1 Hz), 7.85 (d, 2H, ar, J= 9.1 Hz), 11.30 (br s, 1H, NH). 
Anal. Calc. for C13H12N4O3.  
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2-(4-Methoxyphenyl)-6-phenyl-1,2,4-triazolo[4,3-a]pyrazine-3,8(2H,7H)-dione (137). 
Yield 75% m.p. >300 °C (DMF). 1H NMR (DMSO-d6) 3.82 (s, 3H, CH3), 7.14 (d, 2H, ar, J= 9.0 
Hz), 7.26 (s, 1H, H-5) 7.46-7.51 (m, 3H, ar), 7.71 (d, 2H, ar, J= 6.2 Hz), 7.88 (d, 2H, ar, J= 9.0 
Hz), 11.60 (br s, 1H, NH). IR 3218, 1688. Anal. Calc. for C18H14N4O3   
2-(4-Nitrophenyl)-6-phenyl-1,2,4-triazolo[4,3-a]pyrazine-3,8(2H,7H)-dione (138). Yield 
92%. m.p. > 300 °C (DMF). 1H NMR (DMSO-d6) 7.32 (s, 1H, H-5), 7.47-7.50 (m, 3H, ar), 
7.72-7.74 (m, 2H, ar), 8.34 (d, 2H, ar, J = 9.2 Hz), 8.46 (d, 2H, ar, J = 9.2 Hz), 11.71 (br s, 1H, 
NH). IR 3260, 1686. Anal. Calc. for C17H11N5O4  
2-(2-Methoxyphenyl)-6-phenyl-1,2,4-triazolo[4,3-a]pyrazine-3,8(2H,7H)-dione (139). 
Yield 85%. m.p. > 300 °C (2-Methoxyethanol). 1H NMR (DMSO-d6) 3.99 (s, 3H, OMe), 7.12 
(t, 1H, ar, J= 7.1 Hz), 7.23 (s, 1H, H-5), 7.27 (d, 1H, ar, J = 7.7 Hz), 7.44-7.50 (m, 4H, ar), 
7.53 (t, 1H, ar, J = 8.5 Hz), 7.71 (s, 2H, ar, J = 8.2 Hz), 11.60 (br s, 1H, NH). IR 3259, 1714, 
1689. Anal. Calc. for C18H14N4O3. 
6-(2-Methoxyphenyl)-2-phenyl-1,2,4-triazolo[4,3-a]pyrazine-3,8(2H,7H)-dione (140). 
Yield 77%. m.p. 279-281 °C (2-Methoxyethanol/DMF). 1H NMR (DMSO-d6) 3.84 (s, 3H, 
CH3), 7.02 (s, 1H, H-5), 7.05 (t, 1H, ar, J = 8.3 Hz), 7.15 (d, 1H, ar, J = 8.00 Hz), 7.36 (t, 1H, 
ar, J = 7.4 Hz), 7.41-7.49 (m, 2H, ar), 7.56 (t, 2H, ar, J = 8.4  Hz), 8.01 (d, 2H, ar, J =7.6 Hz) 
11.39 (br s, 1H, NH). Anal. Calc. for C18H14N4O3. 
6-(3-Methoxyphenyl)-2-phenyl-1,2,4-triazolo[4,3-a]pyrazine-3,8(2H,7H)-dione (141). 
Yield 79%. m.p.> 300 °C (2-Methoxyethanol). 1H NMR (DMSO-d6) 3.85 (s, 3H, CH3), 6.99-
7.02 (m, 1H, ar), 7.27-7.30 (m, 2H, ar), 7.35-7.40 (m, 2H, 1 ar + H-5), 7.57 (t, 2H, ar, J = 7.1 
Hz), 8.02 (d, 2H, ar, J = 8.6 Hz), 11.60 (s, 1H, NH). Anal. Calc. for C18H14N4O3.  
6-(4-Methoxyphenyl)-2-phenyl-1,2,4-triazolo[4,3-a]pyrazine-3,8(2H,7H)-dione (142). 
Yield 70%. m.p. 290-291 °C (2-Methoxyethanol). 1H NMR (DMSO-d6) 3.82 (s, 3H, CH3), 7.03 
(d, 2H, ar., J = 8.8 Hz), 7.19 (s, 1H, H5), 7.36 (t, 1H, ar, J = 7.4 Hz), 7.56 (t, 2H, ar, J = 8.0 Hz), 
7.66 (d, 2H, ar., J = 8.8 Hz), 8.02 (d, 2H, ar, J = 7.8 Hz), 11.55 (br s, 1H, NH). IR 3229, 1682 
cm-1. Anal. Calc. for C18H14N4O3. 
6-(4-Methylphenyl)-2-phenyl-1,2,4-triazolo[4,3-a]pyrazine-3,8(2H,7H)-dione (143) . 
Yield 80%. m.p. > 300 °C (EtOH/2-Methoxyethanol). 1H NMR (DMSO-d6) 2.36 (s, 3H, CH3), 
7.23 (s, 1H, H-5), 7.29 (d, 2H, ar, J = 8.0 Hz), 7.37 (t, 1H, ar, J = 7.1 Hz), 7.54-7.62 (m, 4H, 
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ar.), 8.02 (d, 2H, ar, J = 8.5 Hz), 11.59 (br s, 1H, NH). IR 3387, 1688. Anal. Calc. For 
C18H14N4O2. 
6-(3,4-methylendioxyphenyl)-2-phenyl-1,2,4-triazolo[4,3-a]pyrazine-3,8(2H,7H)-dione 
(144). Yield 78%. m.p. 279-281 °C (AcOH/DMF). 1H NMR (DMSO-d6) 6.10 (s, 2H, CH2), 7.01 
(d, 1H, ar, J = 8.16 Hz), 7.20-7.23 (m, 2H, 1 ar, H-5), 7.30 (d, 1H, ar, J = 1.6 Hz), 7.36 (t, 1H, 
ar, J = 7.4 Hz), 7.56 (t, 2H, ar, J =  7.7 Hz), 8.01 (d, 2H, ar, J = 7.8 Hz) 11.53 (br s, 1H, NH). 
Anal. Calc. For C18H12N4O4. 
6-(3-Bromophenyl)-2-phenyl-1,2,4-triazolo[4,3-a]pyrazine-3,8(2H,7H)-dione (145). 
Yield 47%. m.p. > 300 °C (2-Methoxyethanol). 1H NMR (DMSO-d6) 7.37 (t, 1H, ar, J = 7.4 
Hz), 7.41-7.45 (m, 2H, 1 ar, H-5), 7.56 (t, 2H, ar, J = 8.4 Hz), 7.64 (d, 1H, ar, J = 8.0 Hz), 7.74 
(d, 1H, ar, J = 8.6 Hz), 7.96 (s, 1H, ar), 8.02 (d, 2H, ar, J = 8.8 Hz), 11.67 (br s, 1H, NH). Anal. 
Calc. For C17H11BrN4O2. 
6-(4-Bromophenyl)-2-phenyl-1,2,4-triazolo[4,3-a]pyrazine-3,8(2H,7H)-dione (146). Yield 
49%. m.p. > 300 °C (AcOH/DMF). 1H NMR (DMSO-d6) 7.35-7.38 (m, 2H, 1 ar, H-5), 7.56 (t, 
2H, ar, J = 7.7 Hz), 7.67 (s, 4H, ar), 8.01 (d, 2H, ar, J = 7.7 Hz), 11.62 (br s, 1H, ar). Anal. 
Calc. For C17H11BrN4O2. 
6-(3-Chlorophenyl)-2-phenyl-1,2,4-triazolo[4,3-a]pyrazine-3,8(2H,7H)-dione (147). Yield 
76%. m.p. > 300 °C (2-Methoxyethanol). 1H NMR (DMSO-d6) 7.37 (t, 1H, ar, J = 7.3 Hz), 
7.44 (s, 1H, H-5), 7.50-7.54 (m, 2H, ar), 7.56 (t, 2H, ar, J = 7.8 Hz), 7.69-7.71 (m, 1H, ar), 
7.83 (s, 1H, ar), 8.01 (d, 2H, ar, J = 7.80 Hz ) 11.65 (br s, 1H, NH). Anal. Calc. For 
C17H11ClN4O2. 
6-(4-Chlorophenyl)-2-phenyl-1,2,4-triazolo[4,3-a]pyrazine-3,8(2H,7H)-dione (148). Yield 
81%. m.p. > 300 °C (2-Methoxyethanol/DMF). 1H NMR (DMSO-d6) 7.35-7.38 (m, 2H, 1 ar, 
H-5), 7.53-7.58 (m, 4H, ar), 7.74 (d, 2H, ar, J = 8.6 Hz ), 8.01 (d, 2H, ar, J = 8.00 Hz), 11.66 
(br s, 1H, ar). 13C NMR (DMSO-d6) 100.92, 119.58, 126.98, 127.27, 128.77, 129.22, 129.81, 
130.31, 134.37, 135.96, 137.67, 147.67, 153.47. Anal. Calc. For C17H11ClN4O2. 
6-(2-Nitrophenyl)-2-phenyl-1,2,4-triazolo[4,3-a]pyrazine-3,8(2H,7H)-dione (149). Yield 
66%. m.p. > 300 °C (2-Methoxyethanol). 1H NMR (DMSO-d6), 7.20 (s, 1H, H-5), 7.41 (t, 1H, 
ar, J = 7.4 Hz), 7.60 (t, 2H, ar, J = 7.6 Hz ), 7.75 (d, 1H, ar, J = 6.1 Hz), 7.84 (t, 1H, ar, J = 7.6 
Hz), 7. 93 (t, 1H, ar, J = 7.5 Hz), 8.02 (d, 2H, ar, J = 8.5 Hz), 8.31 (d, 1H, ar, J = 8.1 Hz), 11.8 
(br s, 1H, NH). Anal. Calc. For C17H11N5O4. 
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6-(3-Nitrophenyl)-2-phenyl-1,2,4-triazolo[4,3-a]pyrazine-3,8(2H,7H)-dione (150). Yield 
62%. m.p. > 300 °C (AcOH). 1H NMR (DMSO-d6), 7.37 (t, 1H, ar, J = 7.4 Hz ), 7.55-7-59 (m, 
3H, 2 ar, H-5), 7.77 (t, 1H, ar, J = 8. 00 Hz), 8.02 (d, 2H, ar, J = 7.8 Hz), 8.19 (d, 1H, ar, J = 
7.7 Hz), 8.29 (d,1H, ar, J = ) 8.57 (s, 1H, ar) 11. 87 (br s, 1H, NH). Anal. Calc. For C17H11N5O4. 
6-(4-Nitrophenyl)-2-phenyl-1,2,4-triazolo[4,3-a]pyrazine-3,8(2H,7H)-dione (151). Yield 
88%. m.p. > 300 °C (2-Methoxyethanol/DMF). 1H NMR (DMSO-d6) 7.37 (t, 1H, ar, J = 7.4 
Hz), 7.57 (m, 3H, 2 ar, H-5), 8.00-8.03 (m, 4H, ar), 8.29 (d, 2H, ar, J = 8.7 Hz), 11.83 (br s, 
1H, NH). Anal. Calc. For C17H11N5O4. 
6-(2-Furan-2-yl)-2-phenyl-1,2,4-triazolo[4,3-a]pyrazine-3,8(2H,7H)-dione (152). Yield 
73%. m.p. 298-299 °C (EtOH). 1H NMR (DMSO-d6) 6.65-6.67 (m, 1H, furan proton), 7.16 (s, 
1H, H-5), 7.21 (d, 1H, furan proton, J= 1.8 Hz),7.35-7.38 (m, 1H, ar), 7.54-7.58 (m, 2H, ar), 
7.80-7.82 (m, 1H, furan proton), 7.99-8.01 (m, 2H, ar), 11.71 (br s, 1H, NH). IR 3187, 3123, 
1691. Anal. Calc. For C15H10N4O3. 
6-(5-Methylfuran-2-yl)-2-phenyl-1,2,4-triazolo[4,3-a]pyrazine-3,8(2H,7H)-dione (153). 
Yield 75%. m.p. 281-283 °C (AcOH). 1H NMR (DMSO-d6) 2.35 (s, 3H, CH3), 6.26 (d, 1H, furan 
proton, J = 2.3 Hz), 7.07- 7.08 (m, 2H, H-5 + furan proton), 7.36 (t, 1H, ar, J = 7.5 Hz), 7.56 
(t, 2H, ar, J = 7.7 Hz), 8.00 (d, 2H, ar, J = 7.6 Hz) 11.63 (br s, 1H, NH).  Anal. Calc. For 
C16H12N4O3. 
2-Phenyl-6-(2-thienyl)-1,2,4-triazolo[4,3-a]pyrazine-3,8(2H,7H)-dione (154). Yield 55% 
m.p. > 300 °C (2-Methoxyethanol). 1H NMR (DMSO-d6) 7.17 (q, 2H, ar, J = 3.6 Hz), 7.36 (t, 
1H, ar, J = 7.4 Hz), 7.56 (t, 2H, ar, J = 7.9 Hz), 7.67 (d, 2H, ar + H-5, J = 4.4 Hz), 8.00 (d, 2H, 
ar, J = 7.9 Hz), 11.70 (br. s, 1H, NH). Anal. Calc. For C15H10N4O2S. 
2-Phenyl-6-(2-pyridyl)-1,2,4-triazolo[4,3-a]pyrazine-3,8(2H,7H)-dione (155). Yield 70%.  
m.p. 264-265 °C (EtOH/2-Methoxyethanol). 1H NMR (DMSO-d6) 7.38 (t, 1H, ar, J = 7.4 Hz), 
7.46 (t, 1H, ar, J = 4.1 Hz), 7.57 (t, 2H, ar, J = 8.0 Hz), 7.92-7.97 (m, 2H, ar + H-5), 8.02 (d, 
2H, ar, J = 8.4 Hz), 8.19 (d, 1H, ar, J = 8.1 Hz), 8.68 (d, 1H, pyridine proton, J = 4.8 Hz), 11.02 
(br s, 1H, NH). IR 3254, 1688. Anal. Calc. For C16H11N5O2. 
2-Benzyl-6-phenyl-1,2,4-triazolo[4,3-a]pyrazine-3,8(2H,7H)-dione (156). Yield 32%. m.p. 
278-279 °C (2-Methoxyethanol). 1H NMR (DMSO-d6) 5.13 (s, 2H, CH2), 7.20 (s, 1H, H-5), 
7.35-7.38 (m, 5H, ar), 7.45-7.47 (m, 3H, ar), 7.68-7.69 (m, 2H, ar), 11.49 (br s, 1H, NH). . 
Anal. Calc. For C18H14N4O2. 
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2-Benzyl-6-(furan-2-yl)-1,2,4-triazolo[4,3-a]pyrazine-3,8(2H,7H)-dione (157). Yield 81%. 
m.p. 280-282 °C (AcOH). 1H NMR (DMSO-d6) 5.11 (s, 2H, CH2), 6.63 (dd, 1H, furan proton, 
J = 1.6 Hz, J = 1.8 Hz), 7.11 (s, 1H, H-5), 7.16 (d, 1H, ar, J = 3. 4 Hz), 7.32-7.39 (m, 5H, 4ar + 
1 furan proton), 7.8 (s, 1H, furan proton), 11.56 (br s, 1H, NH). Anal. Calc. For C16H12N4O3. 
2-Benzyl-6-(5-methylfuran-2-yl)-1,2,4-triazolo[4,3-a]pyrazine-3,8(2H,7H)-dione (158). 
Yield 28%. m.p. 286-288 °C (AcOH). 1H NMR (DMSO-d6) 2.32 (s, 3H, CH3), 5.11 (s, 2H, CH2), 
6.22 (s, 1H, furan proton), 7.01 (s, 1H, furan proton), 7.03 (s, 1H, H-5), 7.34-7.37 (m, 5H, 
ar), 11.46 (br s, 1H, NH). Anal. Calc. For C17H14N4O3. 
6-(2,4-Dimethoxyphenyl)-2-phenyl-1,2,4-triazolo[4,3-a]pyrazine-3,8(2H,7H)-dione 
(159). Yield 64%. mp 252-254 °C (AcOH). 1H NMR (DMSO-d6) 3.84 (s, 6H, CH3), 6.60 (dd, 
1H, ar, J = 2.4 Hz, J = 6.1 Hz),  6.67 (d, 1H, ar, J = 2.3 Hz), 6.93 (s, 1H, H-5), 7.33-7.37 (m, 
2H, ar), 7.55 (t, 2H, ar, J = 7.60 Hz),  8.00 (d, 2H, ar, J = 7.7 Hz),  11.34 (br s, 1H, NH). Anal. 
Calc. For C19H16N4O4. 
6-(3,4-Dimethoxyphenyl)-2-phenyl-1,2,4-triazolo[4,3-a]pyrazine-3,8(2H,7H)-dione 
(160). Yield 53%. m.p. >300 °C (EtOH/2-Methoxyethanol). 1H NMR (DMSO-d6) 3.81 (s, 3H, 
OCH3), 3.87 (s, 3H, OCH3), 7.03 (d, 2H, ar, J = 9.0 Hz), 7.27-7.29 (m, 3H, 2 ar + H-5), 7.36 (t, 
1H, ar, J = 7.4 Hz), 7.56 (t, 2H, ar, J = 7.7 Hz), 8.02 (d, 2H, ar, J = 7.9 Hz), 11.54 (br s, 1H, 
NH). Anal. Calc. for C19H16N4O4. 
6-(3,4,5-Trimethoxyphenyl)-2-phenyl-1,2,4-triazolo[4,3-a]pyrazine-3,8(2H,7H)-dione 
(161). Yield 25%. m.p. > 300 °C (AcOH/DMF). 1H NMR (DMSO-d6) 3.70 (s, 3H, CH3),                         
3.89 (s, 6H, CH3),  7.02 (s, 2H, ar),  7.37 (t, 1H, ar, J = 7.4 Hz),  7.49 (s, 1H, H-5),  7.57 (t, 2H, 
ar, J = 7.7 Hz), 8.02 (d, 2H, ar, J = 7.7 Hz), 11.59 (br s, 1H, NH). Anal. Calc. For C20H18N4O5. 
6-(4-Methoxy-3,5-dimethylphenyl)-2-phenyl-[1,2,4]triazolo[4,3-a]pyrazine-3,8(2H,7H)-
dione (162). Yield 70%. m.p. > 300 °C (2-Methoxyethanol/DMF). 1H-NMR (DMSO-d6)            
2.28 (s, 6H, CH3), 3.70 (s, 3H, CH3),  7.21 (s, 1H, ar),  7.36 (t, 1H, ar, J = 7.4 Hz), 7.44 (s, 2H, 
ar),  7.56 (t, 2H, ar, J = 7.9 Hz), 8.01 (d, 2H, ar, J = 7.9 Hz), 11.48 (br. s, 1H, NH). Anal. Calc. 
For C20H18N4O3. 
6-(3,5-di-tert-butyl-4-methoxyphenyl)-2-phenyl-[1,2,4]triazolo[4,3-a]pyrazine-
3,8(2H,7H)-dione (163). Yield 75%. m.p.  > 300°C (AcOH/DMF). 1H-NMR (DMSO-d6)                
1.44 (s, 18H, (CH3)3), 3.67 (s, 3H, CH3),  7.24 (s, 1H, ar), 7.36 (t, 1H, ar, J = 7.4 Hz), 7.49 (s, 
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2H, ar), 7.56 (t, 2H, ar, J = 7.4 Hz),  8.02 (d, 2H, ar, J = 8.2 Hz), 11.63 (br. s, 1H, NH). Anal. 
Calc. For C26H30N4O3. 
 
General procedure for the synthesis of 8-chloro-1,2,4-triazolo[4,3-a]pyrazin-3-(2H)-one 
derivatives (164-193). 
 
A suspension of the suitable 8-oxo-triazolopyrazine derivatives 134-163 (2 mmol) in 
phosphorus oxychloride (10 mL) was heated in the following conditions: microwave 
irradiation at 160 °C for 90 min otherwise at 160 °C for 20 min (compound 165), 1 h 
(compound 168) and 3.5 h (compound 169) or at 170 °C for 30 min (compound 171) and 
1.5 h (compounds 172 and 173); sealed tube in a bath oil at 140 °C for 16 h (compounds 
164, 166) or at 180 °C for 3 h (compound 167). The excess of phosphorus oxychloride was 
distilled off and the residue was treated with water (about 5−10 mL). The obtained solid 
was collected by filtration. These intermediates were pure enough (NMR, TLC) to be used 
for the next step without further purification. 
8-Chloro-6-methyl-2-phenyl-1,2,4-triazolo[4,3-a]pyrazin-3(2H)-one (164). Yield 81%. 1H 
NMR (DMSO-d6) 2.21 (s, 3H, CH3), 7.36-7.40 (m, 1H, ar), 7.47 (s, 1H, H-5), 7.55-7.58 (m, 
1H, ar), 7.54 (t, 2H, ar, J = 7.7 Hz), 8.01-8.3 (m, 2H, ar). Anal. Calc. For C12H9ClN4O. 
8-Chloro-2,6-diphenyl-1,2,4-triazolo[4,3-a]pyrazin-3(2H)-one (165). Yield 78%. 1H NMR 
(DMSO-d6) 7.41-7.43 (m, 2H, ar), 7.50 (t, 2H, ar, J = 7.3 Hz), 7.60 (t, 2H, ar, J = 8.0 Hz), 8.04-
8.09 (m, 4H, ar), 8.61 (s, 1H, H-5). Anal. Calc. For C17H11ClN4O. 
8-Chloro-6-methyl-2-(4-methoxyphenyl)-1,2,4-triazolo[4,3-a]pyrazin-3(2H)-one (166). 
Yield 80%. 1H NMR (DMSO-d6) 2.31 (s, 3H, CH3), 3.82 (s, 3H, OCH3), 7.12 (d, 2H, ar, J = 8.0 
Hz), 7.90-7.93 (m, 3H, 2 ar + H-5). Anal. Calc. For C13H11ClN4O2. 
8-Chloro-2-(4-methoxyphenyl)-6-phenyl-1,2,4-triazolo[4,3-a]pyrazin-3(2H)one (167). 
Yield 96%. 1H NMR (DMSO-d6) 3.84 (s, 3H, CH3), 7.15 (d, 2H, ar, J= 9.1 Hz), 7.04-7.63 (m, 
3H, ar), 7.94 (d, 2H, ar, J= 9.1 Hz), 8.05 (d, 2H, ar, J= 7.5 Hz), 8.61 (s, 1H, H-5). Anal. Calc. 
For C18H13ClN4O2. 
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8-Chloro-2-(4-nitrophenyl)-6-phenyl-1,2,4-triazolo[4,3-a]pyrazin-3(2H)one (168). Yield 
72%. 1H NMR (DMSO-d6) 7.42 (t, 1H, ar, J= 7.4 Hz), 7.51 (d, 2H, ar, J= 7.4 Hz), 8.07 (d, 2H, 
ar, J= 7.4 Hz), 8.39 (d, 2H, ar, J= 7.1 Hz), 8.47 (d, 2H, ar, J= 7.1 Hz), 8.67 (s, 1H, H-5). Anal. 
Calc. For C17H10ClN5O3. 
8-Chloro-2-(2-methoxyphenyl)-6-phenyl-1,2,4-triazolo[4,3-a]pyrazin-3(2H)one (169). 
Yield 96%. 1H NMR (DMSO-d6) 3.83 (s, 3H, OCH3), 7.14 (t, 1H, ar, J= 7.6 Hz), 7.30 (d, 1H, 
ar, J= 8.4 Hz), 7.42 (t, 1H, ar, J= 7.3 Hz), 7.46-7.55 (m, 1H; ar), 7.57 (t, 1H, ar), 8.02 (d, 2H, 
ar, J= 7.3 Hz), 8.56 (s, 1H, H-5). Anal. Calc. For C18H13ClN4O2. 
8-Chloro-6-(2-methoxyphenyl)-2-phenyl-1,2,4-triazolo[4,3-a]pyrazin-3-(2H)-one (170). 
Yield 81%. 1H NMR (DMSO-d6) 3.98 (s, 3H, OCH3), 7.13 (t, 1H, ar, 7.5 Hz), 7.21 (d, 1H, ar, 
J= 8.3 Hz), 7.38-7.45 (m, 2H, ar), 7.59 (t, 2H, ar, J= 7.8 Hz), 8.00 (d, 1H; ar, J= 7.8 Hz), 8.06 
(d, 2H, ar, J= 8.2 Hz), 8.46 (s, 1H, H-5).  Anal. Calc. For C18H13ClN4O2. 
8-Chloro-6-(3-methoxyphenyl)-2-phenyl-1,2,4-triazolo[4,3-a]pyrazin-3 (2H)-one (171). 
Yield 87%. 1H NMR (DMSO-d6) 3.85 (s, 3H, OCH3), 6.98 (d, 1H, ar, J = 7.6 Hz), 7.38-7.42 (m, 
2H, ar), 7.57-7.63 (m, 4H, ar), 8.07 (d, 2H, ar, J = 7.7 Hz), 8.68 (s, 1H, H-5).  Anal. Calc. For 
C18H13ClN4O2. 
8-Chloro-6-(4-methoxyphenyl)-2-phenyl-1,2,4-triazolo[4,3-a]pyrazin-3 (2H)-one (172). 
Yield 92%. 1H NMR (DMSO-d6) 3.82 (s, 3H, CH3), 7.05 (d, 2H, ar, J = 8.8 Hz), 7.40 (t, 1H, ar, 
J = 7.4 Hz), 7.59 (t, 2H, ar, J = 7.9 Hz), 7.98 (d, 2H, ar, J = 8.8 Hz), 8.07 (d, 2H, ar, J = 7.9 Hz), 
8.49 (s, 1H, H5). Anal. Calc. For C18H13ClN4O2. 
8-Chloro-6-(4-methylphenyl)-2-phenyl-1,2,4-triazolo[4,3-a]pyrazin-3 (2H)-one (173). 
Yield 90%. 1H NMR (DMSO-d6) 2.36 (s, 3H, CH3), 7.30 (d, 2H, ar, J = 8.1 Hz), 7.40 (t, 1H, ar, 
J = 7.8 Hz), 7.59 (t, 2H, ar, J = 7.8 Hz), 7.94 (d, 2H, ar, J = 8.1 Hz), 8. 07 (d, 2H, ar, J = 8.5 
Hz), 8.55 (s, 1H, H-5). Anal. Calc. For C18H13ClN4O. 
8-Chloro-6-(3,4-methylendioxyxyphenyl)-2-phenyl-1,2,4-triazolo[4,3-a]pyrazin-3 (2H)-
one (174). Yield 64%. 1H NMR (DMSO-d6) 6.10 (s, 2H, CH2), 7.03 (d, 1H, ar, J = 8.1 Hz),  7.40 
(t, 1H, ar, J = 7.3 Hz), 7.57-7.59 (m, 3H, ar), 7.65 (s, 1H, ar), 8.07 (d, 2H, ar, J = 8.00 Hz), 
8.55 (s, 1H, H-5).  Anal. Calc. For C18H11ClN4O3. 
6-(3-Bromophenyl)-8-chloro-2-phenyl-1,2,4-triazolo[4,3-a]pyrazin-3-(2H)-one (175). 
Yield 82%. 1H NMR (DMSO-d6) 7.36-7.41 (m, 2H, ar), 7.53-7.59 (m, 3H, ar), 7.82 (d, 1H, ar, 
J = 7.9 Hz), 7.09-7.11 (m, 2H, 1 ar + H-5), 8. 15 (d, 2H, ar, J = 7.7 Hz). Anal. Calc. For 
C17H10BrClN4O. 
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6-(4-Bromophenyl)-8-chloro-2-phenyl-1,2,4-triazolo[4,3-a]pyrazin-3-(2H)-one (176). 
Yield 93%. 1H NMR (DMSO-d6) 7.41 (t, 1H, ar, J = 7.3 Hz), 7.60 (t, 2H, ar, J = 8.1 Hz), 7.68 
(d, 2H, ar, J = 8.5 Hz), 8.02 (d, 2H, ar, J = 8.5 Hz), 8.07 (d, 2H, ar, J = 8.6 Hz), 8.71 (s, 1H, H-
5). Anal. Calc. For C17H10BrClN4O. 
8-Chloro-6-(3-chlorophenyl)-2-phenyl-1,2,4-triazolo[4,3-a]pyrazin-3-(2H)-one (177). 
Yield 77%. 1H NMR (DMSO-d6) 7.41 (t, 1H, ar, J = 7.3 Hz), 7.47-7.54 (m, 2H, ar), 7.60 (t, 2H, 
ar, J = 7.4 Hz), 8.03-8.08 (m, 3H, ar), 8.13 (s, 1H, ar) 8.80 (s, 1H, H-5). Anal. Calc. For 
C17H10Cl2N4O. 
8-Chloro-6-(4-chlorophenyl)-2-phenyl-1,2,4-triazolo[4,3-a]pyrazin-3-(2H)-one (178). 
Yield 75%. 1H NMR (DMSO-d6) 7.40 (t, 1H, ar, J = 7.3 Hz), 7.53-7.61 (m, 4H, ar), 8.05-8.09 
(m, 4H, ar), 8.69 (s, 1H, H-5). Anal. Calc. For C17H10Cl2N4O. 
8-Chloro-6-(2-nitrophenyl)-2-phenyl-1,2,4-triazolo[4,3-a]pyrazin-3 (2H)-one (179). Yield 
93%. 1H NMR (DMSO-d6) 7.45 (t, 1H, ar, J = 7.4 Hz), 7.63 (t, 2H, ar, J = 7.5 Hz), 7.76-7.75 
(m, 1H, ar), 7.86-7.89 (m, 2H, ar), 8.06-8.08 (m, 3H, ar), 8.63 (s, 1H, H-5).  Anal. Calc. For 
C17H10ClN5O3.              
8-Chloro-6-(3-nitrophenyl)-2-phenyl-1,2,4-triazolo[4,3-a]pyrazin-3 (2H)-one (180). Yield 
95%. 1H NMR (DMSO-d6) 7.42 (t, 1H, ar, J = 7.1 Hz), 7.60 (t, 2H, ar, J = 7.6 Hz), 7.79 (t, 1H, 
ar, J = 7.8 Hz), 8.07 (d, 2H, ar, J = 7.8 Hz), 8.26 (d, 1H, ar, J = 7.7 Hz), 8.54 (d, 1H, ar, J = 7.8 
Hz), 8.82 (s, 1H, ar), 8.98 (s, 1H, H-5). Anal. Calc. For C17H10ClN5O3. 
8-Chloro-6-(4-nitrophenyl)-2-phenyl-1,2,4-triazolo[4,3-a]pyrazin-3 (2H)-one (181). Yield 
89%. 1H NMR (DMSO-d6) 7.42 (t, 1H, ar, J = 7.4 Hz), 7.61 (t, 2H, ar, J = 7.7 Hz), 8.07 (d, 2H, 
ar, J = 7.7 Hz), 8.32 (d, 2H, ar, J = 9.2 Hz), 8.36 (d, 2H, ar, J = 9.2 Hz), 8.95 (s, 1H, H-5). Anal. 
Calc. For C17H10ClN5O3. 
8-Chloro-6-(2-furyl)-2-phenyl[1,2,4]triazolo[4,3-a]pyrazin-3-(2H)-one (182). Yield 90%. 
1H NMR (DMSO-d6) 6.65-6.66 (d, 1H, furan proton), 6.98 (d, 1H, furan proton, J = 1.8 Hz), 
7.39 (t, 1H, ar, J = 7.3 Hz), 7.58 (t, 2H, ar, J = 7.3 Hz), 7.83 (s, 1H, furan proton), 8.03 (d, 
2H, ar, J= 7.1 Hz), 8.07 (s, 1H, H-5). Anal. Calc. For C15H9ClN4O2. 
8-Chloro-6-(5-methylfuran-2-yl)-2-phenyl[1,2,4]triazolo[4,3-a]pyrazin-3-(2H)-one (183). 
Yield 92%. 1H NMR (DMSO-d6) 2.38 (s, 3H, CH3), 6.28 (s, 1H, furan proton), 6.86 (s, 1H, 
furan proton), 7.41 (t, 1H, ar, J = 7.4 Hz), 7.59 (t, 2H, ar, J = 7.4 Hz), 7.96 (s, 1H, H-5), 8.05 
(d, 2H, ar, J = 8.3 Hz). Anal. Calc. For C16H11ClN4O2. 
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8-Chloro-6-(2-thienyl)-2-phenyl[1,2,4]triazolo[4,3-a]pyrazin-3-(2H)-one (184). Yield 
72%. 1H NMR (DMSO-d6) 7.18 (t, 1H, ar, J = 4.3 Hz), 7.41 (t, 1H, ar, J = 7.4 Hz), 7.58-7.65 
(m, 3H, ar), 7.89 (d, 1H, thiophene proton, J = 3.6 Hz), 8.07 (d, 2H, ar, J = 8.3 Hz), 8.62 (s, 
1H, H5). C15H9ClN4OS. 
8-Chloro-2-phenyl-6-(2-pyridyl)[1,2,4]triazolo[4,3-a]pyrazin-3-(2H)-one (185). Yield 
87%. 1H NMR (DMSO-d6) 7.42 (t, 1H, ar, J = 7.1 Hz), 7.50 (t, 1H, ar, J = 6.1 Hz), 7.60 (t, 2H, 
ar, J = 7.8 Hz), 8.01-8.14 (m, 4H, ar), 8.62 (d, 1H, pyridine proton, J = 4.5 Hz), 8.71 (s, 1H, 
H5). Anal. Calc. For C16H10ClN5O. 
2-Benzyl-8-chloro-6-phenyl-1,2,4-triazolo[4,3-a]pyrazin-3-(2H)-one (186). Yield 68%. 1H 
NMR (DMSO-d6) 5.24 (s, 2H, CH2), 7.33-7.42 (m, 6H, ar), 7.48 (t, 2H, ar, J = 7.1), 8.01 (d, 
2H, ar, J = 7.2 Hz), 8.53 (s, 1H, H-5). Anal. Calc. For C18H13ClN4O. 
2-Benzyl-8-chloro-6-(furan-2-yl)-1,2,4-triazolo[4,3-a]pyrazin-3-(2H)-one (187). Yield 
85%. 1H NMR (DMSO-d6) 5.22 (s, 2H, CH2), 6.65 (dd, 1H, furan proton, J = 1.7 Hz, J = 1.5 
Hz), 6.95 (d, 1H, furan proton, J = 3.2 Hz), 7.36-7.41 (m, 5H, ar), 7.82 (s, 1H, furan proton), 
8.02 (s, 1H, H-5). Anal. Calc. For C16H11ClN4O2. 
2-Benzyl-8-chloro-6-(5-methylfuran-2-yl)-1,2,4-triazolo[4,3-a]pyrazin-3-(2H)-one (188). 
Yield 95%. 1H NMR (DMSO-d6) 2.36 (s, 3H, CH3), 5.22 (s, 2H, CH2), 6.25 (d, 1H, furan proton, 
J = 2.1 Hz), 6.81 (d, 1H, furan proton, J = 2.8 Hz), 7.33-7.38 (m, 5H, ar), 7.89 (s, 1H, H-5). 
Anal. Calc. For C17H13ClN4O2. 
8-Chloro-6-(2,4-dimethoxyphenyl)-2-phenyl-1,2,4-triazolo[4,3-a]pyrazin-3 (2H)-one 
(189). Yield 96 % 1H NMR (DMSO-d6) 3.90 (s, 3H, CH3), 3.97 (s, 3H, CH3),  6.71-6.75 (m, 2H, 
ar), 7.39 (t, 1H, ar, J = 7.4 Hz), 7.58 (t, 2H, ar, J = 7.6 Hz),  7.92 (d, 1H, ar, J =  8.6 Hz), 8.06 
(d, 2H. ar, J = 7.8 Hz), 8.34 (s, 1H, H-5). Anal. Calc. For C19H15ClN4O3. 
8-chloro-6-(3,4-dimethoxyphenyl)-2-phenyl-[1,2,4]triazolo[4,3-a]pyrazin-3(2H)-one 
(190). Yield 85 % 1H NMR (DMSO-d6) 3.81 (s, 3H, CH3), 3.88 (s, 3H, CH3), 7.06 (d, 1H, ar, J 
= 8.2 Hz),  7.41 (t, 1H, ar, J = 7.4 Hz), 7.62-7.58 (m, 4H, ar), 8.08 (d, 2H, ar, J = 8.1 Hz), 8.63 
(s, 1H, H-5). Anal. Calc. For C19H15ClN4O3. 
8-Chloro-6-(3,4,5-trimethoxyphenyl)-2-phenyl-1,2,4-triazolo[4,3-a]pyrazin-3 (2H)-one 
(191). Yield 96 % 1H NMR (DMSO-d6) 3.71 (s, 3H, CH3), 3.89 (s, 6H, CH3), 7.33 (s, 2H, ar), 
7.41 (t, 1H, ar, J = 7.6 Hz), 7.62 (t, 2H, ar, J = 7.8 Hz), 8.07 (d, 2H, ar, J = 7.9 Hz), 8.79 (s, 1H, 
H-5).  Anal. Calc. For C20H17ClN4O4. 
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8-Chloro-6-(4-methoxy-3,5-dimethylphenyl)-2-phenyl-[1,2,4]triazolo[4,3-a]pyrazin-
3(2H)-one  (192).  Yield 82 %  1H-NMR (DMSO-d6) 2.30 (s, 6H, CH3), 3.70 (s, 3H, CH3),  7.41 
(t, 1H, ar, J = 7.5 Hz),  7.59 (t, 2H, ar, J = 7.9 Hz), 7.73 (s, 2H, ar),  8.07 (d, 2H, ar, J = 8.1 Hz),  
8.48 (s, 1H, ar). Anal. Calc. For C20H17ClN4O2. 
8-Chloro-6-(3,5-di-tert-butyl-4-methoxyphenyl)-2-phenyl-[1,2,4]triazolo[4,3-a]pyrazin-
3(2H)-one (193). Yield 90 % 1H-NMR (DMSO-d6) 1.45 (s, 18H, tBu), 3.67 (s, 3H, CH3),                    
7.41 (t, 1H, ar, J = 7.56 Hz), 7.60 (t, 2H, ar, J = 7.80 Hz),  7.85 (s, 2H, ar),  8.07 (d, 2H, ar, J = 
7.92 Hz),  8.65 (s, 1H, ar). Anal. Calc. For C26H29ClN4O2. 
 
General procedure for the synthesis of 8-amino-1,2,4-triazolo[4,3-a]pyrazin-3(2H)-one 
derivatives (1-6, 11-13, 17, 29-36, 62-73). 
 
A suspension of the 8-chloro-triazolopirazine derivatives 164-193 (1 mmol) in a saturated 
ethanolic solution of NH3 (30 mL) was heated at 130 °C in a sealed tube overnight with 
the exception of the 6-(2-furyl) derivative 182 that was reacted at 100 °C for 4 h. After 
cooling the mixture at room temperature, the solid was collected by filtration, washed 
with water (about 5-10 mL), dried and recrystallized. Derivatives 63, 67, 68 and 71 were 
purified by column chromatography.  
8-Amino-6-methyl-2-phenyl-1,2,4-triazolo[4,3-a]pyrazin-3(2H)-one (1). Yield 92%. m.p. 
258-259 °C (Toluene). 1H NMR (DMSO-d6) 2.11 (s, 3H, CH3), 7.09 (s, 1H, H-5), 7.35 (t, 1H, 
ar, J = 6.6 Hz), 7.40 (br s, 2H, NH2), 7.54 (t, 2H, ar, J = 7.7 Hz), 8.05 (d, 2H, ar, J = 7.7 Hz). 
Anal. Calc. for C12H11N5O. 
8-Amino-2,6-diphenyl-1,2,4-triazolo[4,3-a]pyrazin-3(2H)-one (2). Yield 50%. m.p. 276-
277 °C (Nitromethane). 1H NMR (DMSO-d6) 7.33-7.38 (m, 2H, ar), 7.43 (t, 2H, ar, J = 7.4 
Hz), 7.55-7.59 (m, 4H, 2 ar + NH2), 7.77 (s, 1H, H-5), 7.98 (d, 2H, ar, J = 7.5 Hz), 8.08 (d, 2H, 
ar, J = 7.9 Hz). Anal. Calc. for C17H13N5O. 
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8-Amino-6-methyl-2-(4-methoxyphenyl)-1,2,4-triazolo[4,3-a]pyrazin-3(2H)-one (3). 
Yield 83%. m.p. 243-244 °C (EtOH/2-Methoxyethanol). 1H NMR (DMSO-d6) 2.11 (s, 3H, 
CH3), 3.81 (s, 3H, OCH3), 7.07 (s, 1H, H-5), 7.09 (d, 2H, ar, J = 9.1 Hz), 7.36 (br s, 2H, NH2), 
7.90 (d, 2H, ar, J = 9.1 Hz). Anal. Calc. for C13H13N5O2. 
8-Amino-2-(4-methoxyphenyl)-6-phenyl-1,2,4-triazolo[4,3-a]pyrazin-3(2H)-one (4). 
Yield 84%. m.p. 254-255 °C (Nitromethane). 1H NMR (DMSO-d6) 3.82 (s, 3H, OCH3), 7.13 
(d, 2H, ar, J= 8.8 Hz), 7.33-7.45 (m, 3H, ar), 7.56 (br s, 2H, NH2), 7.75 (s, 1H, H-5), 7.92-7.99 
(m, 4H, ar). IR 3366, 3311, 1644. Anal. Calc. for C18H15N5O2.  
8-Amino-2-(4-nitrophenyl)-6-phenyl-1,2,4-triazolo[4,3-a]pyrazin-3(2H)-one (5). Yield 
62%. m.p. 290-291 °C (Cyclohexane/EtOAc). 1H NMR (DMSO-d6) 7.13 (t, 1H, ar, J= 8.8 Hz), 
7.35 (t, 2H, ar, J = 7.5 Hz), 7.69 (br s, 2H, NH2), 7.79 (s, 1H, H-5), 7.99 (d, 2H, ar, J = 7.5 Hz), 
8.38 (d, 2H, ar, J = 9.3 Hz), 8.48 (d, 2H, ar, J = 9.3 Hz). IR 3366, 3311, 1644. Anal. Calc. for 
C17H12N6O3. 
8-Amino-2-(2-methoxyphenyl)-6-phenyl-1,2,4-triazolo[4,3-a]pyrazin-3(2H)-one (6). 
Yield 74%. m.p. 257-258 °C (Nitromethane). 1H NMR (DMSO-d6) 3.80 (s, 3H, OCH3), 7.11 
(t, 1H, ar, J= 7.6 Hz), 7.26 (d, 1H, ar, J= 8.3 Hz), 7.35 (t, 1H, ar, J= 7.3 Hz), 7.43 (t, 2H, ar, J= 
7.3 Hz), 7.49-7.56 (m, 4H, 2ar + NH2), 7.73 (s, 1H, H-5), 7.97 (d, 2H, ar, J= 7.5 Hz). Anal. 
Calc. for C18H15N5O2. 
8-Amino-6-(2-methoxyphenyl)-2-phenyl-1,2,4-triazolo[4,3-a]pyrazin-3(2H)-one (11). 
Yield 68%. m.p. 249-251 °C (EtOH). 1H NMR (DMSO-d6) 3.93 (s, 3H, OCH3), 7.06 (t, 1H, ar, 
J = 8.1 Hz), 7.14 (d, 1H, ar, J = 8.1 Hz), 7.34-7.37 (m, 2H, ar), 7.48 (br s, 2H, NH2), 7.56 (t, 
2H, ar, J = 7.8 Hz), 7.9 (s, 1H, H-5), 8.06-8.09 (m, 3H, ar). Anal. Calc. for C18H15N5O2. 
8-Amino-6-(3-methoxyphenyl)-2-phenyl-1,2,4-triazolo[4,3-a]pyrazin-3(2H)-one (12). 
Yield 66%. m.p. 249-251 °C (EtOH). 1H NMR (DMSO-d6) 3.83 (s, 3H, CH3), 6.90-6.93 (m, 1H, 
ar), 7.31-7.37 (m, 2H, ar), 7.53-7.58 (m, 6H, 4 ar + NH2), 7.81 (s, 1H, H-5), 8.07 (d, 2H, ar, J 
= 7.5 Hz). IR = 3358, 3312, 1703, 1645 cm-1. Anal. Calc. for C18H15N5O2. 
8-Amino-6-(4-methoxyphenyl)-2-phenyl-1,2,4-triazolo[4,3-a]pyrazin-3(2H)-one (13). 
Yield 94%. m.p. 251-252 °C (EtOH/2-Methoxyethanol). 1H NMR (DMSO-d6) 3.80 (s, 3H, 
CH3), 6.99 (d, 2H, ar, J = 8.7Hz), 7.36 (t, 1H, ar, J = 7.5 Hz), 7.54-7.58 (m 4H, 2ar + NH2), 7.67 
(s, 1H, H5), 7.92 (d, 2H, ar, J = 8.7 Hz), 8.08 (d, 2H, ar, J = 8.5 Hz). IR  3381, 3308, 1697, 
1649. Anal. Calc. for C18H15N5O2. 
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8-Amino-6-(4-methylphenyl)-2-phenyl-1,2,4-triazolo[4,3-a]pyrazin-3(2H)-one (17). 
Yield 75%. m.p. 287-288 °C (2-Methoxyethanol). 1H NMR (DMSO-d6) 2.34 (s, 3H, CH3), 7.24 
(d, 2H, ar., J = 7.9 Hz), 7.36 (t, 1H, ar, J = 7.4 Hz), 7.54-7.58 (m, 4H, 2 ar + NH2), 7.70 (s, 1H, 
H5), 7.87 (d, 2H, ar, J = 7.9 Hz), 8.07 (d, 2H, ar, J = 7.6 Hz). IR 3366, 3310, 1701, 1651. Anal. 
Calc. for C18H15N5O. 
8-Amino-6-(3,4-methylendioxyxyphenyl)-2-phenyl-1,2,4-triazolo[4,3-a]pyrazin-3 (2H)-
one (29). Yield 96%. m.p. > 300 °C (AcOH/DMF). 1H NMR (DMSO-d6) 6.06 (s, 2H, CH2), 6.96 
(d, 1H, ar, J = 7.9 Hz), 7.35 (t, 1H, ar, J = 7.4 Hz), 7.54-7.58 (m, 6H, 4 ar + NH2), 7.72 (s, 1H, 
H-5), 8.07 (d, 2H, ar, J = 7.8 Hz). Anal. Calc. for C18H13N5O3. 
8-Amino-6-(3-bromophenyl)-2-phenyl-1,2,4-triazolo[4,3-a]pyrazin-3(2H)-one (30). Yield 
87%. m.p.  281-283 °C (2-Methoxyethanol). 1H NMR (DMSO-d6) 7.35-7.40 (m, 2H, ar), 
7.52-7.59 (m, 3H, ar), 7.66 (br s, 2H, NH2), 7.93 (s, 1H, H-5), 8.02 (d, 1H, ar, J = 7.8 Hz), 8.07 
(d, 2H, ar, J = 8.0 Hz), 8.23 (s, 1H, ar). 13C NMR (DMSO-d6) 102.93, 119.90, 122.57, 124.64, 
126.83, 128.65, 129.68, 131.04, 131.09, 131.60, 134.18, 137.89, 139.26, 147.63, 147.94. 
Anal. Calc. for  C17H12BrN5O. 
8-Amino-6-(4-bromophenyl)-2-phenyl-1,2,4-triazolo[4,3-a]pyrazin-3(2H)-one (31). Yield 
92%. m.p. 266-268 °C (2-Methoxyethanol). 1H NMR (DMSO-d6) 7.36 (t, 1H, ar, J = 7.4 Hz), 
7.57 (t, 2H, ar, J = 7.8 Hz), 7.63-7.61 (m, 4H, 2 ar + NH2), 7.85 (s, 1H, H-5), 7.96 (d, 2H, ar, 
J = 8.6 Hz), 8.07 (d, 2H, ar, J = 7.8 Hz). 13C NMR (DMSO-d6) 102.35, 119.89, 121.63, 126.79, 
128.01, 129.66, 131.57, 131.81, 134.82, 136.15, 137.93, 147.63, 147.94. Anal. Calc. for 
C17H12BrN5O. 
8-Amino-6-(3-chlorophenyl)-2-phenyl-1,2,4-triazolo[4,3-a]pyrazin-3(2H)-one (32). Yield 
85%. m.p. 279-281 °C (EtOH/2-Methoxyethanol). 1H NMR (DMSO-d6) 7.34-7.47 (m, 3H, 
ar), 7.57 (t, 2H, ar, J = 7.7 Hz), 7.65 (br s, 2H, NH2), 7.92 (s, 1H, H-5), 7.98 (d, 1H, ar, J = 7. 
7 Hz), 8.06-8.08 (m, 3H, ar). 13C NMR (DMSO-d6) 102.96, 119.92, 124.30, 125.78, 126.82, 
128.14, 129.67, 130.78, 131.62, 133.96, 134.33, 137.91, 139.09, 147.64, 147.95. Anal. 
Calc. for C17H12ClN5O. 
8-Amino-6-(4-chlorophenyl)-2-phenyl-1,2,4-triazolo[4,3-a]pyrazin-3(2H)-one (33). Yield 
87%. m.p. 256-258 °C (2-Methoxyethanol). 1H NMR (DMSO-d6) 7.36 (t, 1H, ar, J = 7.4 Hz), 
7.48 (d, 2H, ar, J = 8.6 Hz), 7.56 (t, 2H, ar, J = 7.6 Hz), 7.63 (br s, 2H, NH2), 7.84 (s, 1H, H-5), 
8.02 (d, 2H, ar, J = 8.5 Hz), 8.07 (d, 2H, ar, J = 7.6 Hz). 13C NMR (DMSO-d6) 102.40, 119.88, 
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127.70, 128.97, 129.57, 129.72, 131.55, 132.99, 134.75, 135.76, 137.92, 147.62, 147.92. 
Anal. Calc. for C17H12ClN5O. 
8-Amino-6-(2-nitrophenyl)-2-phenyl-1,2,4-triazolo[4,3-a]pyrazin-3 (2H)-one (34). Yield 
83%. m.p. 281-283 °C (AcOH). 1H NMR (DMSO-d6) 7. 40 (t, 1H, ar, J = 7. 4 Hz), 7.58- 7.69 
(m, 6H, 4ar + NH2), 7.76-7.80 (m, 2H, 1 ar + H-5), 7.98 (d, 1H, ar, J = 7. 8 Hz), 8.09 (d, 2H, 
ar, J = 7.7 Hz). Anal. Calc. for C17H12N6O3. 
8-Amino-6-(3-nitrophenyl)-2-phenyl-1,2,4-triazolo[4,3-a]pyrazin-3 (2H)-one (35). Yield 
72%. m.p. 280-281 °C (AcOH). 1H NMR (DMSO-d6) 7.37 (t, 1H, ar, J = 7.2 Hz), 7.57 (t, 2H, 
ar, J = 7.6 Hz), 7.71 (t, 1H, ar, J = 7.7 Hz), 7.77 (br s, 2H, NH2), 8.07-8.09 (m, 3H, 2 ar + H-
5), 8.19 (d, 1H, ar, J = 7.6 Hz), 8.48 (d, 1H, ar, J = 7.6 Hz), 8.85 (s, 1H, ar). Anal. Calc. for 
C17H12N6O3. 
8-Amino-6-(4-nitrophenyl)-2-phenyl-1,2,4-triazolo[4,3-a]pyrazin-3 (2H)-one (36). Yield 
69%. m.p. 297-299 °C (2-Methoxyethanol/DMF). 1H NMR (DMSO-d6) 7.36 (t, 1H, ar, J = 7.4 
Hz), 7.57 (t, 2H, ar, J = 7.7 Hz), 7.73 (br s, 2H, NH2), 8.06-8.08 (m, 3H, 2 ar + H-5), 8.28 (s , 
4H, ar). 13C-NMR (DMSO-d6) 104.87, 119.91, 124.19, 126.80, 126.87, 129.69, 131.56, 
133.78, 137.85, 143.48, 147.17, 147.64, 148.08. IR = 1713, 3373, 3485 cm-1. Anal. Calc. for 
C17H12N6O3. 
8-Amino-6-(2-furyl)-2-phenyl-1,2,4-triazolo[4,3-a]pyrazin-3-(2H)-one (62). Yield 25%. 1H 
NMR (DMSO-d6) 6.59-6.60 (m, 1H, furan ptoton), 6.78 (d, 1H, furan proton, J = 1.8 Hz), 
7.38 (t, 1H, ar, J = 7.4 Hz), 7.41 (s, 1H, H-5), 7.58 (t, 2H, ar, J = 7.8 Hz), 7.65 (br s, 2H, NH2), 
7.74 (s, 1H, furan proton), 8.06 (d, 2H, ar, J= 7.8 Hz). Anal. Calc. for C15H11N5O2. 
8-Amino-6-(5-methylfuran-2-yl)-2-phenyl-1,2,4-triazolo[4,3-a]pyrazin-3-(2H)-one (63). 
Yield 52%. m.p. 263-265 °C Purified by column chromatography. (Cyclohexane 6/EtOAc 
4). 1H NMR (DMSO-d6) 2.34 (s, 3H, CH3), 6.20 (s, 1H, furan proton), 6.66 (s, 1H, furan 
proton), 7.33-7.37 (m, 2H, 1ar + 1 furan proton), 7.56 (t, 2H, ar, J= 7.8 Hz), 7.63 (br s, 2H, 
NH2), 8.06 (d, 2H, ar, J= 7.8 Hz). 13C NMR (DMSO-d6) 13.89, 99.15, 108.39, 108.79, 119.81, 
126.78, 129.58, 129.65, 131.47, 137.88, 147.51, 148.27, 150.06, 152.30. Anal. Calc. for 
C16H13N5O2. 
8-Amino-2-phenyl-6-(2-thienyl)-1,2,4-triazolo[4,3-a]pyrazin-3(2H)-one (64). Yield 58%. 
m.p. 283-284 °C (EtOH/2-Methoxyethanol). 1H NMR (DMSO-d6) 7.11 (t, 1H, ar, J = 4.4 Hz), 
7.36 (t, 1H, ar, J = 7.5 Hz), 7.51-7.71 (m, 6H, 4ar + NH2), 7.80 (s, 1H, H5), 8.07 (d, 2H, ar, J = 
7.8 Hz).13C NMR (DMSO-d6) 100.20, 119.85, 123.09, 126.50, 126.79, 128.62, 129.67, 
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131.52, 132.25, 137.92, 142.42, 147.53, 147.92. IR = 3318, 3223, 1715, 1643 cm-1. Anal. 
Calc. for C15H11N5OS. 
8-Amino-2-phenyl-6-(2-pyridyl)- 1,2,4-triazolo[4,3-a]pyrazin-3(2H)-one (65). Yield 62%. 
m.p. 251-252 °C (EtOH). 1H NMR (DMSO-d6) 7.36 (t, 2H, ar, J = 5.9 Hz), 7.57 (t, 2H, ar, J = 
8.0 Hz), 7.65 (br s, 2H, NH2), 7.90 (t, 1H, pyridine proton, J = 3.9 Hz), 7.92-8.10 (m, 4H, 3ar 
+ H5), 8.62 (d, 1H, ar, J = 3.8 Hz). IR = 3217, 3167, 1715, 1634 cm-1. Anal. Calc. for C16H12N6O. 
8-Amino-2-benzyl-6-phenyl-1,2,4-triazolo[4,3-a]pyrazin-3(2H)-one (66). Yield 79%. m.p. 
288-290 °C (DMF). 1H NMR (DMSO-d6) 5.18 (s, 2H, CH2), 7.31-7.45 (m, 10H, 8 ar + NH2), 
7.72 (s, 1H, H-5), 7.95 (d, 2H, ar, J = 7.2 Hz). Anal. Calc. for C18H15N5O. 
8-Amino-2-benzyl-6-(furan-2-yl)-1,2,4-triazolo[4,3-a]pyrazin-3(2H)-one (67). Yield 38%. 
m.p. 185-187 °C. Purified by column chromatography (n-Hexane 7/EtOAc 3 / MeOH 0.1). 
1H NMR (DMSO-d6) 5.16 (s, 2H, CH2), 6.58 (dd, 1H, furan proton, J = 1.6 Hz, J =  1.8 Hz), 
6.75 (d, 1H, furan proton, J = 3.1 Hz), 7.31-7.37 (m, 6H, 5 ar + H-5), 7.51 (br s, 2H, NH2), 
7.72 (s, 1H, furan proton). Anal. Calc. for C16H13N5O2. 
8-Amino-2-benzyl-6-(5-methylfuran-2-yl)-1,2,4-triazolo[4,3-a]pyrazin-3-(2H)-one (68). 
Yield 54%. m.p. 215-217 °C Purified by column chromatography. (Cyclohexane 5 /EtOAc 4 
/MeOH 1). 1H NMR (DMSO-d6) 2.33 (s, 3H, CH3), 5.15 (s, 2H, CH2), 6.17-6.18 (m, 1H, furan 
proton), 6.61 (d, 1H, furan proton, J = 3.0 Hz), 7.30-7.39 (m, 6H, ar + H-5), 7.47 (br s, 2H, 
NH2). Anal. Calc. for C17H15N5O2. 
8-Amino-6-(2,4-dimethoxyphenyl)-2-phenyl-1,2,4-triazolo[4,3-a]pyrazin-3 (2H)-one 
(69).  Yield 43%. m.p. 255-257 °C (EtOH/2-Methoxyethanol). 1H NMR (DMSO-d6) 3.82 (s, 
3H, CH3), 3.92 (s, 3H, CH3),  6.64-6.68 (m, 2H, ar),  7.35 (t, 1H, ar, J = 7.4 Hz),  7.43 (br s, 
2H, NH2),  7.57 (t, 2H, ar, J = 8.4 Hz),  7.80 (s, 1H, H-5),  8.02 (d, 1H, ar, J = 8.6 Hz),  8.07 (d, 
2H, ar, J = 8.4 Hz). Anal. Calc. for C19H17N5O3. 
8-Amino-6-(3,4-dimethoxyphenyl)-2-phenyl-1,2,4-triazolo[4,3-a]pyrazin-3(2H)-one 
(70). Yield 65%. m.p. 212-214 °C (EtOH/2-Methoxyethanol). 1H NMR (DMSO-d6) 3.80 (s, 
3H, OCH3), 3.86 (s, 3H, OCH3), 7.00 (d, 2H, ar, J = 8.4 Hz), 7.36 (t, 1H, ar, J = 7.4 Hz),  7.52-
7.58 (m, 6H, 4 ar + NH2), 7.76 (s, 1H, H-5), 8.08 (d, 2H, ar, J = 7.7 Hz).13C-NMR (DMSO-d6) 
55.98,  56.09, 100.99, 109.59, 112.05, 118.63, 119.85, 126.72, 129.57, 129.64, 131.54, 
135.92, 137.99, 147.63, 149.20, 149.42. IR = 3348.42, 3340.00-3300.00, 1714.72, 1699.29 
cm-1. Anal. Calc. for C19H17N5O3. 
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8-Amino-6-(3,4,5-trimethoxyphenyl)-2-phenyl-1,2,4-triazolo[4,3-a]pyrazin-3 (2H)-one 
(71). Yield 95%. m.p.  231-232 °C. Purified by liquid chromatography (CHCl3 9.5/MeOH 
0.4). 1H NMR (DMSO-d6) 3.70 (s, 3H, CH3), 3.87 (s, 6H, CH3), 7.28 (s, 2H, ar), 7.35 (t, 1H, ar, 
J = 7.4 Hz), 7.56-7.58 (m, 4H, ar + NH2), 7.90 (s, 1H, H-5), 8.08 (d, 2H, ar, J = 7.7 Hz). Anal. 
Calc. for C20H19N5O4. 
8-Amino-6-(4-methoxy-3,5-dimethylphenyl)-2-phenyl-[1,2,4]triazolo[4,3-a]pyrazin-
3(2H)-one (72). Yield 70%. m.p. 228-229°C (EtOH). 1H-NMR (DMSO-d6) 2.27 (s, 6H, CH3), 
3.68 (s, 3H, CH3),  7.35 (t, 1H, ar, J = 7.4 Hz), 7.58-7.54 (m, 4H, ar + NH2), 7.71-7.66 (m, 3H, 
ar),  8.07 (d, 2H, ar, J = 7.8 Hz).13C-NMR (DMSO-d6) 16.43, 59.79, 101.15, 119.91, 126.38, 
126.76, 129.66, 130.67, 131.51, 132.02, 135.79, 137.96, 147.62, 147.75, 157.12. IR = 
3400.50, 3298.28, 1699.29 cm-1. Anal. Calc. for C20H19N5O2. 
8-Amino-6-(3,5-di-tert-butyl-4-methoxyphenyl)-2-phenyl-[1,2,4]triazolo[4,3-a]pyrazin-
3(2H)-one (73).  Yield 75%. m.p. 263-264°C (2-Methoxyethanol). 1H-NMR (DMSO-d6) 1.44 
(s, 18H, tBu), 3.66 (s, 3H, CH3), 7.35 (t, 1H, ar, J = 7.4 Hz), 7.54 (br. s, 2H, NH2), 7.56 (t, 2H, 
ar, J = 7.7 Hz), 7.68 (s, 1H, ar), 7.78 (s, 2H, ar), 8.08 (d, 2H, ar, J = 7.7 Hz).IR = 3473.80, 
3296.35, 1716.65 cm-1. Anal. Calc. for C26H31N5O2. 
 
General procedure for the Synthesis of Hydroxy-substituted 8-amino-1,2,4-triazolo[4,3-
a]pyrazin-3(2H)-one derivatives (7-9, 14-16, 74-77). 
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1 M solution of BBr3 in DCM (5.1 mL) was slowly added at 0 °C, under nitrogen 
atmosphere, to a suspension of the methoxy-substituted triazolopirazines 3,4,6, 11-13, 
69-72 (1.02 mmol) in anhydrous DCM (20 mL). The mixture was stirred at room 
temperature until the disappearance of the starting material (TLC monitoring, 5-16 h), 
then was diluted with water (10 mL) and neutralized with a NaHCO3 saturated solution. 
The organic solvent was removed by evaporation at reduced pressure and the solid was 
collected by filtration. The crude compounds were dried and purified by recrystallization 
(compounds 7-9, 14-16, 75) or liquid chromatography (compounds 74, 76, 77). 
8-Amino-2-(4-hydroxyphenyl)-6-methyl-1,2,4-triazolo[4,3-a]pyrazin-3(2H)-one (7). 
Yield 65%. m.p. > 300 °C (EtOH/2-Methoxyethanol). 1H NMR (DMSO-d6) 2.11 (s, 3H, CH3), 
6.88 (d, 2H, ar, J = 6.8 Hz), 7.06 (s, 1H, H-5), 7.33 (br s, 2H, NH2), 7.75 (d, 2H, ar, J = 6.8 Hz). 
9.69 (br s, 1H, OH). Anal. Calc. for C12H11N5O2. 
8-Amino-2-(4-hydroxyphenyl)-6-phenyl-1,2,4-triazolo[4,3-a]pyrazin-3(2H)-one (8). 
Yield 72%. m.p. > 300 °C (EtOH). 1H NMR (DMSO-d6) 6.91 (d, 2H, ar, J = 8.5 Hz), 7.34 (t, 1H, 
ar, J = 7.5 Hz), 7.43 (t, 3H, ar, J = 7.5 Hz), 7.53 (br s, 2H, NH2), 7.74 (s, 1H, H-5), 7.78 (d, 2H, 
ar, J = 8.5 Hz), 7.97 (d, 2H, ar, J = 7.8 Hz), 9.72 (s, 1H, OH). IR = 3393-3122, 1642, 1667 cm-
1. Anal. Calc. for C17H13N5O2. 
8-Amino-2-(2-hydroxyphenyl)-6-phenyl-1,2,4-triazolo[4,3-a]pyrazin-3(2H)-one (9). 
Yield 67%. m.p. 271-273 °C (2-Methoxyethanol). 1H NMR (DMSO-d6) 6.95 (t, 1H, ar, J = 7.5 
Hz), 7.03 (d, 1H, ar, J = 8.1 Hz), 7.33-7.44 (m, 5H ar), 7.55 (br s, 2H, NH2), 7.75 (s, H, H-5), 
7.98 (d, 2H, ar, J = 7.5 Hz), 9.88 (s, 1H, OH). Anal. Calc. for C17H13N5O2. 
8-Amino-6-(2-hydroxyphenyl)-2-phenyl-1,2,4-triazolo[4,3-a]pyrazin-3(2H)-one (14). 
Yield 88%. m.p. 274-276 °C (EtOH). 1H NMR (DMSO-d6) 6.83-6.87 (m, 2H, ar), 7.18 (t, 1H, 
ar, J = 8.1 Hz), 7.37 (t, 1H, ar, J = 7.8 Hz), 7.57 (t, 2H, ar, J = 8.0 Hz), 7.91- 7.93 (m, 4H, 1ar 
+ H-5 + NH2), 8.07 (d, 2H, ar, J = 8. 0 Hz). 11.93 (s, 1H, OH). 13C NMR (DMSO-d6) 102.57, 
117.76, 119.46, 119.61, 119.90, 126.87, 127.18, 129.70, 129.87, 131.27, 134.75, 137.88, 
147.12, 147.59, 157.06. Anal. Calc. for C17H13N5O2. 
8-Amino-6-(3-hydroxyphenyl)-2-phenyl-1,2,4-triazolo[4,3-a]pyrazin-3(2H)-one (15). 
Yield 93%. m.p. > 300 °C (EtOH/2-Methoxyethanol). 1H NMR (DMSO-d6) 6.75 (d, 1H, ar J = 
7.3 Hz), 7.21 (t, 1H, ar, J = 7.4 Hz), 7.36-7.38 (m, 3H, ar), 7.55-7.61 (m, 5H, 3 ar + NH2), 7.61 
(s, 1H, H-5), 8.08 (d, 2H, ar, J = 8.1 Hz), 9.45 (s, 1H, OH). Anal. Calc. for C17H13N5O2.  
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8-Amino-6-(4-hydroxyphenyl)-2-phenyl-1,2,4-triazolo[4,3-a]pyrazin-3(2H)-one (16). 
Yield 85%. m.p. 285-286 °C (EtOH/2-Methoxyethanol). 1H NMR (DMSO-d6) 6.81 (d, 2H, ar., 
J = 6.8 Hz), 7.35 (t, 1H, ar, J = 7.4 Hz), 7.40 (t, 2H, ar, J= 7.6 Hz), 7.53 (br s, 2H, NH2), 7.73 
(s, 1H, H-5), 7.79 (d, 2H, ar, J = 6.8 Hz), 8.08 (d, 2H, ar, J = 7.6 Hz), 9.58 (s, 1H, OH). IR = 
3379-3294, 1694, 1643 cm-1. Anal. Calc. for C17H13N5O2. 
8-Amino-6-(4-hydroxy-2-methoxyphenyl)-2-phenyl-[1,2,4]triazolo[4,3-a]pyrazin-3(2H)-
one (74) . Yield 90%. m.p. 282-284 °C. Purified by liquid chromatography (Cyclohexane 
5/EtOAc 5/MeOH 1). 1H-NMR (DMSO-d6) 9.67 (br. s, 1H, OH), 8.07 (d, 2H, ar, J = 7.8 Hz), 
7.91 (d, 1H, ar, J = 8.6 Hz), 7.77 (s, 1H, H-5), 7.56 (t, 2H, ar, J = 7.7 Hz), 7.39-7.33 (m, 3H, 
NH2+ ar), 6.53 (s, 1H, ar), 6.47 (d, 1H, ar, J = 8.5 Hz), 3.87 (s, 3H, CH3). Anal. Calc. for 
C18H15N5O3. 
8-Amino-6-(3,4-dihydroxyphenyl)-2-phenyl-1,2,4-triazolo[4,3-a]pyrazin-3(2H)-one (75). 
Yield 88%. m.p. 256-258 °C (EtOH). 1H NMR (DMSO-d6) 6.77 (d, 1H, ar, J = 8.1 Hz), 7.23 
(dd, 1H, ar, J = 8.1, 1.5 Hz), 7.38-7.36 (m, 2H, ar), 7.43-7.53 (s + br s, H-5 + NH2), 7.55 (t, 
2H, ar, J = 7.5 Hz), 8.08 (d, 2H, ar, J = 8.6 Hz), 9.00 (br s, 2H, 2 OH). 13C-NMR (DMSO-d6) 
99.83, 113.69, 116.06, 117.26, 119.81, 126.71, 128.23, 129.65, 131.51, 136.46, 137.99, 
145.66, 146.14, 147.56, 147.59, IR = 3417.86-3091.89, 1693.50, 1681.93 cm-1. Anal. Calc. 
for C17H13N5O3.  
8-Amino-6-(3,4,5-trihydroxyphenyl)-2-phenyl-1,2,4-triazolo[4,3-a]pyrazin-3(2H)-one 
(76).  Yield 79%. m.p. 281-283 °C. Purified by liquid chromatography (CHCl3 9/MeOH 1). 
1H-NMR (DMSO-d6) 6.85 (s, 2H, ar), 7.30 (s, 1H, H-5), 7.35 (t, 1H, ar, J = 7.4 Hz), 7.46 (br. S, 
2H, NH2),  7.56 (t, 2H, ar, J = 7.6 Hz), 8.07 (d, 2H, ar, J = 7.8 Hz), 8.29 (br s, 1H, OH),  8.91 
(br. s, 2H, OH). Anal. Calc. for C17H13N5O4. 
8-amino-6-(4-hydroxy-3,5-dimethylphenyl)-2-phenyl-[1,2,4]triazolo[4,3-a]pyrazin-
3(2H)-one (77). Yield 90%. m.p. 236 °C. Purified by liquid chromatography (Cyclohexane 1 
/EtOAc 1). 1H-NMR (DMSO-d6) 2.21 (s, 6H, CH3), 7.35 (t, 1H, ar, J = 7.3 Hz), 7.45 (s, 2H, ar), 
7.54 (s, 1H, ar), 7.55-7.52 (m, 7H, ar + NH2), 8.07 (d, 2H, ar, J = 7.9 Hz) 8.40 (br. s, 1H, OH). 
13C-NMR (DMSO-d6) 17.21, 99.91, 119.85, 124.54, 126.04, 126.71, 127.54, 129.65, 131.49, 
136.39, 137.99, 147.59, 147.64, 153.94. IR = 3550-3450, 3363.86, 3323.35, 1699.29 cm-1. 
Anal. Calc. for C19H17N5O2. 
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Synthesis of 8-amino-6-(3-(tert-butyl)-4-hydroxyphenyl)-2-phenyl-[1,2,4]triazolo[4,3-
a]pyrazin-3(2H)-one (78).  
 
A solution of 48% aqueous HBr (2.5 mL) was added to a mixture of 8-amino-6-(3,5-di-tert-
butyl-4-methoxyphenyl)-2-phenyl-[1,2,4]triazolo[4,3-a]pyrazin-3(2H)-one (73) (0.50 
mmol) in glacial AcOH (2 mL). The mixture was refluxed 24 h, then the cooled suspension 
was treated with ice and water (30 mL) and the solid was collected by filtration and rinsed 
with Et2O. The crude product was purified by column chromatography (CHCl3 9.5/MeOH 
0.5). Yield 89%.  m.p. > 300 °C  1H-NMR (DMSO-d6) 1H NMR (400 MHz, DMSO) δ 9.54 (s, 
1H, OH), 8.08 (d, 2H, ar, J = 7.7 Hz), 7.72 (d, 1H, ar, J = 2.0 Hz), 7.58-7.54 (m, 3H, ar + H-5), 
7.50 (s, 3H, ar + NH2), 7.35 (t, 1H, ar, J = 7.4 Hz), 6.82 (d, 1H, ar, J = 8.3 Hz), 1.40 (s, 9H, 
(CH3)3). 13C NMR (DMSO-d6) 37.26, 45.14, 52.50, 101.01, 119.35, 119.85, 126.02, 126.33, 
126.74, 128.73, 129.65, 131.45, 131.56, 135.74, 137.97, 139.58, 142.94, 144.95, 145.36, 
147.61, 147.79, 170.84. Anal. Calc. for C21H21N5O2. 
 
General procedure for the synthesis of 8-amino-6-(alkyloxyphenyl)-2-phenyl-1,2,4-
triazolo[4,3-a]pyrazin-3(2H)-ones (18-28).  
 
 
 
 
 
 
 
 R  R 
18 3-O-propargyl 24 4-O-iC3H7 
19 4-O-propargyl 25 4-OCH2-iC3H7 
20 3-OCH2Ph 26 4-OCH2cC3H5 
21 4-OCH2Ph 27 4-OCH2cC4H7 
22 4-OC2H5 28 4-OCH2-CH=CH2 
23 4-O-nC3H7  
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A solution of the suitable alkyl bromide (1.2 mmol) in butan-2-one (3 mL) was added 
dropwise to a mixture of the hydroxyphenyl- derivative 15 or 16 (1 mmol) and K2CO3 (2 
mmol) in butan-2-one (5 mL). The mixture was heated at reflux until the disappearance of 
the starting hydroxy-derivative (TLC monitoring, 7-58 h). After cooling at room 
temperature, the solid was collected by filtration, washed with water and recrystallized. 
8-Amino-2-phenyl-6-(3-propargyloxyphenyl)-1,2,4-triazolo[4,3-a]pyrazin-3(2H)-one 
(18). Yield 58%. m.p. 217-219 °C (EtOH/2-Methoxyethanol). 1H NMR (DMSO-d6) 3.58 (t, 
1H, CH, J = 2.3 Hz), 4.89 (d, 2H, CH2, J = 2.3 Hz), 6.97 (d, 1H, ar, J = 6.5 Hz), 7.36 (t, 2H, ar, J 
= 7.6 Hz), 7.55-7.63 (m, 6H, 4ar + NH2), 7.84 (s, 1H, H-5), 8.08 (d, 2H, ar, J = 7.6 Hz). IR = 
3443, 3298, 1721, 1643 cm-1. Anal. Calc. for C20H15N5O2.   
8-Amino-2-phenyl-6-(4-propargyloxy)phenyl-1,2,4-triazolo[4,3-a]pyrazin-3(2H)-one 
(19).  Yield 56%. m.p. 244-245 °C (AcOH). 1H NMR (DMSO-d6) 3.59 (t, 1H, CH, J = 2.3 Hz), 
4.85 (d, 2H, CH2, J = 2.4 Hz), 7.04 (d, 2H, ar, J = 6.9 Hz), 7.36 (t, 1H, ar, J = 7.4 Hz), 7.54-7.59 
(m, 4H, 2ar + NH2), 7.69 (s, 1H, H-5), 7.93 (d, 2H, ar, J = 6.9 Hz), 8.08 (d, 2H, ar, J = 7.6 Hz). 
IR = 3458, 3331, 3219, 1695, 1620 cm-1. Anal. Calc. for C20H15N5O2.  
8-Amino-6-(3-benzyloxyphenyl)-2-phenyl-1,2,4-triazolo[4,3-a]pyrazin-3(2H)-one (20). 
Yield 78%. m.p. 264-266 °C (2-Methoxyethanol). 1H NMR (DMSO-d6) 5.19 (s, 2H, CH2), 6.99 
(d, 1H, ar, J = 8.3 Hz), 7.32-7.65 (m, 13H, 11ar + NH2), 7.84 (s, 1H, H-5), 8.07 (d, 2H, ar, J = 
8.0 Hz). Anal. Calc. for C24H19N5O2.  
8-Amino-6-(4-benzyloxyphenyl)-2-phenyl-1,2,4-triazolo[4,3-a]pyrazin-3(2H)-one (21). 
Yield 78%. m.p. 284-285 °C (2-Methoxyethanol). 1H NMR (DMSO-d6) 5.16 (s, 2H, CH2), 7.07 
(d, 2H, ar, J = 8.9 Hz), 7.34-7.48 (m, 6H, ar), 7.51-7.58 (m, 4H, 2ar + NH2), 7.67 (s, 1H, H-5), 
7.92 (d, 2H, ar, J = 8.9 Hz), 8.08 (d, 2H,ar, J = 7.6 Hz). IR = 3362, 3310, 1697, 1647 cm-1. 
Anal. Calc. for C24H19N5O2. 
8-Amino-6-(4-ethoxyphenyl)-2-phenyl-1,2,4-triazolo[4,3-a]pyrazin-3(2H)-one (22). Yield 
72%. m.p. 267-268 °C (EtOH/2-Methoxyethanol). 1H NMR (DMSO-d6) 1.35 (t, 3H, CH3, J = 
7.0 Hz), 4.07 (q, 2H, CH2, J = 7.0 Hz), 6.96 (d, 2H, ar, J = 6.8 Hz), 7.36 (t, 1H, ar, J = 8.8 Hz), 
7.53-7.58 (m, 4H, 2ar + NH2), 7.65 (s, 1H, H-5), 7.90 (d, 2H, ar, J = 6.8 Hz), 8.08 (d, 2H, ar, J 
= 8.8 Hz). IR = 3119, 3102, 1697, 1647 cm-1. Anal. Calc. for C19H17N5O2.  
8-Amino-6-(4-n-propyloxyphenyl)-2-phenyl-1,2,4-triazolo[4,3-a]pyrazin-3(2H)-one 
(23). Yield 67%. m.p. 266-267 °C (2-Methoxyethanol). 1H NMR (DMSO-d6) 0.99 (t, 3H, CH3, 
J = 7.4 Hz), 1.72-1.77 (m, 2H, CH2), 3.97 (t, 2H, CH2, J = 6.5 Hz), 6.97 (d, 2H, ar, J = 8.8 Hz), 
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7.35 (t, 1H, ar, J = 7.3 Hz), 7.54-7.58 (m, 2ar + NH2), 7.65 (s, 1H, H-5), 7.89 (d, 2H, ar, J = 
8.8 Hz), 8.07 (d, 2H, ar, J = 7.9 Hz). Anal. Calc. for C20H19N5O2.  
8-Amino-6-(4-isopropyloxyphenyl)-2-phenyl-1,2,4-triazolo[4,3-a]pyrazin-3(2H)-one 
(24). Yield 70%. m.p. 240-241 °C (EtOH/2-Methoxyethanol). 1H NMR (DMSO-d6) 1.30 (d, 
6H, 2CH3, J = 6.0 Hz), 4.63-4.69 (m, 1H, CH), 6.96 (d, 2H, ar, J = 8.7 Hz), 7.36 (t, 1H, ar, J = 
7.4 Hz), 7.52 (br s, 2H, NH2), 7.58 (m, 2H, ar, J = 7.7 Hz), 7.64 (s, 1H, H5), 7.88 (d, 2H, ar, J = 
8.7 Hz), 8.08 (d, 2H, ar, J = 7.9 Hz). IR = 3385, 3310, 1701, 1638 cm-1. Anal. Calc. for 
C20H19N5O2.  
8-Amino-6-(4-isobutyloxyphenyl)-2-phenyl-1,2,4-triazolo[4,3-a]pyrazin-3(2H)-one (25). 
Yield 64%. m.p. 249-251 °C (2-Methoxyethanol). 1H NMR (DMSO-d6) 1.00 (d, 6H, 2CH3, J= 
6.5 Hz), 1.99-2.06 (m, 1H, CH), 3.78 (d, 2H, CH2, J = 6.5 Hz), 6.97 (d, 2H, J = 8.7 Hz), 7.35 (t, 
1H, ar, J = 7.3 Hz), 7.54-7.57 (m, 2ar + NH2), 7.65 (s, 1H, H-5), 7.98 (d, 2H, ar, J = 8.7 Hz), 
8.07 (d, 2H, ar, J = 7.9 Hz). Anal. Calc. for C21H21N5O2.  
8-Amino-6-[(4-cyclopropylmethoxy)phenyl]-2-phenyl-1,2,4-triazolo[4,3-a]pyrazin-
3(2H)-one (26). Yield 86%. m.p. 276-278 °C (EtOH/2-Methoxyethanol). 1H NMR (DMSO-
d6) 0.32-0.36 (m, 2H, 2CH), 0.57-0.60 (m, 2H, 2CH), 1.21-1.24 (m, 1H, CH), 3.85 (d, 2H, CH2, 
J = 7.0 Hz), 6.97 (d, 2H, ar, J = 8.9 Hz), 7.36 (t, 1H, ar, J = 7.4 Hz), 7.54 (br s, 2H, NH2), 7.56 
(t, 2H, ar, J = 7.4 Hz), 7.65 (s, 1H, H-5), 7.91 (d, 2H, ar, J = 8.9 Hz), 8.08 (d, 2H, ar, J = 7.4 Hz). 
IR = 3362, 3316, 1669, 1649 cm-1. Anal. Calc. for C21H19N5O2.  
8-Amino-6-[(4-cyclobutylmethoxy)phenyl]-2-phenyl-1,2,4-triazolo[4,3-a]pyrazin-3(2H)-
one (27). Yield 45%. m.p. 266-268 °C (EtOH/2-Methoxyethanol). 1H NMR (DMSO-d6) 1.88-
1.96 (m, 4H, 4CH), 2.06-2.13 (m, 2H, 2CH), 2.72-2.75 (m, 1H, CH), 3.99 (d, 2H, CH2, J = 6.7 
Hz), 6.98 (d, 2H, ar, J = 8.8 Hz), 7.36 (t, 1H, ar, J = 7.4 Hz), 7.56 (br s, 2H, NH2),  (t, 2H, ar, J 
= 7.8 Hz), 7.65 (s, 1H, H-5), 7.90 (d, 2H, ar, J = 8.8 Hz), 8.08 (d, 2H, ar, J = 7.8 Hz). IR = 3354, 
3312, 1699, 1647 cm-1.  Anal. Calc. for C22H21N5O2.  
8-Amino-2-phenyl-6-(4-allyloxy)phenyl-1,2,4-triazolo[4,3-a]pyrazin-3(2H)-one (28). 
Yield 75%. m.p. 260-261 °C (2-Methoxyethanol). 1H NMR (DMSO-d6) 4.60 (d, 2H, CH2), 
5.27 (d, 1H, geminal CH, J = 10.4 Hz), 5.42 (d, 1H, geminal CH=, J = 17.4 Hz), 6.02-6.11 (m, 
1H, CH=), 7.00 (d, 2H, ar, J = 8.8 Hz), 7.35 (t, 1H, ar, J = 7.9 Hz), 7.54-7.58 (m, 2ar + NH2), 
7.66 (s, 1H, H-5), 7.90 (d, 2H, ar, J = 8.8 Hz), 8.07 (d, 2H, ar, J = 7.9 Hz). Anal. Calc. for 
C20H17N5O2.  
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General procedure for the synthesis of amino-substituted 8-amino-1,2,4-triazolo[4,3-
a]pyrazin-3(2H)-one derivatives (10, 37-39). 
 
10% Pd/C (10% w/w with respect to the nitro derivative) was added to a solution of the 
6-(nitrophenyl) derivatives 5, 34-36 (1.2 mmol) in DMF (10 mL). The mixture was 
hydrogenated in a Parr apparatus at 40 psi for 24 h (TLC, monitoring). Then the catalyst 
was filtered off and the clear solution was diluted with water (about 50 mL) to obtain a 
solid that was collected by filtration, washed with water and Et2O, dried and 
recrystallized. 
8-Amino-2-(4-aminophenyl)-6-phenyl-1,2,4-triazolo[4,3-a]pyrazin-3-(2H)one (10). . 
Yield 39%. m.p. >300 °C (2-Methoxyethanol). 1H NMR (DMSO-d6) 5.33 (br s, 2H, NH2), 6.68 
(d, 2H, ar, J = 8.7 Hz), 7.34 (t, 1H, ar, J = 7.2 Hz), 7.42 (t, 2H, J = 7.4 Hz), 7.49 (br s, 2H, NH2), 
7.57 (d, 2H, J= 8.7 Hz), 7.72 (s, 1H, H-5), 7.96 (d, 2H, ar, J = 7.4 Hz). Anal. Calc. for. 
C17H14N6O. 
8-Amino-6-(2-aminophenyl)-2-phenyl-1,2,4-triazolo[4,3-a]pyrazin-3 (2H)-one (37). Yield 
59%. m.p. 256-258 °C (2-Methoxyethanol). 1H NMR (DMSO-d6) 5.78 (br s , 2H, NH2), 6.58 
(t, 1H, ar, J = 7.4 Hz), 6.72 (d, 1H, ar, J = 8. 00 Hz), 7.05 (t, 1H, ar, J = 7.2 Hz), 7.30-7.38 (m, 
3H, 2 ar + H-5), 7.56 (t, 2H, ar, J = 7.9 Hz), 7.62 (br s, 2H, NH2), 8.07 (d, 2H, ar, J = 7.9 Hz). 
Anal. Calc. for. C17H14N6O. 
8-Amino-6-(3-aminophenyl)-2-phenyl-1,2,4-triazolo[4,3-a]pyrazin-3 (2H)-one (38). Yield 
75%. m.p. 280-282 °C (2-Methoxyethanol). 1H NMR (DMSO-d6) 5.10 (br s , 2H, NH2), 6.54-
6.57 (m, 1H, ar), 7.04-7.10 (m, 2H, ar), 7.16 (s, 1H, ar), 7.36 (t, 1H, ar, J = 7.4 Hz), 7.50 (s, 
1H, H-5), 7.51 (br s, 2H, NH2), 7.56 (t, 2H, ar, J = 7.7 Hz), 8.08 (d, 2H, ar, J = 7.7 Hz). Anal. 
Calc. for. C17H14N6O. 
8-Amino-6-(4-aminophenyl)-2-phenyl-1,2,4-triazolo[4,3-a]pyrazin-3 (2H)-one (39). Yield 
78%. m.p. 294-296 °C (Nitromethane/DMF). 1H NMR (DMSO-d6) 5.27 (br s, 2H, NH2), 6.59 
(d, 2H, ar, J = 8.6 Hz), 7.35 (t, 1H, ar, J = 7.4 Hz), 7.44 (br s , 2H, NH2), 7.46 (s, 1H, H-5), 7.56 
(t, 2H, ar, J = 8. 5 Hz), 7.64 (d, 2H, ar, J = 8.6 Hz), 8.08 (d, 2H, ar, J = 7. 6 Hz). 13C-NMR 
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(DMSO-d6) 98.70, 114.1 119.83, 124.15, 126.68, 126.89, 129.64, 131.50, 136.93, 138.03, 
147.54, 147.56, 149.40. IR = 1703, 3292-3115, 3350, 3435 cm-1. Anal. Calc. for. C17H14N6O. 
 
General procedure for the synthesis of 8-amino-2-phenyl-6-(piperazinylphenyl)-1,2,4-
triazolo[4,3-a]pyrazin-3-(2H)one (40-42). 
 
A suspension of the 8-amino-6-(aminophenyl) derivatives 37-39 (1.1 mmol) and bis-(2-
chloroethyl)amine hydrochloride in sulfolane (5 mL) was heated at 150 °C until the 
disappearance of  starting material (TLC-monitoring 16-24 h). After cooling at 0-5 °C, the 
mixture was treated with acetone (30 mL) and the obtained ammonium salts were 
collected by filtration and dissolved in water (50 mL). The solution was neutralized with a 
NaHCO3 saturated solution and extracted with EtOAc (40 mL x 5). The organic phase was 
anhydrified (Na2SO4) and reduced to dryness under vacuum to give a yellow solid. All the 
crude derivatives were purified by recrystallization. 
8-Amino-2-phenyl-6-(2-piperazin-1-yl-phenyl)-1,2,4-triazolo[4,3-a]pyrazin-3-(2H)one 
(40). Yield 52%. m.p. 214-216 °C (Nitromethane). 1H NMR (DMSO-d6) 2.82 (s , 8H, 4 CH2), 
7.08-7.11 (m, 2H, ar), 7.28 (t, 1H, ar, J = 7.6 Hz), 7.36 (t, 1H, ar, J = 7.4 Hz), 7.51 (br s, 2H, 
NH2), 7.56 (t, 2H, ar, J = 7.7 Hz), 7.84 (d, 1H, ar, J = 6.6 Hz), 8.09 (d, 2H, ar, J = 7.8 Hz), 8.40 
(s, 1H, H-5). Anal. Calc. for. C21H21N7O. 
8-Amino-2-phenyl-6-(3-piperazin-1-yl-phenyl)-1,2,4-triazolo[4,3-a]pyrazin-3-(2H)one 
(41). Yield 47%. m.p. 234-235 °C (Nitromethane). 1H NMR (DMSO-d6) 2.86 (t, 4H, 2 CH2, J 
= 4. 9 Hz), 3.11 (t, 4H, 2 CH2, J = 5.1 Hz), 6. 90 (dd, 1H, ar, J = 6.3 Hz, J = 1.9 Hz), 7.25 (t, 1H, 
ar), 7.34-7.39 (m, 2H, ar), 7.51-7.58 (m, 5H, 3 ar + NH2), 7.77 (s, 1H, H-5), 8.08 (d, 2H, ar, J 
= 8.6 Hz). Anal. Calc. for. C21H21N7O. 
8-Amino-2-phenyl-6-(4-(piperazin-1-yl-)phenyl)-1,2,4-triazolo[4,3-a]pyrazin-3-(2H)one 
(42). Yield 56%. m.p. 255-257 °C (Nitromethane). 1H NMR (DMSO-d6) 1H NMR (DMSO-d6) 
2.84 (t, 4H, 2 CH2, J = 4.9 Hz), 3.11 (t, 4H, 2 CH2, J = 5.1 Hz), 7. 96 (d, 2H, ar, J = 8.9 Hz), 
6.EXPERIMENTAL SECTION 
 
125 
7.36 (t, 1H, ar, J = 7.4 Hz), 7. 50 (br s, 2H, NH2), 7. 54- 7.59 (m, 2H, 1 ar + H-5), 7.82 (d, 2H, 
ar, J = 8.8 Hz), 8.08 (d, 2H, ar, J = 7.7 Hz). Anal. Calc. for. C21H21N7O. 
 
Synthesis of 4-(3-(8-amino-3-oxo-2-phenyl-2,3-dihydro-1,2,4-triazolo[4,3-a]pyrazin-6-
yl)phenyl)-1,1-dimethyl-piperazin-1-ium (43).  
 
A mixture of compound 41 (0.4 mmol), methyl iodide (0.7 mmol) and potassium 
carbonate in anhydrous DMF (0.5 mL) was stirred at room temperature for 7 h, then it 
was diluted with H2O (about 50 mL) and EtOAc (about 40 mL). The obtained solid was 
collected by filtration and recrystallized. Yield 35%. m.p. > 300 °C (DMF). 1H NMR (DMSO-
d6) 3.23 (s, 6H, 2CH3), 3.61 (br s, 8H, piperazine protons), 7.02 (d, 1H, ar, J = 7.6 Hz), 7.32-
7.38 (m, 2H, ar), 7.52-7.59 (m, 6H, 4 ar + NH2), 7.87 (s, 1H, H-5), 8.07 (d, 2H, ar, J = 8.2 Hz). 
). Anal. Calc. for C23H26N7O+. 
 
General procedure for the synthesis of 8-amino-6-((4-benzylpiperazin-1-yl)-phenyl)-2-
phenyl-1,2,4-triazolo[4,3-a]pyrazin-3-(2H)one (44, 45). 
 
A suspension of the 8-amino-6-(piperazinyl)phenyl derivative 41 or 42 (0.7 mmol), 
anhydrous triethylamine (0.9 mmol) and benzylchloride (0.9 mmol) in anhydrous dioxane 
(10 mL) was refluxed until the disappearance of starting material (TLC monitoring, 24-48 
h). In case of compound 44, the organic solvent was removed by evaporation at reduced 
pressure and the residue treated with EtOAc (50 mL). The organic phase was washed with 
water (30 mL x 3), anhydrified (Na2SO4) and reduced to dryness under vacuum to give a 
solid. To isolate compound 45, the solvent was evaporated under vacuum and the residue 
was treated with water (30 mL). The resulting solid was collected by filtration and washed 
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with diethyl ether (about 20 mL). The crude products were purified by recrystallization 
(44) or column chromatography (45). 
8-Amino-6-[3-(4-benzylpiperazin-1-yl)phenyl]-2-phenyl-1,2,4-triazolo[4,3-a]pyrazin-3-
(2H)one (44). Yield 34%. m.p. 208-210 °C (EtOH). 1H NMR (DMSO-d6) 2.55 (t, 4H, 2 CH2, J 
= 4. 8 Hz), 3.22 (t, 4H, 2 CH2, J = 4.9 Hz), 6.91 (dd, 1H, ar, J = 6.2, J = 2.00 Hz), 7.24-7.30 (m, 
2H, ar), 7.34-7.31 (m, 6H, ar), 7.52-7.59 (m, 5H, 3 ar + NH2), 7.77 (s, 1H, H-5), 8.08 (d, 2H, 
ar, J = 7.6 Hz). Anal. Calc. for.  C28H27N7O. 
8-Amino-6-[4-(4-benzylpiperazin-1-yl)phenyl]-2-phenyl-1,2,4-triazolo[4,3-a]pyrazin-3-
(2H)one (45). Purified by liquid chromatography (Cyclohexane 5.5 /EtOAc 4.5/ MeOH 0.1). 
Yield 63%. m.p. 244-246 °C (EtOH). 1H NMR (CDCl3-d6 ) 2.65 (t, 4H, 2 CH2, J = 4. 8 Hz), 3.30 
(t, 4H, 2 CH2, J = 4.9 Hz), 5.54 (br s, 2H, NH2), 6.98 (d, 2H, ar, J = 8.8 Hz), 7.30-7.40 (m, 6H, 
ar), 7.52 (t, 2H, ar, J = 7.7 Hz), 7.60 (s, 1H, H-5), 7.76 (d, 2H, ar, J = 8.8 Hz), 8.12 (d, 2H, ar, 
J = 7.8 Hz). 13C NMR (DMSO-d6) 48.63, 52.95, 63.07, 101.56, 110.64, 119.84, 126.64, 
126.85, 127.21, 128.32, 129.19, 129.24, 130.81, 136.62, 137.58, 146.38, 147.47, 151.50. 
Anal. Calc. for.  C28H27N7O. 
 
General procedure for the synthesis 2-(4-(8-amino-3-oxo-2-phenyl-2,3-dihydro-
[1,2,4]triazolo[4,3-a]pyrazin-6-yl)phenoxy)acetonitrile/acetamide (46-47). 
 
2-Chloroacetamide (7.05 mmol, 46) or 2-chloroacetonitrile (6.28 mmol, 47) was added to 
a suspension of 8-amino-6-(4-hydroxyphenyl)-2-phenyl-[1,2,4]triazolo[4,3-a]pyrazin-
3(2H)-one (16) (1.57 mmol) and K2CO3 (3.14 mmol) in anhydrous acetone (20 mL) . The 
mixture was stirred at room temperature overnight (TLC monitoring). The resulting solid 
was collected by filtration, rinsed with water (20 mL) and petroleum ether, dried and 
purified by recrystallization. 
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2-(4-(8-amino-3-oxo-2-phenyl-2,3-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-6-
yl)phenoxy)acetamide (46). 
 
 Yield 51%. m.p. 260-263 °C (EtOH/ 2-Methoxyethanol). 1H NMR (DMSO-d6) 8.08 (d, 2H, 
ar, J = 7.8 Hz), 7.92 (d, 2H, ar, J = 8.3 Hz), 7.68 (s, 1H, H-5), 7.56-7-55 (m, 4H, ar + NH2), 
7.41 (br s, 1H, NH2), 7.34 (t, 1H, ar, J = 7.2 Hz), 7.01 (d, 2H, ar, J = 8.3 Hz), 4.47 (s, 2H, CH2). 
13C NMR (DMSO-d6) 39.39, 39.59, 39.8, 40.01, 40.22, 40.43, 40.64, 43.05, 67.25, 100.73, 
102.92, 115.12, 119.87, 126.74, 127.22, 129.64, 129.88, 131.53, 135.75, 137.98, 147.62, 
147.78, 158.26, 170.32. IR = 3458, 3371, 3284, 3209, 2671, 1707, 1377 cm-1). Anal. Calc. 
for C19H16N6O3. 
 
2-(4-(8-amino-3-oxo-2-phenyl-2,3-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-6 
yl)phenoxy)acetonitrile (47). 
 
Yield 89%. m.p. 249-250 °C (EtOH). 1H NMR (DMSO d6) 8.08 (d, 2H, ar, J = 7.7 Hz), 8.00 (d, 
2H, ar, J = 8.8 Hz), 7.75 (s, 1H, H-5), 7.63–7.50 (m, 4H, ar + NH2), 7.36 (t, 1H, ar, J = 7.4 Hz), 
7.13 (d, 2H, ar, J = 8.9 Hz), 5.22 (s, 2H). 13C NMR (DMSO-d6) 39.39, 39.60, 39.81, 40.02, 
40.23, 40.44, 40.65, 54.01, 101.21, 115.28, 117.11, 119.87, 126.74, 127.46, 129.64, 
131.23, 131.54, 135.42, 137.97, 147.63, 147.83, 156.74. IR = 3406, 3311, 3169, 1701, 
1643, 1460 cm-1. Anal. Calc. for.  C19H14N6O2. 
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Synthesis of 8-amino-6-(4-(2-aminoethoxy)phenyl)-2-phenyl-[1,2,4]triazolo[4,3-
a]pyrazin-3(2H)-one (48). 
 
 2-(4-(8-Amino-3-oxo-2-phenyl-2,3-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-
yl)phenoxy)acetonitrile (47) (0.78 mmol) was added  portionwise to a suspension of LiAlH4 
(1.95 mmol) in anhydrous THF (20 mL) at 0 °C. The mixture was stirred at room 
temperature for 2 h, then treated with ice and water (15 mL) and extracetd with EtOAc 
(20 mL x 3). The organic phase was washed with water (20 mL x 3) and anhydrified 
(Na2SO4), then the solvent eliminated under reduced pressure. The resulting residue was 
treated with water (20 mL) and collected by filtration. The crude was purified by column 
chromatography (CHCl3 9.5/MeOH 0.5). Yield 78%. m.p. 239-241 °C 1H NMR (DMSO-d6) 
2.89 (t, 2H, CH2, J = 5.3 Hz), 3.96 (t, 2H, CH2, J = 5.4 Hz), 6.98 (d, 2H, ar, J = 8.5 Hz), 7.35 (t, 
1H, ar, J = 7.3 Hz), 7.45 – 7.60 (m, 4H, ar + NH2), 7.65 (s, 1H, H-5), 7.90 (d, 2H, ar, J = 8.5 
Hz), 8.07 (d, 2H, ar, J = 7.9 Hz). IR: 3391, 3329, 3215, 3111, 2677, 1705, 1655, 1547, 1510, 
1456, 1360, 1246 cm-1. Anal.Calc. for  C19H18N6O2. 
 
Synthesis of 8-amino-6-(4-(2-hydroxyethoxy)phenyl)-2-phenyl-[1,2,4]triazolo[4,3-
a]pyrazin-3(2H)-one (49). 
 
Ethylene carbonate (2.96 mmol) was added to a suspension of 8-amino-6-(4-
hydroxyphenyl)-2-phenyl-[1,2,4]triazolo[4,3-a]pyrazin-3(2H)-one (16) (1.41 mmol) and 
K2CO3 (1.41 mmol) in anhydrous DMF (1.5 mL), The mixture was heated at 110 °C for 6h 
then treated with water (20 mL). The solid was collected by filtration, rinsed with 
petroleum ether, dried and recrystallized. Yield 88 %. m.p. 269-269 °C (2-
Methoxyethanol).1H NMR (DMSO-d6) 3.73 (dd, 2H, J = 10.1, 5.2 Hz), 4.03 (t, 2H, J = 5.0 Hz), 
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4.88 (t, 1H, OH, J = 5.5 Hz), 6.99 (d, 2H, ar, J = 8.8 Hz), 7.35 (t, 1H, ar, J = 7.4 Hz), 7.54 – 
7.58 (m, 4H, ar + NH2), 7.65 (s, 1H, H-5), 7.90 (d, 2H, ar, J = 8.8 Hz), 8.08 (d, 2H, ar, J = 7.9 
Hz). 13C NMR (DMSO-d6) 59.20, 152.15, 147.76, 140.65, 137.99, 137.05, 135.88, 129.65, 
129.19, 127.28, 126.73, 125.19, 119.85, 119.12, 114.85, 70.02, 61.53, 60.04. Anal. Calc. 
for  
 
Synthesis of 8-amino-6-(4-(2,3-dihydroxypropoxy)phenyl)-2-phenyl-[1,2,4]triazolo[4,3-
a]pyrazin-3(2H)-one (50). 
 
 A solution of 3-chloropropane-1,2-diol in anhyrous acetonitrile (2 mL) was added to a 
suspension of 8-amino-6-(4-hydroxyphenyl)-2-phenyl-[1,2,4]triazolo[4,3-a]pyrazin-3(2H)-
one (16)  (0.626 mmol) and anhydrous K2CO3 (3.13 mmol) in acetonitrile (5 mL). The 
mixture was refluxed for 36 h (TLC monitoring). The solvent was eliminated under 
reduced pressure and the residue was treated with water (20 mL). The solid was collected 
by filtration, rinsed with Et2O/acetone (20 + 10 mL), dried and recrystallized. Yield 73%. 
m.p. 237-239 °C. (2-Methoxyethanol) 1H NMR (DMSO-d6) 3.47 (t, 2H, J = 5.5 Hz), 3.81 (dd, 
1H, J = 11.1, 4.2 Hz), 3.91 (dd, 1H, J = 9.8, 6.1 Hz), 4.05 (dd, 1H, J = 9.8, 4.2 Hz), 4.65 (t, 1H, 
OH, J = 5.6 Hz), 4.93 (d, 1H, OH, J = 5.1 Hz), 6.99 (d, 2H, ar, J = 8.9 Hz), 7.36 (t, 1H, ar, J = 
7.4 Hz ), 7.56 (7, 4 H, J =), 7.65 (s, 1H, H-5), 7.90 (d, 2H, J = 8.8 Hz), 8.08 (d, 2H, J = 7.8 Hz). 
). Anal. Calc. for. C20H19N5O4. 
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Synthesis of N-(4-(8-amino-3-oxo-2-phenyl-2,3-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-6-
yl)phenyl)acrylamide (194).  
 
A mixture of 8-amino-6-(4-aminophenyl)-2-phenyl-[1,2,4]triazolo[4,3-a]pyrazin-3(2H)-
one (39) (1.00 mmol), 3-chloropropionic acid (1.2 mmol), EDCI. HCl (1.2 mmol), DIPEA (1.2 
mmol) in anhydrous DMF (3 mL) was stirred at room temperature for 2h. The mixture was 
treated with water (30 mL). The resulting solid was collected by filtration washed with 
Et2O and recrystallized. Yield 99%. m.p. > 300 °C (Nitromethane) 1H-NMR (DMSO-d6) 5.76 
(m, 1H, CH), 6.28 (m, 1H, CH), 6.50 (m, 1H, CH), 7.33 (t, 1H, ar, J = 7.2 Hz), 7.52-7.54 (m, 
4H, ar + NH2), 7.69 (s, 1H, H-5), 7.75 (d, 2H, ar, J = 8.5 Hz), 7.93 (d, 2H, ar, J = 8.9 Hz), 8.07 
(d, 2H, ar, J = 7.9 Hz), 10.33 (br. s, 1H, NH). 13C-NMR (DMSO-d6) 101.15, 119.65, 119.82, 
126.37, 126.69, 127.28, 129.60, 131.54, 131.91, 132.36, 135.70, 137.96, 139.40, 147.59, 
147.79, 163.63. IR = 3375.43, 3331.07, 3296.35, 3205.69, 3180.62, 1693.50, 1681.93, 
1643.35, 1633.71 cm-1. Anal. Calc. for C20H16N6O2. 
 
Synthesis of 3-amino-N-(4-(8-amino-3-oxo-2-phenyl-2,3-dihydro-[1,2,4]triazolo[4,3-
a]pyrazin-6-yl)phenyl)propenamide(51). 
 
A suspension of N-(4-(8-amino-3-oxo-2-phenyl-2,3-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-
6-yl)phenyl)acrylamide (194) (0.13 mmol) in a saturated ethanolic solution of NH3 (15 mL) 
was heated at 130 °C in a sealed tube for 3 h. The mixture was cooled at room 
temperature, the solid was collected by filtration and washed with water (about 5-10 mL) 
and petroleum ether. Purified by liquid chromatography (DCM 8/MeOH 2/NH3 0.2). Yield 
89%. m.p. 239-241 °C.  1H-NMR (DMSO-d6) 2.43 (t, 2H, CH2, J = 6.4 Hz), 2.87 (t, 2H, CH2, J 
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= 6.2 Hz), 7.35 (t, 1H, ar, J = 7.4 Hz), 7.54-7.58 (m, 4H, ar + NH2, J = 7.8 Hz), 7.65 – 7.69 (m, 
3H, ar + H-5),  7.91 (d, 2H, ar, J = 8.7 Hz), 8.08 (d, 2H, ar, J = 7.9 Hz),  10.18 (br s, 1H, NH). 
13C-NMR (DMSO-d6) 38.45, 39.37, 100.98, 119.33, 119.85, 126.31, 126.74, 129.65, 131.40, 
131.56, 135.76, 137.98, 139.63, 147.61, 147.79, 170.98. Anal. Calc. for.  C20H19N7O2. 
 
General procedure for the Synthesis of N-(4-(8-amino-3-oxo-2-phenyl-2,3-dihydro-
[1,2,4]triazolo[4,3-a]pyrazin-6-yl)phenyl)-3-propanamide derivatives (52-55). 
 
A suspension of N-(4-(8-amino-3-oxo-2-phenyl-2,3-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-
6-yl)phenyl)acrylamide 194 (1 mmol) and the suitable amine (pyrrolidine, 5 mmol; 
piperidine and morpholine, 4 mmol; N-methylpiperazine, 3 mmol) in anhydrous THF (20 
mL) was refluxed for 2-16 h (TLC monitoring). The solvent was removed under reduced 
pressure and the resulting solid was collected bt filtration. The crude product was dryed 
and purified by recrystallization (52, 54, 55) or column chromatography (53). 
 
N-(4-(8-amino-3-oxo-2-phenyl-2,3-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-6-yl)phenyl)-3-
(pyrrolidin-1-yl)propenamide (52). Yield 59%. m.p.  212-214 °C. (EtOH) 1H-NMR (DMSO-
d6) 1.70 (m, 4H), 2.74 (t, 2H, CH2, J = 7.0 Hz), 7.35 (t, 1H, ar, J = 7.4 Hz), 7.56-7.55 (m, 2H, 
ar), 7.56 (s, 2H, NH2 ), 7.64 (d, 2H, ar, J = 7.9 Hz), 7.69 (s, 1H, ar), 7.91 (d, 2H, ar, J = 7.9 Hz),    
8.08 (d, J = 7.9 Hz, 2H, ar), 10.20 (br. S, 1H, NH). 13C NMR (DMSO-d6) 23.62, 36.53, 51.98,  
53.89, 100.99, 119.24, 119.85, 126.37,  126.74, 129.65, 131.44, 131.56, 135.74,  137.97,   
139.63, 147.61, 147.79, 170.62. Anal. Calc. for C24H25N7O2. 
N-(4-(8-amino-3-oxo-2-phenyl-2,3-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-6-yl)phenyl)-3-
(piperidin-1-yl)propenamide (53). Purified by column chromatography (CHCl3 9/MeOH 
1). Yield 60%. m.p. > 300 °C. 1H-NMR (DMSO-d6) 1.40 (m, 2H), 1.53 (m, 4H), 2.45 (m, 4H), 
2.66 (m, 2H), 3.37 (m, 2H), 7.35 (t, 1H, ar, J = 7.36 Hz), 7.56 (t, 2H, ar, J = 8.00 Hz),  7.56 (br. 
s, 2H, NH2),   7.63 (d, 2H, ar, J = 8.50 Hz), 7.69 (s, 1H, ar), 7.91 (d, 2H, ar, J = 8.50 Hz), 8.08 
6.EXPERIMENTAL SECTION 
                                                                                                                                                                           
132 
(d, 2H, ar, J = 7.96 Hz), 10.27 (br. s, 1H, NH). 13C-NMR (DMSO-d6) 24.28, 25.84, 34.27, 54.02, 
54.72, 101.0, 119.23, 119.83, 126.37, 126.74, 129.66, 131.46, 131.55, 135.70, 137.96, 
139.58, 147.61, 147.79, 170.62. IR = 3360.00, 3305.99, 1681.93, 1651.07 cm-1. Anal. Calc. 
for C25H27N7O2. 
N-(4-(8-amino-3-oxo-2-phenyl-2,3-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-6-yl)phenyl)-3-
morpholinopropanamide (54). 
Yield 65%. m.p. 267-268 °C (EtOH /2-methoxyethanol) 1H-NMR (DMSO-d6) 2.41 (m, 4H), 
2.50 (m, 2H), 2.63 (m, 2H), 3.58 (m, 4H), 7.35 (t, 1H, ar, J = 6.94 Hz), 7.54-7.56 (m, 4H, ar + 
NH2), 7.64 (d, 2H, ar, J = 8.04 Hz), 7.69 (s, 1H, ar),  7.91 (d, 2H, ar, J = 7.96 Hz), 8.07 (d, 2H, 
ar, J = 7.92 Hz), 10.13 (br. s, 1H, NH). 13C-NMR (DMSO-d6) 34.39, 53.51, 54.64, 66.65, 101.0, 
119.28, 119.83, 126.36, 126.75, 129.66, 131.55, 135.69, 137.97, 139.58, 147.61, 147.79, 
170.60. IR = 3437.15, 3358.07, 3331.07, 1693.50, 1622.13, 1593.20 cm-1. Anal. Calc. for 
C24H25N7O3. 
N-(4-(8-amino-3-oxo-2-phenyl-2,3-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-6-yl)phenyl)-3-
(4-methylpiperazin-1-yl)propanamide (55). Yield 70%. m.p.  246-248°C (Nitromethane). 
1H-NMR (DMSO-d6) 2.15 (s, 3H, CH3), 2.33 (m, 2H), 2.48 (m, 8H), 2.62 (m, 2H), 7.35 (t, 1H, 
ar, J = 7.08 Hz), 7.56 (m, 4H, ar + NH2), 7.63 (d, 2H, ar, J = 8.34 Hz), 7.69 (s, 1H, ar), 7.91 (d, 
2H, ar, J = 8.34 Hz), 8.08 (d, 2H, ar, J = 7.80 Hz), 10.18 (br. s, 1H, NH). 13C-NMR (DMSO-d6) 
34.62, 46.21, 52.83, 54.19, 55.22, 100.99, 119.24, 119.83, 126.36, 126.74, 129.66, 131.46, 
131.55, 135.70, 137.97, 139.59, 147.61, 147.79, 170.68. IR = 3371.57, 3336.85, 3201.83, 
1712.79, 1674.21 cm-1. Anal. Calc. for C25H28N8O2.  
 
Synthesis of 8-amino-6-(4-(2-chloroethoxy)phenyl)-2-phenyl-[1,2,4]triazolo[4,3-
a]pyrazin-3(2H)-one (195). 
 
Thionyl chloride (0.66 mmol) was slowly added at 10-15 °C to a suspension of 8-amino-6-
(4-(2-hydroxyethoxy)phenyl)-2-phenyl-[1,2,4]triazolo[4,3-a]pyrazin-3(2H)-one (49) (0.44 
mmol) and pyridine (0.66 mmol) in anhydrous toluene (20 mL). The mixture was stirred 
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at the same temperature for 15 minutes and then refluxed for 2h (TLC monitoring). The 
mixture was treated with water (20 mL), the solid was collected by filtration and rinsed 
with petroleum ether. The crude product was purified by column chromatography 
(Cyclohexane 5/EtOAc 5). Yield 65%. m.p. 270-272 °C. 1H NMR (DMSO-d6) 4.03 - 3.91 (m, 
2H), 4.36 – 4.27 (m, 2H), 7.02 (d, 2H, J = 8.8 Hz), 7.36 (t, 1H, J = 7.4 Hz), 7.60 - 7.51 (m, 4H), 
7.68 (s, 1H), 7.93 (d, 2H, J = 8.8 Hz), 8.08 (d, 2H, J = 7.7 Hz). 13C NMR (DMSO-d6) 158.97, 
148.29, 147.40, 137.63, 131.58, 129.78, 127.66, 127.15, 119.92, 115.26, 68.51, 43.52. 
Anal. Calc. for.  C19H16ClN5O2. 
 
General procedure for the Synthesis of 8-amino-2-phenyl-6-(4-ethoxy)phenyl)-
[1,2,4]triazolo[4,3-a]pyrazin-3(2H)-one derivatives (56-59). 
 
To a suspension of 8-amino-6-(4-(2-chloroethoxy)phenyl)-2-phenyl-[1,2,4]triazolo[4,3-
a]pyrazin-3(2H)-one (195) (0.37 mmol), anhydrous K2CO3 (0.74 mmol), KI (catalytic 
amount) in anhydrous DMF (3 mL), the suitable amine (pyrrolidine, 1.85 mmol; 
morpholine, 6.76 mmol; piperidine, 6.24 mmol; N-methylpiperazine, 1.84 mmol) was 
added. The mixture was refluxed for 8 h (TLC monitoring) and then diluted with water (20 
mL). The resulting solid was collected by filtration, rinsed with water (20 mL), petroleum 
ether and purified by column chromatography. 
8-amino-2-phenyl-6-(4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-[1,2,4]triazolo[4,3-a]pyrazin-
3(2H)-one (56). Purified by column chromatography (DCM3 8/MeOH 2).  Yield 35%. m.p. 
213-214 °C 1H NMR (DMSO-d6) 1.72 (s, 4H), 2.61 (s, 4H), 2.88 (s, 2H, CH2), 4.13 (t, 2H, CH2, 
J = 5.7 Hz), 6.99 (d, 2H, ar, J = 8.8 Hz), 7.35 (t, 1H, ar, J = 7.4 Hz), 7.54 – 7.58 (m, 4H, ar 
+NH2), 7.66 (s, 1H, H-5), 7.91 (d, 2H, ar, J = 8.8 Hz), 8.08 (d, 2H, ar, J = 7.8 Hz). Anal. Calc. 
for C23H24N6O2. 
8-amino-2-phenyl-6-(4-(2-(piperidin-1-yl)ethoxy)phenyl)-[1,2,4]triazolo[4,3-a]pyrazin-
3(2H)-one (57). Purified by column chromatography (Cyclohexane 2/ EtOAc 8; CHCl3 9/ 
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MeOH 1). Yield 20%. m.p. 220-222 °C 1H NMR (DMSO-d6) 1.38 -1.48 (m, 2H), 1.53 (dt, 4H, 
J = 10.9, 5.6 Hz), 2.44 (m, 4H), 2.67 (t, 2H, J = 5.9 Hz), 4.10 (t, CH2, 2H, J = 5.9 Hz), 6.99 (d, 
2H, ar, J = 8.9 Hz), 7.35 (t, 1H, ar, J = 7.4 Hz), 7.58 – 7.50 (m, 4H, ar + NH2), 7.65 (s, 1H, H-
5), 7.90 (d, 2H, ar, J = 8.8 Hz), 8.08 (dd, 2H, ar, J = 8.5, 0.9 Hz). IR = 3356, 1707, 1458 cm-1. 
Anal. Calc. for. C24H26N6O2.   
8-amino-6-(4-(2-morpholinoethoxy)phenyl)-2-phenyl-[1,2,4]triazolo[4,3-a]pyrazin-
3(2H)-one (58). Purified by column chromatography (Cyclohexane 2/EtOAc 8; 
Cyclohexane 6/EtOAc 6/MeOH 1) Yield 52%. m.p. 219-221 °C 1H NMR (DMSO-d6) 2.50 (d, 
4H, J = 1.5 Hz), 2.71 (t, 2H, CH2, J = 5.7 Hz), 3.58-3.62(m, 4H), 4.13 (t, 2H, CH2, J = 5.7 Hz), 
6.99 (d, 2H, ar, J = 8.8 Hz), 7.36 (t, 1H, ar,  J = 7.4 Hz), 7.54-7.58 (m, 4H, ar + NH2), 7.66 (s, 
1H, 5-H), 7.90 (d, 2H, ar, J = 8.7 Hz), 8.08 (d, 2H, ar, J = 8.0 Hz). 13C NMR (DMSO-d6) 45.50, 
53.98, 56.42, 57.36, 62.40, 66.45, 100.57, 107.83, 114.92, 119.87, 126.76, 127.28, 129.34, 
129.65, 131.53, 133.85, 135.84, 137.97, 144.80, 147.62, 147.76, 155.66, 158.90. IR = 3462, 
3367, 2795, 1707, 1614, 1454, 1114 cm-1. Anal. Calc. for C23H24N6O3.    
8-amino-6-(4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)-2-phenyl-[1,2,4]triazolo[4,3-
a]pyrazin-3(2H)-one (59). Purified by column chromatography (Cyclohexane 2/EtOAc 6/ 
MeOH 2; CHCl3 9/MeOH 1). Yield 43 % m.p. 242-244 °C. 1H NMR (CDCl3) 2.33 (s, 3H, CH3), 
2.52 (m, 4H), 2.67 (m, 4H), 2.87 (t, 2H, CH2, J = 5.8 Hz), 4.18 (t, 2H, CH2, J = 5.8 Hz), 5.53 (br 
s, 2H, NH2), 6.99 (d, 2H, ar, J = 8.8 Hz), 7.34 (t, 1H, ar, J = 7.4 Hz), 7.52 (t, 2H, ar, J = 7.9 Hz), 
7.61 (s, 1H, H-5), 7.79 (d, 2H, ar, J = 8.8 Hz), 8.13 (d, 2H, ar, J = 7.8 Hz). 13C NMR (DMSO-d6) 
39.33, 39.54, 39.75, 39.96, 40.17, 40.38, 40.59, 45.95, 53.24, 55.02, 114.90, 118.38, 
119.87, 122.64, 127.28, 129.26, 129.66. IR = 3312, 2727, 1714, 1456, 1377, 1163 cm-1. 
Anal. Calc. for C24H27N7O2.   
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Synthesis of 8-amino-6-(4-(oxiran-2-ylmethoxy)phenyl)-2-phenyl-[1,2,4]triazolo[4,3-
a]pyrazin-3(2H)-one (196). 
 
Epichlorohydrin (6.90 mmol) was added to a suspension of 8-amino-6-(4-hydroxyphenyl)-
2-phenyl-[1,2,4]triazolo[4,3-a]pyrazin-3(2H)-one (16) (0.627 mmol) and K2CO3 (1.25 
mmol) in anhydrous acetone (10 mL). The mixture was  refluxed for 24 h. The solvent was 
evaporated under reduced pressure and the resulting residue was treated with water (20-
25 mL). The solid was collected by filtration, rinsed with diethyl ether (25-30 mL) and 
petroleum ether (20 mL), dried and recrystallized. Yield 68 % m.p. > 300°C (EtOH). 1H NMR 
(DMSO-d6) 2.72 (s, 1H), 2.85 (t, 1H, J = 4.5 Hz), 3.83 (dd, 2H, J = 11.2, 6.5 Hz), 4.37 (d, 1H, 
J = 11.6 Hz), 7.01 (d, 2H, J = 8.7 Hz), 7.35 (t, 1H, J = 7.3 Hz), 7.55 (t, 3H, J = 7.7 Hz), 7.63 (s, 
1H), 7.87 (d, 2H, J = 8.5 Hz), 8.04 (d, 2H, J = 8.1 Hz). Anal. Calc. for. C20H17N5O3. 
 
General procedure for the synthesis of 8-amino-6-(4-(2-hydroxy-3-
morpholino/(piperidin-1-yl)propoxy)phenyl)-2-phenyl-[1,2,4]triazolo[4,3-a]pyrazin-
3(2H)-one (60-61). 
 
Piperidine (10.60 mmol, 60) or morpholine (14.4 mmol, 61) was added to a suspension of 
8-amino-6-(4-(oxiran-2-ylmethoxy)phenyl)-2-phenyl-[1,2,4]triazolo[4,3-a]pyrazin-3(2H)-
one (196) (0.533 mmol) and K2CO3 (1.066 mmol) in absolute EtOH (5 mL). The mixture 
was refluxed for 24 h (TLC monitoring). The solvent was evaporated under reduced 
pressure to dryness and the resulting residue was treated with water (20-25 mL). The solid 
was collected by filtration, rinsed with diethyl ether and petroleum ether, dried and 
recrystallized. 
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8-amino-6-(4-(2-hydroxy-3-(piperidin-1-yl)propoxy)phenyl)-2-phenyl-
[1,2,4]triazolo[4,3-a]pyrazin-3(2H)-one (60). Yield 65%. m.p. 202-204 °C (2-
Methoxyethanol). 1H NMR (DMSO-d6) 1.57 – 1.42 (m, 2H), 1.65 (dd, 4H, J = 10.3, 5.5 Hz), 
2.46 (s, 2H), 2.56 (d,2H, J = 6.8 Hz), 2.68 (s, 2H), 4.04 (dd, 2H, J = 9.8, 4.9 Hz), 4.14 (dd, J = 
12.5, 5.7 Hz, 1H), 5.54 (s, 1H), 7.01 (d, 2H, J = 8.7 Hz), 7.34 (t, 1H, J = 7.3 Hz), 7.52 (t,2H, J 
= 7.9 Hz), 7.61 (s, 1H), 7.79 (d, 2H, J = 8.7 Hz), 8.13 (d, 2H, J = 8.1 Hz). Anal. Calc. for.  
C25H28N6O3. 
8-amino-6-(4-(2-hydroxy-3-morpholinopropoxy)phenyl)-2-phenyl-[1,2,4]triazolo[4,3-
a]pyrazin-3(2H)-one (61). Yield 65%. m.p. 231-233 °C (2-Methoxyethanol). 1H NMR 
(DMSO-d6) 2.47 (d, 4H, J = 22.9 Hz), 3.58 (s, 4H), 4.13 – 3.73 (m, 3H), 4.88 (s, 1H), 6.99 (d, 
2H, J = 5.9 Hz), 7.36 (s, 1H), 7.55 (d, 4H, J = 9.0 Hz), 7.66 (s, 1H), 7.90 (d, 2H, J = 5.7 Hz), 
8.08 (d, 2H, J = 5.7 Hz). Anal. Calc. for  C24H26N6O4. 
 
General procedure for the synthesis of (R)-2-oxothiazolidine-4-carboxamide-
substituted 8-amino-1,2,4-triazolo[4,3-a]pyrazin-3(2H)-one derivatives (79, 81) 
A mixture of the suitable triazolopirazine (39, 48) (1 mmol), (R)-2-oxothiazolidine-4-
carboxylic acid (2 mmol), EDCI. HCl (2 mmol), HOBt monohydrate (2 mmol), DIPEA (2 
mmol) in anhydrous DMF (3 ml) was heated at 60 °C per 18 h (TLC monitoring). The 
mixture was treated with water (20 mL) and the solid was collected by filtration and rinsed 
with Et2O and petroleum ether. The crude product was purified by recrystallization (79) 
or column chromatography (80). 
 
(R)-N-(4-(8-amino-3-oxo-2-phenyl-2,3-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-6-
yl)phenyl)-2-oxothiazolidine-4-carboxamide (79) 
 
Yield 99%. m.p. > 300 °C. Purified by column chromatography (CHCl3 9.4/MeOH 0.6).                
1H-NMR (DMSO-d6) 3.51 (m, 1H, CH), 3.78 (m, 1H, CH), 4.50 (m, 1H, CH), 7.35 (t, 1H, ar, J 
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= 7.3 Hz), 7.56 (t, 2H, ar, J = 8.00 Hz), 7.65 (br. s, 2H, NH2), 7.68 (d, 2H, ar, J = 8.6 Hz), 7.73 
(s, 1H, ar), 7.96 (d, 2H, ar, J = 8.6 Hz), 8.08 (d, 2H, ar, J = 8.00 Hz), 8.37 (s, 1H, NH), 10.26 
(s, 1H, NH). 13C-NMR (DMSO-d6) 32.79, 57.49, 101.26, 119.71, 119.84, 126.44, 126.76, 
129.66, 131.56, 132.18, 135.56, 137.96, 138.90, 147.62, 147.83, 169.11, 174.06. 
Anal.Calc. for C21H17N7O3S. 
 
(R)-N-(2-(4-(8-amino-3-oxo-2-phenyl-2,3-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-6-
yl)phenoxy)ethyl)-2-oxothiazolidine-4-carboxamide (81). 
 
Yield 100%. m.p. 255-257 °C (EtOH/2-Methoxyethanol). 1H-NMR (DMSO-d6) 3.51 (q, 2H, 
CH2, J = 5.5 Hz), 3.67 (m, 1H, CH), 4.07 (t, 2H, CH2, J = 5.5 Hz), 4.32 (m, 1H, CH), 7.00 (d, 
2H, ar, J = 8.9 Hz), 7.35 (t, 1H, ar,  J = 7.4 Hz), 7.56 (m, 4H, ar + NH2), 7.67 (s, 1H, H-5), 7.92 
(d, 2H, ar, J = 8.8 Hz), 8.07 (d, 2H, ar, J = 7.8 Hz), 8.32 ( br s, 1H, NH), 8.37 (t, 1H, NH, J = 
5.4 Hz). Anal. Calc. for C23H21N7O4S. 
 
General procedure for the synthesis of the 5-(1,2-dithiolan-3-yl)pentanamide 
substituted 8-amino-1,2,4-triazolo[4,3-a]pyrazin-3(2H)-one derivatives (80, 82, 84).  
A mixture of the suitable triazolopirazine (39, 48, 51) (1.00 mmol), racemic lipoic acid 
(1.35 mmol), EDCI.HCl (1.35 mmol), HOBt monohydrate (1.35 mmol) and DIPEA (1.70 
mmol) in anhydrous DMF (3mL) was stirred at room temperature 24 h (TLC monitoring). 
The mixture was treated with water (20 mL). The obtained solid was collected by filtration, 
rinsed with Et2O and petroleum ether. The crude product was purified by recrystallization 
(80) or column chromatography (82, 84) 
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N-(4-(8-amino-3-oxo-2-phenyl-2,3-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-6-yl)phenyl)-5-
(1,2-dithiolan-3-yl)pentanamide (80).  
 
Yield 99%. m.p. 229-233 °C (Nitromethane). 1H-NMR (DMSO-d6) 1.43 (m, 2H), 1.63 (m, 
2H), 1.71 (m, 2H), 1.88 (m, 1H, J = 6.6 Hz), 2.34 (t, 2H, J = 7.3 Hz),  2.43 (m, 1H, J = 6.3 Hz), 
3.14 (m, 1H), 3.19 (m, 1H), 3.64 (m, 1H, J = 6.2 Hz), 7.35 (t, 1H, ar, J = 7.4 Hz), 7.54 (br s, 
2H, NH2), 7.56 (t, 2H, ar, J = 8.1 Hz), 7.65 (d, 2H, ar, J = 8.7 Hz), 7.69 (s, 1H, H-5), 7.91 (d, 
2H, ar, J = 8.9 Hz), 8.08 (d, 2H, ar, J = 7.9 Hz), 9.96 (br s, 1H, NH). 13C-NMR (DMSO-d6) 25.35, 
28.82, 34.64, 36.74, 38.58, 56.58, 100.98, 119.30, 120.00, 126.31, 126.75, 129.67, 131.39, 
131.56, 135.75, 137.98, 139.68, 147.61, 147.79, 171.60. IR = 3431.36, 3311.78, 3207.62, 
1693.50, 1681.93 cm-1. Anal.Calc. for C25H26N6O2S2. 
 
N-(2-(4-(8-amino-3-oxo-2-phenyl-2,3-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-6-
yl)phenoxy)ethyl)-5-(1,2-dithiolan-3-yl)pentanamide (82). 
 
Yield 82%. m.p. 202-204 °C. Purified by liquid chromatography (Cyclohexane 2/EtOAc 8). 
1H NMR (DMSO-d6) 1.35 (dd, 2H, J = 14.7, 7.5 Hz), 1.53 (dd, 3H, J = 15.1, 7.4 Hz), 1.64 (dd, 
1H, J = 13.5, 7.5 Hz), 1.75 – 1.90 (m, 1H), 2.11 (t, 2H, J = 7.1 Hz), 2.38 (dd, 1H, J = 12.5, 6.2 
Hz), 3.02 – 3.21 (m, 2H), 3.43 (d, 2H, J = 5.2 Hz), 3.53 – 3.64 (m, 1H), 4.02 (d, 2H, J = 5.0 
Hz), 6.99 (d, 2H, ar, J = 8.2 Hz), 7.36 (t, 1H, ar, J = 7.3 Hz), 7.49– 7.63 (m, 4H, ar + NH2), 
7.66 (s, 1H, H-5), 7.91 (d, 2H, ar, J = 8.1 Hz), 8.08 (m, 3H, ar + NH, J = 8.4 Hz). IR = 3358, 
3285, 3179, 1709,1628, 1541, 1462 cm-1. Anal. Calc. for C27H30N6O3S2. 
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N-(3-((4-(8-amino-3-oxo-2-phenyl-2,3-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-6-
yl)phenyl)amino)-3-oxopropyl)-5-(1,2-dithiolan-3-yl)pentanamide (84). 
 
Yield 89%. m.p. 250-251 °C. Purified by column chromatography (DCM 9.7/MeOH 0.3). 1H 
NMR (DMSO-d6) 1.29-1.36 (m, 2H), 1.47-1.54 (m, 3H), 1.59-1.66 (m, 1H), 1.83 (m, 1H), 
2.07 (t, 2H, J = 7.2 Hz), 2.36 (m, 1H, J = 6.2 Hz), 3.04-3.11 (m, 1H), 3.12-3.19 (m, 1H), 3.52-
3.59  (m, 1H), 7.35 (t, 1H, ar, J = 7.4 Hz), 7.54-7.58  (m, 4H, ar + NH2), 7.65-7.69 (m, 3H, ar 
+ H-5), 7.92 (m, 3H, ar + NH), 8.08 (d, 2H, ar, J = 7.9 Hz), 10.03 (br s, 1H, NH).  Anal. Calc. 
for C28H31N7O3S2. 
 
General procedure for the Synthesis of substituted the 3,5-di-tert-butyl-4-
hydroxybenzamide 8-amino-1,2,4-triazolo[4,3-a]pyrazin-3(2H)-one derivatives (83, 85).  
A mixture of the suitable triazolopirazine (48, 51), 3,5-di-tert-butyl-4-hydroxybenzoic acid 
(2 mmol), EDCI. HCl (2 mmol), HOBt monohydrate (2 mmol), DIPEA (2 mmol) in anhydrous 
DMF (3 mL) was heated at 60 °C per 18 h. The mixture was treated with water (20 mL). 
The solid was collected by filtration, rinsed with Et2O and petroleum ether. The crude 
product was purified by recrystallization (83) or column chromatography (85). 
 
N-(3-((4-(8-amino-3-oxo-2-phenyl-2,3-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-6-
yl)phenyl)amino)-3-oxopropyl)-3,5-di-tert-butyl-4-hydroxybenzamide (83). 
 
 Yield 90%. m.p. 250-252 °C (Nitromethane). 1H NMR (DMSO-d6) 1.41 (s, 18H, (CH3)3), 3.62 
(m, 2H, CH2),  4.15 (t, 2H, CH2, J = 5.8 Hz), 7.02 (d, 2H, ar, J = 8.8 Hz) 7.36 (t, 1H, ar, J = 7.4 
Hz) 7.39 (s, 1H, ar), 7.50-7.59 (m, 4H, ar + NH2), 7.63 (s, 2H, ar), 7.66 (s, 1H, ar, H-5), 7.91 
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(d, 2H, ar,  J = 8.6 Hz), 8.08 (d, 2H, ar, J = 7.9 Hz), 8.51 (t, 1H, NH, J = 5.5 Hz).13C NMR 
(DMSO-d6) 30.68, 35.03, 36.38, 37.19, 101.02, 119.45, 119.88, 124.47, 126.29, 126.75, 
129.64, 131.52, 131.57, 135.77, 137.99, 138.66, 139.58, 147.62, 147.80, 157.02, 167.64, 
170.19. Anal. Calc. for C35H39N7O4.  
 
N-(2-(4-(8-amino-3-oxo-2-phenyl-2,3-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-6-
yl)phenoxy)ethyl)-3,5-di-tert-butyl-4-hydroxybenzamide (85). 
 
Yield 78%. m.p. 259-260°C. Purified by column chromatography (Cyclohexane 6/EtOAc 4). 
1H NMR (DMSO-d6) 1.41 (s, 18H, (CH3)3), 3.62 (d, 2H, CH2, J = 5.6 Hz), 4.15 (t, 2H, CH2, J = 
5.8 Hz), 7.02 (d, 2H, ar, J = 8.8 Hz), 7.36 (t, 1H, ar, J = 7.4 Hz), 7.39 (s, 1H, OH), 7.54–7.59 
(m, 4H, ar + NH2), 7.63 (s, 2H, ar), 7.66 (s, 1H, H-5), 7.91 (d, 2H, ar, J = 8.7 Hz), 8.08 (d, 2H, 
ar, J = 7.9 Hz), 8.51 (t, 1H, NH, J = 5.5 Hz). 13C NMR (DMSO-d6) 30.68, 35.05, 66.69, 114.90, 
119.87, 124.54, 125.97, 126.75, 127.33, 129.39, 129.64, 131.53, 135.84, 137.34, 137.98, 
138.69, 144.69, 147.61, 147.77, 157.14, 158.99, 167.75. IR = 3315, 3213, 1699, 1616, 1456 
1377, 1315, 1248, 1178 cm-1. Anal. Calc. for C34H38N6O4. 
 
Synthesys of N-(4-(8-amino-3-oxo-2-phenyl-2,3-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-6-
yl)phenyl)-3-hydrazinylpropanamide (197). 
 
Hydrazine monohydrate (13.425 mmol) was added to a suspension of N-(4-(8-amino-3-
oxo-2-phenyl-2,3-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-6-yl)phenyl)acrylamide 194 
(0.537 mmol) in anhydrous THF and the resulting mixture was refluxed for 21 h (TLC 
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monitoring, CHCl3 9/MeOH 1). The solvent was eliminated under reduced pressure and 
the residue was treated with Et2O (20 mL). The obtained solid was collected by filtration 
and rinsed with pethroleum ether (20 mL). Yield 78%. (Nitromethane). 1H NMR 
(DMSO-d6) 2.48 (t, 2H, CH2, J = 6.7 Hz ), 2.91 (t, 2H, CH2, J = 6.7 Hz), 7.35 (t, 1H, ar, J =7.4 
Hz), 7.54-7.58  (m, 4H, ar + NH2), 7.63-7.69 (m, 3H, ar + H-5), 7.91 (d, 2H, ar, J = 8.7 Hz), 
8.08 (d, 2H, ar, J = 7.6 Hz), 8.93 ( br s, 1H, NH), 10.17 (s, 1H, NH),   Anal. Calc. for C20H20N8O2. 
 
N-(4-(8-amino-3-oxo-2-phenyl-2,3-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-6-yl)phenyl)-3-
(3-methyl-5-oxo-2,5-dihydro-1H-pyrazol-1-yl)propenamide (86). 
 
To a suspension of N-(4-(8-amino-3-oxo-2-phenyl-2,3-dihydro-[1,2,4]triazolo[4,3-
a]pyrazin-6-yl)phenyl)-3-hydrazinylpropanamide (197) (0.42 mmol) in EtOH (20 mL) ethyl 
acetoacetate (0.42 mmol) was added. The resulting mixture was heated at 60 °C for 2h 
(TLC monitoring). The solid was filtered off and the ethanolic organic layer was 
evaporated under reduced pressure. The obtained residue was taken up with Et2O (20 
mL) and the solid was collected by filtration. The crude product was purified by column 
chromatography (CHCl3/MeOH 1). Yield 56%. m.p. 226-228 °C. 1H NMR (DMSO-d6) 2.01 
(s, 3H, CH3), 2.77 (m, 2H, CH2), 4.05 (m, 2H, CH2), 5.14 (s, 1H), 7.35 (t, 1H, ar, J = 7.4 Hz), 
7.54-7.59  (m, 4H, ar + NH2), 7.63 (d, 2H, ar, J = 8.7 Hz), 7.70 (s, 1H, H-5), 7.90 (d, 2H, ar, J 
= 8.7 Hz), 8.06 (d, 2H, ar, J =7.6 Hz), 10.10 (s, 1H, NH), 10.69 ( br s, 1H, NH). Anal. Calc. for 
C24H22N8O3. 
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7. VISITING PERIOD AT THE LEIDEN CENTRE OF DRUG RESEARCH 
(LACDR) 
 
7.1 Introduction 
Between the second and third year of my PhD course, I spent six months (September 
2017-March 2018) at the Leiden Academic Centre for Drug Research (LACDR) in 
Netherlands, where I joined the research group of Prof. A.P. IJzerman, Professor of 
Medicinal Chemistry and Head of the Medicinal Chemistry group at the Division of Drug 
Discovery & Safety. The research topic assigned to me was the synthesis of non-
adenosine-like compounds designed to target the hA2AAR and based on the structure of 
LUF5833 (Figure 37). 
As largely anticipated in the “Introduction” chapter, A2AARs play an important role in a 
variety of physiopathogical conditions including both neurodegenerative disorders and 
inflammatory tissue damage. At present, it is well known the beneficial application of 
selective A2AARantagonists in the treatment of neurodegenerative disorders such as 
Parkinson’s disease379 (PD), Huntington’s disease378, and Alzheimer’s disease 382,383. 
However, several animal models of neurodegenerative disorders have given evidence 
that also the A2A AR agonists are able to exert   neuroprotective effect through the 
reduction of the excitatory neurotransmitter release, apoptosis, and inflammatory 
responses280,437. Also in the cardiovascular field a number of A2AAR agonists have been 
tested as candidate for myocardial perfusion since they are able to modulate the coronary 
arterial vasodilation446,447. A2A AR agonists could be also beneficial in the treatment of 
neuropathic pain, being capable of modulating the production of glial cytokines448. 
Moreover, a large body of evidence has clearly show that A2AAR agonists exert anti-
inflammatory properties modulating the activity of neutrophils, macrophages, and T 
lymphocytes446,449. A2AAR stimulation also inhibits neutrophil adherence to the 
endothelium, degranulation of neutrophils and monocytes, and superoxide anion 
generation280, thus indicating that A2AARs are involved in inflammation processes and 
selective agonists could be developed as potential therapeutic agents in the treatment 
allergic rhinitis, asthma, and chronic obstructive pulmonary disease446,450.  
7.VISITING PERIOD AT LACDR  
 
143 
In the past, adenosine receptor agonists were usually associated to a adenosine-like 
structure where the ribose moiety was tought to play a crucial role for the agonistic 
functional activty451. Several studies, in fact, highlighted that in the agonist-bound crystal 
structure, the ribose moiety of the ligands inserts deeply into a predominantly hydrophilic 
region of the binding cavity and enganges contacts or hydrogen bonds with important 
amicnoacid residues at this level452-454. However, progress has been made and novel non-
nucleoside AR ligands belonging to the amino-3,5-dicyanopyridine series were identified. 
These compounds possessed both a significant affinity and efficacy toward different 
adenosine receptor subtypes275,276,455,456 and, among these derivatives, the 2-amino-4-
(phenyl/4-hydroxyphenyl)-6-(1H-imidazol-2-yl-methylsulfanyl)-pyridine-3,5-
dicarbonitrile (LUF5833, and LUF5834 Figure 37) turned out to be a high-affinity non-
adenosine partial agonists at the A2AAR276 . 
 
Figure 37. Structure of the hA2A AR partial agonists LUF5833 and LUF5834 
Table 13. aInteraction of compounds LUF5833 and LUF5834 with the hA2A adenosine 
receptor, bStimulation (A2A) of cAMP production by the compounds LUF5833 and LUF5834 
compared to reference Agonist276.  
 
 ahA2A Ki (nM) cEfficacy 
LUF5833 8.13 ± 0.05 55 ± 20 
LUF5834 6.25 ± 0.08 55 ± 12 
                 
a Radioligand binding experiments were carried out on membranes made from HEK293 cells stably expressing 
the A2A with [3H]ZM241385 as radio ligand. bProduction of cAMP was studied in CHO cells stably expressing 
the hA2A adenosine receptor (n = 3). cEfficacy is expressed with respect to reference agonist CGS21680, 
compounds were tested at 100 times their Ki values. 
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7.2 Aim of the work 
Recently, a crystal structure of the hA2AAR containing the 2-((1H-imidazol-2-
yl)methylthio)-6-amino-4-phenylpyridine-3,5-dicarbonitrile (LUF5833, Figure 37) in the 
binding pocket has been obtained. Since the structural determinants involved in the 
functional activity of these compounds are largely unknown, the design and synthesis 
of compounds structurally related to LUF5833 have been undertaken to shed light on 
the hypothetical binding mode of these ligands at the A2AAR crystal structure. The 
project I worked on concerned the synthesis of the non-nucleoside compounds 
LUF7760, LUF7762 and LUF7763 (87-89) which were designed together with the 
pyrimidine derivatives LUF7724 and LUF7740 to target the hA2AAR (Figure 38). The 
triazine derivative 87 ensued from the replacement of the two CN groups of LUF5833 
with endocyclic nitrogen atoms, while the pyridine derivatives 88-89 derived from 
removal of the CN group(s) of the lead. Hopefully, combination of the synthetic and 
computational studies will led to valuable information about the role of the 
substituents and scaffold properties on the functional profile of A2AAR non-adenosine-
like agonists.                                                                                                                             
 
Figure 38. LUF5833-based structures of the newly synthetized derivatives. 
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It has to be pointed that compounds LUF7724 and LUF7740, were already synthesized 
and tested before I joined Professor’s IJzerman group and are herein reported as 
reference compounds. 
 
7.3 Chemistry 
 
Synthesis of the 4-(((1H-imidazol-2-yl)methyl)thio)-6-phenyl-1,3,5-triazin-2-amine 1 
(LUF7760).  
 
The synthesis of the 4-(((1H-imidazol-2-yl)methyl)thio)-6-phenyl-1,3,5-triazin-2-amine 87 
(LUF7760), depicted in Scheme 15, started from the commercial cyanuric chloride which 
was reacted with phenylmagnesium bromide at room temperature in anhydrous THF to 
give the 2,6-dichloro-4-phenyl-1,3,5-triazine (198). Treatment of 198 with 25% aqueous 
ammonia in dichloromethane yielded the amino derivative 199 which was reacted with 
anhydrous sodium sulfide in DMF at 80 °C to give the corresponding 4-amino-6-phenyl-
1,3,5-triazine-2-thiol 200. Reaction of intermediate 200 with the properly synthesized 2-
(bromomethyl)-1H-imidazole276 in anhydrous DMF and in the presence of NaHCO3, at 
room temperature, afforded the desired triazine 87 (LUF7760). 
 
Scheme 15: a) Phenylmagnesium bromide, anhydrous THF, r.t.; b) NH3 25% in H2O, dichloromethane, r.t.; 
c) anhydrous Na2S, DMF, 80 °C; d) 2-Bromomethyl-(1H)-imidazole, NaHCO3, anhydrous DMF, r.t. 
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Synthesis of 6-(((1H-imidazol-2-yl)methyl)thio)-4-phenylpyridin-2-amine 2 (LUF7762). 
 
Scheme 16 shows the synthesis of 6-(((1H-imidazol-2-yl)methyl)thio)-4-phenylpyridin-2-
amine 88 (LUF7762). The 2,6-dichloro-4-phenylpyridine 201 was obtained from the 
commercial 2,6-dichloro-4-iodopyridine which was reacted with phenylboronic acid 
pinacol esther, Pd(PPh3)Cl2, Na2CO3 in H2O/MeCN at 70 °C, under Suzuki-Miyaura 
conditions. Treatment of 201 with 2-methyl-propanethiol, and Cs2CO3, in DMF at 80 °C 
afforded 202 intermediate whose reaction with t-butyl carbamate in anhydrous 1,4-
dioxane at 110 °C, and in presence of the couple Pd(OA)2, Xantphos and Cs2CO3, gave the 
tert-butyl-(6-(tert-butylthio)-4-phenylpyridin-2-yl)-carbamate 203. Deprotection of its 
amino-group, performed with TFA in dichloromethane at room temperature, yielded 
compound 204 which was allowed to react with boiling 37% hydrochloric acid to give the 
6-amino-4-phenylpyridine-2-thiol 205. Finally, the desired product LUF7762 was achieved 
by alkylating compound 205 with 2-(bromomethyl)-1H-imidazole, in presence of NaHCO3 
in anhydrous DMF. 
 
 
Scheme 16. a) Phenylboronic acid pinacol esther, Pd(PPh3)Cl2,Na2CO3, H2O/acetonitrile, 70 °C;                        
b) 2-Methyl-propanethiol, Cs2CO3, DMF, 80 °C; c) Pd(OA)2, xantphos, Cs2CO3, t-butyl carbamate, anydrous 
1,4-dioxane, 110 °C; d) TFA, dichloromethane, reflux; e) 37% HCl, 100 °C; f) Bromomethyl-(1H)-imidazole, 
NaHCO3, anydrous DMF, r.t. 
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Synthesis of (2)6-(((1H-imidazol-2-yl)methyl)thio)-2(6)-amino-4-phenylnicotinonitrile 3 
(LUF7763).  
 
The synthetic pathway yielding the novel compound 89 (LUF7763) is outlined in Scheme 
17. The commercial ethyl benzoyl acetate, 2-cyanoacetamide and KOH were refluxed in 
EtOH to give the 2,6-dihydroxy-4-phenylnicotinonitrile 206 which was chlorinated to the 
corresponding 2,6-dichloro-4-phenylnicotinonitrile 207 with phosphorus oxychloride in 
autoclave at 130 °C. Treatment of 207 with t-butyl carbamate, under Buchwald-Hartwig 
conditions, i.e. in presence of Pd(OA)2/Xantphos, and Cs2CO3, in anhydrous 1,4-dioxane 
at 110 °C, gave the tert-butyl-(6-chloro-5-cyano-4-phenylpyridin-2-yl)-carbamate 208. 
Reaction of 208 with 2-methyl-propanethiol, Cs2CO3 in DMF at 80 °C afforded derivative 
209 which was deprotected with boiling 37% hydrochloric acid to give the intermediate 
6-amino-2-mercapto-4-phenylnicotinonitrile 210. The latter was alkylated with                              
2-(bromomethyl)-1H-imidazole, NaHCO3, in anhydrous DMF to give the desired 
compound 89 (LUF7763).  
 
 
Scheme 17: a) NaOH, EtOH, 80 °C, reflux; b) POCl
3, 
in autoclave, 180 °C; c) Pd(OA)
2
, xantphos, Cs2CO3, t-
butyl carbamate, anhydrous 1,4-dioxane 40 °C; d) 2-Methyl-propanethiol, Cs2CO3, DMF, 90 °C; e) 37% HCl, 
100 °C; f) 2-Bromomethyl-(1H)-imidazole, NaHCO3, anhydrous DMF, r.t. 
 
7.4 Structure affinity study 
All the synthesized compounds LUF7760 (87), LUF7762 (88) and LUF7763 (89) were 
investigated to determine their affinity at the human ARs. In particular, the affinity of 
these compounds for the A1, A2A, and A3 receptors stably expressed on Chinese hamster 
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ovary cells (CHO) (A1, A3) or Human embryonic kidney 293 cells (HEK293) (A2A) was 
determined in radioligand binding studies with [3H]DPCPX (KD) 1.6 nM), [3H]ZM241385 
(KD) 1.0 nM), and [3H]PSB11 (17.3 nM) as radioligands, respectively.  
Analyzing the binding data (Table 14), the newly synthesized LUF7760 (87, pKi = 6.25) and 
LUF7763 (89, pKi = 5.99) showed a decreased binding activity at the hA2A AR, in 
comparison with those of the reference compounds LUF5833 (pKi = 8.13), LUF7724 and 
LUF7740 (pKi =7.17 and 8.00, respectively). A similar behavior can also be observed for 
the binding at the hA1 subtype, indeed, bothLUF7760 (pKi = 6.54) and LUF7763 (pKi = 6.95) 
showed lower affinity than the pyrimidine derivatives LUF7724, LUF7740 (pKi = 7.07 and 
pKi = 7.16 respectively) and were much less potent than the reference ligand (LUF5833, 
pKi = 8.54). With regard to the hA3 AR, all the synthesized compounds were endowed with 
very low affinity at this receptor showing a 8-91 fold reduced binding capability than 
LUF5833. These findings suggest that, in LUF5833, the two cyano groups are actively 
involved in binding to ARs so much so that their replacement with nitrogen atoms 
(LUF7724, LUF7760) or their partial removal (LUF7763, 89) result in much lower affinities 
towards the targeted proteins. The only exception was represented by the pyrimidine 
derivative LUF7740 which showed high affinity for the hA2A AR and a pKi value comparable 
with those of LUF5833. The absence of both the cyano moieties led to a completely lack 
of affinity for both the hA1 and hA2A ARs. In fact, the pyridine compound LUF7762 (88) 
was inactive at the investigated ARs (no displacement curves were performed).  
Table 14. Affinities of Synthesized Ligands for the Human Adenosine Receptorsa. 
Compound  hA1 pKib hA2A pKic hA3 pKid 
LUF5833 8.52±0.04 8.13±0.05 7.38±0.01 
LUF7724 7.07±0.01 7.17±0.08 6.46±0.06 
LUF7740 7.16±0.02 8.00±0.05 5.94±0.05 
LUF7760 6.54±0.05 6.25±0.08 5.42±0.06 
LUF7763 6.95±0.08 5.99±0.12 5.87±0.10 
 
aData are expressed as means ± SEM of three separate experiments. bAffinity expressed as pKi value, 
determined from displacement of specific [3H]DPCPX binding from the hA1R at 25 °C incubation. cAffinity 
expressed as pKi value, determined from displacement of specific [3H]ZM241385 binding from the hA2AR at 
25 °C incubation. dAffinity expressed as pKi value, determined from displacement of specific [3H]PSB11 
binding from the hA3R at 25 °C incubation. 
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7.5 Conclusion 
To summarize, during the six months I worked at LACDR, the syntheses of new suitably 
substituted triazine and pyridines (LUF7760, LUF7762 and LUF7763) structurally related 
to the hA2AAR partial agonist LUF5833 were successfully achieved. LUF7760 and LUF7763 
emerged as very weak ligands for the hA2AAR subtype while derivative LUF7762 turned 
out to be completely inactive at this receptor. Molecular modeling studies are currently 
ongoing to rationalize these binding data and shed light on the hypothetical binding mode 
of these derivatives at the hA2AAR. Moreover, with the aim to expand the SAR studies new 
compounds will be synthesized by introducing hydroxy or methoxy moieties at the meta 
or para position of the phenyl ring. 
 
7.6 Experimental section 
All solvents and reagents were purchased from commercial sources and were of analytical 
grade. TLC analysis was performed to monitor the reactions, using Merck silica gel F254 
plates. Grace Davison Davisil silica column material (LC60A, 30−200 μm) was used to 
perform column chromatography. Microwave reactions were performed in an Emrys 
Optimizer (Biotage AB, formerly Personal Chemistry). 1H and 13C NMR spectra were 
recorded on a Bruker DMX-400 (400 MHz) spectrometer, using tetramethylsilane as 
internal standard. Chemical shifts are reported in δ (ppm) and the following abbreviations 
are used: br = broad, s = singlet, d = doublet, dd = doublet of doublets, dt = doublet of 
triplets t = triplet, m = multiplet, tt = triplet of triplets. The analytical purity of the final 
compounds is 95% or higher and was determined by high-performance liquid 
chromatography (HPLC) with a Phenomenex Gemini 3 μm C18 110A column (50 mm × 4.6 
mm, 3 μm), measuring UV absorbance at 254 nm. The sample preparation and HPLC 
method was as follows: 0.3−0.6 mg of compound was dissolved in 1 mL of a 1:1:1 mixture 
of CH3CN/H2O/t-BuOH and eluted from the column within 15 min at a flow rate of 1.3 
mL/min. The elution method was set up as follows: 1−4 min isocratic system of 
H2O/CH3CN/1% TFA in H2O, 80:10:10; from the fourth min, a gradient was applied from 
80:10:10 to 0:90:10 within 9 min, followed by 1 min of equilibration at 0:90:10 and 1 min 
at 80:10:10. Liquid chromatography−mass spectrometry (LC−MS) analyses were 
performed using a Thermo Finnigan Surveyor-LCQ Advantage Max LC−MS system and a 
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Gemini C18 Phenomenex column (50 mm × 4.6 mm, 3 μm). The elution method was set 
up as follows: 1−4 min isocratic system of H2O/CH3CN/1% TFA in H2O, 80:10:10; from the 
fourth min, a gradient was applied from 80:10:10 to 0:90:10 within 9 min, followed by 1 
min of equilibration at 0:90:10 and 1 min at 80:10:10. The following abbreviation are used 
for solvents and reactive products: AcOH = Acetic acid, CDCl3 = Deuterated chloroform,  
DCM = Dichloromethane, DMF = Dimethylformamide, DMSO-d6 = Deuterated dimethyl 
sulfoxide, EtOAc = Ethyl acetate, Et2O = Diethyl ether, EtOH = Ethanol, HCl = Hydrochloric 
acid, MeOD = Deuterated methanol, MeOH = Methanol, TFA = Trifluoroacetic acid,  THF 
= Tetrahydrofuran.  
 
Synthesis of 2,6-Dichloro-4-phenyl-1,3,5-triazine (198) 
 
To a stirred suspension of cyanuric chloride (7.5 g, 40.7 mmol), in anhydrous THF (20 mL) 
at 0°C under nitrogen atmosphere, a 3M solution of phenylmagnesium bromide (0.993 
mL, 2.98 mmol) in THF (10 mL) was added dropwise (over 30 min). The mixture was stirred 
at room temperature for 6h (TLC monitoring, Petroleum ether 8/EtOAc 2) then it was 
treated with 10 % aqueous HCl (50 mL) and extracted with EtOAc (40 mL x 3). The 
combined organic layers were washed with water (30 mL), dried on MgSO4 and 
evaporated under reduced pressure to give a brown solid. The product was used for the 
next step without further purification. Yield 52,3 %. 1H NMR (400 MHz, CDCl3) 7.54 (t, J = 
7.8 Hz, 2H), 7.66 (dd, 1H, J = 11.7, 4.3 Hz,), 8.51 (m, 2H). Anal. Calc. for C9H5Cl2N3  
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Synthesis of 2-amino-6-chloro-4-phenyl-1,3,5-triazine (199) 
 
To a stirred solution of 2,6-dichloro-4-phenyl-triazine 198 (0.3 g, 1.327 mmol) in DCM (5 
mL), 25% aqueous ammonia was added dropwise (0.09 mL, 1.327 mmol). The resulting 
mixture was stirred at room temperature for 8h. (TLC monitoring, Petroleum Ether 8/ 
AcOEt 2). The suspended solid was filtered and rinsed wit DCM (30 mL). The combined 
mother liquors were evaporated under pressure to afford a pale orange solid (180 mg). 
The compound has been used in the next reaction without further purification. Yield 
65.6%. 1H NMR (400 MHz, CDCl3) 5.75 (br s, 2H, NH2), 7.51 (t, 2H, ar, J = 7.6 Hz), 7.61 (t, 
1H, ar, J = 7.3 Hz), 8.43 (d, 2H, ar, J = 7.5 Hz). LC-MS (ESI): 207.1 [M + H] +. Anal. Calc. for 
C9H7ClN4. 
 
Synthesis of 4-amino-6-phenyl-1,3,5-triazine-2-thiol (200) 
 
A suspension of 4-amino-6-phenyl-2-phenylthio-1,3,5-triazine 199 (0.68 g, 3.29 mmol), 
and sodium sulfide monohydrate (1.185 g, 4.93 mmol) in DMF (3 mL) was heated at 80 °C 
for 3h (TLC monitoring, EtOAc 8/Petroleum ether 2). The solvent was eliminated under 
reduced pressure (water bath 80 °C) and the residue was treated carefully with HCl 1M 
solution in EtOAc (10 mL). The resulting solid was collected by filtration and extracted 
with boiling EtOH (20 mL x 5). The collected organic layers were evaporated at reduced 
pressure to afford a pale yellow solid (240 mg) which was purified by recrystallization. 
Yield 28 %. (DCM) 1H NMR (400 MHz, DMSO-d6) 7.53 (m, 2H, ar), 7.60 (m, 1H, ar), 8.24 (m, 
2H, ar), 12.83 (s, 1H, SH). LC-MS (ESI): 205.1 [M + H] +. Anal. Calc. for C9H8N4S.  
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 Synthesis of 4-(((1H-imidazol-2-yl)methyl)thio)-6-phenyl-1,3,5-triazin-2-amine (87) 
LUF7760. 
 
A suspension of 4-amino-6-phenyl-1,3,5-triazine-2-thiol 200 (0.148 g, 0.725 mmol), 
NaHCO3 (0.061 g, 0.725 mmol) and 2-(bromomethyl)-1H-imidazole (0.263 g, 1.087 mmol) 
in DMF (1.5 mL) was stirred at room temperature for 3 h (TLC monitoring DCM 9/ MeOH 
1). Then the solvent was evaporated under reduced pressure (water bath 60 °C) and the 
resulting residue was treated with water (15 mL) and extracted with EtOAc (30 mL x 4). 
The combined organic layers were dried on MgSO4 and evaporated to afford a pale brown 
oil. (93 mg). Purification of the crude product by recrystallization afforded the pure 
compound as a white solid (7 mg).  Yield 3 %. (Petroleum ether/MeOH). 1H NMR (400 
MHz, MeOD) 4.49 (s, 2H, CH2), 6.97 (br s, 2H, imidazole protons), 7.45 (t, 2H, ar, J= 8.0 
Hz),  7.53 (tt, 1H, ar, J = 7.6, 1.2 Hz), 8.34 (d, 2H, ar, J = 8.0 Hz). HPLC: 97,2 %, RT 4.56 min, 
LC-MS (ESI): 285.1 [M + H] + Anal. Calc. for C13H12N6S. 
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Synthesis of 2,6-dichloro-4-phenylpyridine (201) 
 
A suspension of 2,6-dichlo-4-iodopyridine (1 g, 3.65 mmol), Na2CO3 (1.16 g, 10.95 mmol), 
phenylboronic acid pinacol esther (0.745 g, 3.65 mmol) and Pd(PPh3)2Cl2 (0.128 g, 0.183 
mmol) in a mixture of acetonitrile (12 mL) and water (8 mL) under N2 atmosphere was 
heated at 70 °C for 16 h (TLC monitoring, Petroleum ether 9.8/EtOAc 0.2). The obtained 
mixture was diluted with EtOAc (50 mL) and washed with brine (30 mL x 3). The organic 
layer was dried on MgSO4 and evaporated under reduced pressure to afford a brown oil 
which was purified by column chromatography (Petroleum ether 9.8/EtOAc 0.2). Yield 92 
%. 1H NMR (400 MHz, CDCl3) 7.50 (s, 2H, pyridine protons), 7.52-7.55 (m, 3H, ar), 7.60-
7.63 (m, 2H, ar). Anal. Calc. for C11H7Cl2N. 
 
Synthesis of 2-(tert-butylthio)-6-chloro-4-phenylpyridine (202) 
 
A suspension of 2,6-dichloro-4-phenylpyridine (0.2 g, 0.89 mmol), Cs2CO3 (0.58 g, 1.78 
mmol), and 2-methyl-propanethiol (0.0846 mg, 0.93 mmol) in DMF was heated at 80 °C 
overnight (TLC monitoring, Petroleum ether 9/EtOAc 1 and HPLC). The mixture was 
diluted with EtOAc (50 mL) and washed with brine (30 mL x 5). The organic phase was 
dried on MgSO4 and evaporated to afford a pale yellow oil (249 mg) which was used for 
the next step without purification. Quantitative yield. 1H NMR (400 MHz, CDCl3) 1.62 (s, 
9H, (CH3)3), 7.30 (d, 1H, pyridine proton, J = 1.3 Hz), 7.40 (d, 1H, pyridine proton, J = 1.3 
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Hz), 7.46 -7.54 (m, 3H, ar), 7.58-7.61 (m, 2H, ar). LC-MS (ESI): 277.9 [M + H] +. Anal. Calc. 
for C15H16ClNS. 
 
Synthesis of Tert-butyl-(6-(tert-butylthio)-4-phenylpyridin-2-yl)-carbamate (203) 
 
A suspension of 2-(tert-butylthio)-6-chloro-4-phenylpyridine 202 (0.23 g, 0.83 mmol), 
Cs2CO3 (0.54 g, 1.66 mmol), Xantphos (0,144 g, 0,25 mmol), Pd(OAc)2 (0,028 g, 0,124 
mmol), t-butylcarbamate (0,097 g, 0,83 mmol) in anhydrous 1,4-Dioxane (2,8 mL) under 
N2 atmosphere was heated at 110 °C overnight. The reaction progress was monitored by 
TLC (Petroleum ether 9.8/AcOEt 0.2) and HPLC. The mixture was treated with boiling 
acetone (25 mL) and filtered. The organic layer was evaporated to afford a red oil (478 
mg) which was purified by liquid chromatography (Petroleum ether 9.8/AcOEt 0.2). (80 
mg of a yellow solid). Yield 26.9 %. 1H NMR (400 MHz, DMSO-d6) 1.51 (s, 9H, (CH3)3), 1.55 
(s, 9H, (CH3)3), 7.17 (d, 1H, pyridine proton, J = 1.3 Hz), 7.46–7.54 (m, 3H, ar), 7.67-7.69 
(m, 2H, ar), 7.86 (d, 1H, pyridine proton, J = 1.3 Hz), 9.97 (br s, 1H, NH). LC-MS (ESI): 358.9 
[M + H] +. Anal. Calc. for C20H26N2O2S. 
 
Synthesis of 6-(tert-butylthio)-4-phenylpyridin-2-amine (204) 
 
To a solution of tert-butyl (6-(tert-butylthio)-4-phenylpyridin-2-yl)-carbamate 203 (0.25 g, 
0.697 mmol) in DCM (5 mL) TFA (0,266 mL, 3,48 mmol) was added. The mixture was 
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refluxed overnight (TLC monitoring, DCM 9.4/MeOH 0.6 and HPLC). The mixture was 
diluted with EtOAc (50 mL) and washed with water (25 mL x 4). The organic phase was 
dried on MgSO4 and evaporated to afford a brown oil. The crude compound was purified 
by liquid chromatography (Petroleum ether 5/EtOAc 5) to yield a pale yellow oil (135 mg). 
Yield 75%. 1H NMR (400 MHz, DMSO-d6) 1.47 (s, 9H, C(CH3)3), 6.78 (s, 1H, pyridine proton), 
6.96 (s, 1H, pyridine proton), 7.51-7.54 (m, 3H, ar), 7.68 (d, 2H, ar, J = 6.4 Hz). LC-MS (ESI): 
259.0 [M + H] +. Anal. Calc. for C15H18N2S. 
 
Synthesis of 6-amino-4-phenylpyridine-2-thiol (205) 
 
A stirred solution of 6-(tert-butylthio)-4-phenylpyridin-2-amine 204 (0.445 g, 1.722 mmol) 
in 37 % HCl (15 mL) was heated at 100 °C for 10 h (HPLC monitoring). The mixture was 
cooled to 0 °C and carefully neutralized to pH = 7 with NaHCO3 saturated solution. The 
resulting solution was extracted with EtOAc (40 mL x 5). The combined organic phases 
were dried on MgSO4 and evaporated to afford 135 mg of orange solid. The compound 
was used for the next reaction without further purification. Yield 39 %.1H NMR (400 MHz, 
DMSO-d6) 6.42 (s, 1H, pyridine proton), 6.87 (s, 1H, pyridine proton), 7.47-7.48 (m, 3H, 
ar), 7.57-7.59 (m, 2H, ar), 12.07 (br s, 1H, SH). LC-MS (ESI): 203.1 [M + H] +. Anal. Calc. for 
C11H10N2S. 
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Synthesis of 6-(((1H-imidazol-2-yl)methyl)thio)-4-phenylpyridin-2-amine (88) LUF7762  
 
To a suspension of 6-amino-4-phenylpyridine-2-thiol (0.145 g, 0.716 mmol) and NaHCO3 
(0.0602 g, 0,57 mmol) in anhydrous DMF (2 mL) was added bromo-methyl-(1H)-imidazole 
(0.225 g, 0.931 mmol). The mixture was stirred at room temperature for 23 h (HPLC 
monitoring). The solvent was evaporated under reduced pressure (water bath, 70 °C). The 
resulting residue was treated with water (20 mL) and extracted with EtOAc (30 mL x 4). 
The organic phase was dried on MgSO4 and evaporated to afford 282 mg of an orange oil. 
The compound was purified by liquid chromatography (DCM 9/MeOH 1). Yield 33 %. 1H 
NMR (400 MHz, MeOD) 4.39 (s, 2H, CH2), 6.50 (d, 1H, pyridine proton, J = 1.2 Hz), 6.70 (d, 
1H, pyridine proton, J = 1.2 Hz), 6.94 (s, 2H, imidazole protons), 7.32-7.46  (m, 3H, ar), 
7.54 (dd, 2H, ar, J = 8.0, 1.4 Hz). HPLC: 96,52 %, RT 4.30 min, LC-MS (ESI): 283.1 [M + H] +. 
Anal. Calc. for C15H14N4S. 
 
Synthesis of 2,6-dihydroxy-4-phenylnicotinonitrile (206)457 
 
A suspension of ethyl benzoyl acetate (3 g, 15.6 mmol), 2-cyanoacetamide (1.31 g, 15.6 
mmol) and KOH (0.96 g, 15.6 mmol) in EtOH (20 mL) was refluxed for 24 h (TLC monitoring, 
DCM 8/MeOH 2). The mixture was cooled to 0°C. The resulting solid was collected by 
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filtration and then dissolved in warm water (60 mL/60 °C). The alkaline solution was 
carefully treated with 37% HCl solution to pH = 1. The precipitate was collected by 
filtration and dried (1.3 g). Yield 33.6 %. 1H NMR (400 MHz, DMSO-d6) 5.81 (s, 1H, 
nicotinonitrile proton), 7.53 (s, 5H, ar). LC-MS (ESI): 213.1 [M + H] +. Anal. Calc. for 
C12H8N2O2. 
 
Synthesis of 2,6-dichloro-4-phenylnicotinonitrile (207) 
 
A suspension of 2,6-dihydroxy-4-phenylnicotinonitrile 206 (1.2 g, 5.657 mmol) in POCl3 
(5.3 mL, 56.6 mmol) was heated at 180 °C in autoclave for 16 h (HPLC monitoring). The 
mixture was cooled to 0 °C and treated with crushed ice. The suspended solid was 
collected by filtration, rinsed with Petroleum ether (30 mL) and dried (990 mg). The 
product has been used for the next step without further purification. Yield 70 %. 1H NMR 
(400 MHz, CDCl3) 7.47 (s, 1H, nicotinonitrile proton), δ 7.60–7.63 (m, 5H, ar). +. Anal. Calc. 
for C12H6Cl2N2. 
 
Synthesis of tert-butyl-(6-chloro-5-cyano-4-phenylpyridin-2-yl)-carbamate (208) 
 
To a suspension of 2,6-dichloro-4-phenylnicotinonitrile 207 (0.2 g, 0.806 mmol),                      
t-butylcarbamate (0.0944 g, 0.806 mmol), Cs2CO3 (0.54 g, 1.66 mmol) and Xantphos 
(0.139 g, 0.242 mmol) in anhydrous 1,4-dioxane (2.7 mL) under N2 atmosphere was added 
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Pd(OAc)2 (0.027 g, 0.121 mmol). The mixture was heated at 40 °C for 23 h (TLC monitoring, 
Petroleum ether 9.8/EtOAc 0.2). The mixture was treated with boiling acetone (25 mL) 
and filtered. The collected organic layer was evaporated to afford 90 mg of a pale brown 
solid. The product was used for the next reaction without further purification. Yield 33%. 
1H NMR (300 MHz, CDCl3) 1.55 (s, 9H, C(CH3)3), 7. 50 (br s, 1H, NH), 7.52-7.55 (m 3H, ar), 
7.62 – 7.65 (m, 2H, ar), 8.09 (s, 1H, 5-cyano-pyridine proton). LC-MS (ESI): 329.92 [M + H] 
+. Anal. Calc. for C17H16ClN3O2. 
 
Synthesis of tert-butyl (6-(tert-butylthio)-5-cyano-4-phenylpyridin-2-yl)-carbamate 
(209) 
 
A suspension of tert-butyl (6-chloro-5-cyano-4-phenylpyridin-2-yl)-carbamate 208 (0.09 
g, 0.273 mmol), 2-methyl-propanethiol (0.03 mL, 0.273 mmol) and Cs2CO3 (0.546 mmol) 
in DMF (2 mL) was heated at 90 °C for 20 h (HPLC monitoring). The mixture was cooled to 
room temperature, diluted with EtOAc (50 mL) and washed with brine (25 mL x 5). The 
organic layer was dried on MgSO4 and evaporated to afford an orange oil (93 mg). The 
compound was used for the next reaction without further purification. Yield: 89 %.  1H 
NMR (400 MHz, CDCl3) 1.56 (s, 9H, (CH3)3), 1.67 (s, 9H, (CH3)3), 7.34 (br s, 1H, NH), 7.46–
7.50 (m, 3H, ar), 7.58–7.61 (m, 2H, ar), 7.82 (s, 1H, 5-cyano-pyridine proton). LC-MS (ESI): 
384.00 [M + H] +. Anal. Calc. for C21H25N3O2S. 
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Synthesis of 6-amino-2-mercapto-4-phenylnicotinonitrile (210).  
 
A suspension of tert-butyl (6-(tert-butylthio)-5-cyano-4-phenylpyridin-2-yl)-carbamate 
209 (0.7 g, 1.825 mmol) in 37% HCl (7 mL) was heated at 100 °C for 2 h (HPLC monitoring). 
The mixture was cooled to room temperature and diluted with NaHCO3 saturated solution 
(7 mL). The resulting suspension carefully treated with solid NaHCO3 to pH = 7 and 
extracted with EtOAc (30 mL x 5). The combined organic phases were dried on MgSO4 and 
evaporated to afford an orange solid which was purified by column chromatography 
(Petroleum ether 6/EtOAc 4) and (DCM 9/MeOH 1). Pale yellow solid (156 mg). Yield 
37%.1H NMR (300 MHz, MeOD) 6.07 (s, 1H, 5-cyano-pyridine proton), 7.51-7.57 (m, 5H, 
ar). LC-MS (ESI): 228.08 [M + H] +. Anal. Calc. for C12H9N3S. 
 
Synthesis of 2-(((1H-imidazol-2-yl)methyl)thio)-6-amino-4-phenylnicotinonitrile (89) 
(LUF7763) 
 
A suspension 6-amino-2-mercapto-4-phenylnicotinonitrile 210 (0.096 g, 0.422 mmol), 
NaHCO3 (0.0202 g, 0.422 mmol), bromo-methyl-(1H)-imidazole (0.153 g, 0.633 mmol)  in 
anhydrous DMF (2,5 mL) was stirred at room temperature for 4 h (TLC monitoring, DCM 
9 /MeOH 1). The solvent was evaporated under reduced pressure (water bath 70 °C). The 
resulting residue was treated with water (10 mL) and extracted with EtOAc (30 mL x 5). 
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The organic layer was dried on MgSO4 and evaporated to afford a pale brown oil (116 mg). 
First, the crude product was purified by column chromatography (Petroleum ether 1/ 
AcOEt 7.8/MeOH 1.2) and then recrystallized (Et2O/MeOH) to give a yellow solid (10 mg). 
Yield 7.7 %. 1H NMR (400 MHz, MeOD) 4.53 (s, 2H, CH2), 6.28 (s, 1H, nicotinonitrile 
proton), 6.97 (s, 2H, imidazole protons) 7.48 (dt, 5H, ar, J = 6.8, 4.0 Hz). HPLC: 98,2 %, RT 
5.52 min, LC-MS (ESI): 308.1 [M + H] +. Anal. Calc. for C16H13N5S. 
 
7.7 Materials and method 
 
7.7.1 Chemicals and Reagents 
Chinese hamster ovary cells stably expressing the human adenosine A1 receptor 
(CHOhA1R) were kindly provided by Prof. Steve hill (University of Nottingham, UK); Human 
embryonic kidney 293 cells stably expressing the human adenosine A2A receptor 
(HEK293hA2AR) were kindly provided by Dr. J Wang (Biogen/IDEC, Cambridge, MA); Chinese 
hamster ovary (CHO) cells stably expressing the human adenosine A3 receptor (CHOhA3) 
were a gift from Dr. K-N Klotz (University of Würzburg, Germany). [3H]-1,3-dipropyl-8-
cyclopentyl-xanthine([3H]DPCPX, specific activity 120 Ci/mmol) was purchased from ARC. 
(St.Louis, USA); [3H 4-(-2-[7-amino-2-{2-furyl}{1,2,4}triazolo{2,3-a} {1,3,5}triazin-5-yl-
amino]ethyl) phenol ([3H]- ZM241385, specific activity 50 Ci/mmol) was purchased from 
ARC, Inc. (St. Louis, MO); [3H]8-Ethyl-4-methyl-2-phenyl-(8R)-4,5,7,8-tetrahydro-1H-
imidazo[2,1-i]-purin-5-one ([3H]PSB-11, specific activity 56 Ci/mmol) was obtained with 
the kind help of Prof. C.E. Müller (University of Bonn, Germany). 5’-N-
ethylcarboxamidoadenosine (NECA), N6-Cyclopentyladenosine (CPA) and Adenosine 
deaminase (ADA) were purchased from Sigma-Aldrich (Steinheim, Germany). Pierce 
Bicinchoninic acid (BCA) protein assay reagents were obtained from Pierce Chemical 
Company (Rockford, IL, USA). All other chemicals were of analytical grade and obtained 
from standard commercial sources. 
 
7.7.2 Cell Culture and Membrane Preparation 
CHOhA1R and CHOhA3R were Dulbecco’s Modified Eagles Medium (DMEM) and Ham’s 
F12 medium (1:1) supplemented with 10% (v/v) 10% newborn calf serum, 50 µg.mL-1 
7.VISITING PERIOD AT LACDR  
 
161 
streptomycin, 50 IU.mL-1 penicillin, and 200 µg.mL-1 G418 at 37 oC and 5% CO2. CHOhA1R 
cells were subcultured twice a week at a ratio of 1:20 on 10 cm Ø plates and 15 cm Ø 
plates. CHOhA3 cells were subcultured twice a week at a ratio of 1:8 on 10 cm Ø plates 
and 15 cm Ø plates. HEK293hA2AR cells were grown in culture medium consisting of 
Dulbecco’s Modified Eagles Medium (DMEM) supplemented with 10% newborn calf 
serum, 50 µg.mL-1 streptomycin, 50 IU.mL-1 penicillin, and 500 µg.mL-1 G418 at 37 oC and 
7% CO2. Cells were subcultured twice a week at a ratio of 1:8 on 10 cm Ø plates and 15 
cm Ø plates. All cells were grown to 80-90% confluency and detached from plates by 
scraping them into 5 mL PBS. Detached cells were collected and centrifuged at 0.2 x g for 
5 min. Pellets derived from 100 15 cm Ø plates were pooled and resuspended in 70 mL of 
Ice-cold 50 mM Tris-HCl buffer, pH = 7.4. A Heidolph Diax 900 homogenizer was used to 
homogenize the cell suspension. Membranes and the cytosolic fraction were separated 
by centrifugation at 100 000x g in a Beckman Optima LE-80 K ultracentrifuge (Beckman 
Coulter, Fullerton, CA) at 4 oC for 20 min. The pellet was resuspended in 35 mL of the           
Tris-HCl buffer, and the homogenization and centrifugation steps were repeated. Tris-HCl 
buffer (25 mL) was used to resuspend the pellet, and ADA was added (0.8 U/mL) to break 
down endogenous adenosine. Membranes were stored in 250 µL and 500 µL aliquots at 
80 oC. Total protein concentrations were measured using the BCA method458 
 
7.7.3 Radioligand Displacement Assay 
Membrane aliquots containing 5 µg (CHOhA1R), or 30 µg (HEK293hA2AR) or 15 µg 
(CHOhA3R) were incubated in a total volume of 100 µL assay buffer (50 mM Tris-HCl, pH 
= 7.4) for  CHOhA1R and HEK293hA2AR; and assay buffer (50 mM Tris-HCl, pH = 8.0, 
supplemented with 10 mM MgCl2, 1 mM EDTA and 0.01% (w/v) CHAPS) for CHOhA3R at 
25 °C for 1 h (CHOhA1R and HEK293hA2AR) and 2 h (CHOhA3R). Radioligand displacement 
experiments were performed using 6 concentrations of competing ligand in the presence 
of 1.6nM [3H]DPCPX for CHOhA1R, 5.5 nM [3H]ZM241385 for HEK293hA2AR and 10 nM 
[3H]PSB11 for CHOhA3R. At these concentrations total radioligand binding did not exceed 
10% of that added to prevent ligand depletion. Nonspecific binding was determined in 
the presence of 100 µM CPA for CHOhA1R, 100 µM NECA for CHOhA1R and CHOhA3R. 
Incubations were terminated by rapid vacuum filtration to separate the bound and free 
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radioligand through prewetted 96-well GF/B filter plates using a PerkinElmer Filtermate-
harvester (Perkin Elmer, Groningen, the Netherlands). Filters were subsequently washed 
 12 times with ice-cold wash buffer (50 mM Tris-HCl, pH = 7.4) for CHOhA1R and 
HEK293hA2AR; and wash buffer for CHOhA3R (50 mM Tris-HCl supplemented with 10 mM 
MgCl2, 1mM EDTA, pH = 8.0). The plates were dried at 55 oC after which MicroscintTM-20 
cocktail was added (Perkin Elmer, Groningen, The Netherlands). After 3 h the filter-bound 
radioactivity was determined by scintillation spectrometry using a 2450 MicroBeta 
Microplate Counter (Perkin Elmer, Groningen, The Netherlands).  
 
7.7.4 Data analysis 
All experimental data was analyzed by using GraphPad Prism 7.0 (GraphPad Software Inc., 
San Diego, CA). IC50 values obtained from competition displacement binding data were 
converted into Ki values using the Cheng-Prusoff equation459. The KD value of [3H]DPCPX 
at CHOhA1R membrane was taken from Kourounakis, A. et al. Biochem. Pharmacol. G1 
(2001) 137-144. The KD value (1.0 nM) of [3H]ZM241385 at hA2AR membranes and the KD 
value (17.3nM) of [3H]PSB11 at CHOhA3R membranes were taken from in-house 
determination.
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8. ACRONYMS AND ABBREVIATIONS 
The following acronyms and abbreviations are used for the NMR spectra: 
ar = Aromatic protons 
br = Broad 
d = Doublet 
dd = Doublet of doublets 
dt = Doublet of triplets 
m = Multiplet 
q = Quartet 
s = Singlet  
t = Triplet 
tt = Triplet of triplets 
 
The following acronyms and abbreviations are used for solvents and chemical reagents:  
AcOH = Acetic acid 
CDCl3 = Deuterated chloroform 
DIPEA = N,N-Diisopropylethylamine 
DCM = Dichloromethane 
DMF = Dimethylformamide 
DMSO-d6 = Deuterated dimethyl sulfoxide 
EDCI.HCl = N-(3-Dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride 
EDTA = Ethylenediaminetetraacetic acid 
EtOAc = Ethyl acetate 
Et2O = Diethyl ether 
EtOH = Ethanol 
HCl = Hydrochloric acid 
HOBt = Hydroxybenzotriazole 
MeOH = Methanol 
MeOD = Deuterated methanol 
TFA = Trifluoroacetic acid 
THF = Tetrahydrofuran 
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t-BuOH = Tert-butanol 
 
Other acronyms and abbreviations: 
ADP = Adenosine diphosphate 
AMP = Adenosine monophosphate 
cAMP = Cyclic adenosine monophosphate 
ATP = Adenosine triphosphate 
EC50 = Half maximal effective concentration 
g = Gram 
mg = Milligram 
µg = Micrograms 
HPLC = high-performance liquid chromatography 
Hz = Hertz 
IC50 = Half maximal inhibitory concentration 
IR = Infrared radiation 
IU = International Unit 
LC-MS = Liquid chromatography−mass spectrometry 
mL = Milliliter 
μL = Microliter 
mM = Millimolar 
μM = Micromolar 
nM = Nanomolar 
m.p. = Melting point 
mw = Microwave 
NMR = Nuclear magnetic resonance 
PBS = Phosphate-buffered saline 
ppm = Parts per million 
r.t. = Room temperature 
TLC = Thin layer chromatography
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